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Anatomy and physiology of the inner ear
The inner ear consists of the vestibular system and the cochlea (Figure 1a). The cochlea 
is coiled in a spiral shape, like a snail shell, and contains three parallel compartments: the 
scala media, scala vestibuli and scala tympani (Figure 1b). The scala media is filled with 
potassium-rich endolymph, whereas the other two compartments are filled with sodium-
rich perilymph. The diﬀerence in ion concentration between the compartments results in 
a positive voltage in the scala media, known as the encodochlear potential. Endolymph 
is produced by the stria vascularis, localized in the lateral wall of the scala media, which 
is responsible for maintainance of high potassium concentration of the endolymph.1 The 
scala media is separated from the scala vestibuli by Reissner’s membrane, and from the 
scala tympani by the basilar membrane. The organ of Corti is positioned on the thin basilar 
membrane and contains a single row of inner hair cells and three rows of outer hair cells. 
Inner hair cells transduce the vibration of sound into electrochemical signals, whereas 
outer hair cells enhance the sound sensitivity and selectivity.2 The hair cells are surrounded 
by various supporting cells, which play a pivotal role in development of sensory epithelia, 
preservation of structural integrity and homeostasis.3 Junctions between the hair cells and 
supporting cells ensure a selective barrier between endolymph and perilymph and enable 
exchange of electric and chemical signals.4 On the apical surface of hair cells, stereocilia 
are located, the mechano-sensory structures of the cochlea.5 Atop the stereocilia lays a 
gelatinous structure, the tectorial membrane (Figure 1c).
 When sound reaches the ear, it travels through the external auditory canal to the 
tympanic membrane, which starts vibrating. These vibrations are transmitted to the 
cochlea by the three middle ear ossicles (Figure 1a). Sound transmission to the cochlea 
generates vibration of the basilar membrane, causing vertical movement of the organ of 
Corti. This results in deflection of stereocilia against the tectorial membrane. Deflections 
of the stereocilia bundle leads to influx of calcium and potassium from the endolymph 
into the hair cell, inducing depolarization of the cell and release of neurotransmitters at 
the basal end of the hair cell.1 The neurotransmitters stimulate the cochlear nerve, which 
transmits the signal to the auditory cortex.
 Due to variation in stiﬀness and width of the basilar membrane, variation in length of 
the stereocilia and outer hair cell bodies, and variation in width of the tectorial membrane, 
the basal part of the cochlea perceives high-frequency sounds, while low-frequency sounds 
are perceived in the apex.6 Loudness of a tone is determined by the amplitude of basilar 
membrane motion.7 
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The vestibular system consists of three semicircular canals, which detect rotational 
accelerations, and of the utricule and saccule, which detect linear accelerations (Figure 1a). 
Although the anatomy of the vestibular organ is diﬀerent from the cochlea, the physiology 
is very similar. The vestibular structures contain perilymph and endolymph, the latter 
being produced by dark cells in the vestibular system and by the stria vascularis in the 
cochlea. The vestibular system harbors supporting cells, and hair cells with stereocilia and 
one kinocilium per hair cell. In the ampulla of the semicircular canals, the stereocilia and 
kinocilia are embedded in a gelatinous mass, called the cupula (Figure 1d). In the utricule 
and saccule, the gelatinous mass is known as the otolithic membrane, which is covered by 
otoconia (Figure 1e).8,9 
 Rotation of the head causes movement of endolymph that bends the cupula and 
causes movement of the otoliths. This leads to deflection of stereocilia and kinocilia in 
the semicircular canals, and saccule and utricule. As a result, the hair cells depolarize and 
release neurotransmitters, causing signals to be transduced to the brainstem. Here, the 
peripheral vestibular signals are integrated with visual signals from the ocular system, and 
orientation signals from proprioceptors, to maintain balance.8,9
Figure 1 The auditory system (cochlea) and vestibular system (semicircular canals, utricule and saccule) 
are part of the inner ear (a). The snail shell shaped cochlea, consists of the scala media, scala vestibuli and 
scala tympani (b). Within the scala media, the organ of Corti is located, which transduces sound waves 
into electrochemical signals. It contains the basilar membrane, hair cells, supporting cells and the tectorial 
membrane (c). The stereocilia and kinocilia of the semicircular canals, located on the apical surface of the 
hair cells, are embedded in a membranous mass, called the cupula (d). The utricule and saccule contain hair 
cells with stereocilia and kinocilia that are overlaid by a gelatinous membrane, which is covered by otoliths 
(e). The figure was adapted from Frolenkov et al. (2004)10, with approval from the Nature Publishing Group.
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Molecular aspects of hereditary hearing impairment
Given the complexity of the auditory system, defects in many biological processes can 
lead to hearing impairment (HI). Functions of known genes active in the auditory system 
diﬀer from hair bundle morphogenesis, to ion homeostasis, to gene regulation and 
synaptic signal transmission.11,12 Some of the encoded proteins co-function in specific 
biological pathways. Currently, deleterious mutations in more than 100 genes have been 
associated with nonsyndromic HI (NSHI) (Hereditary Hearing Loss Homepage, http://
hereditaryhearingloss.org/) and even more in syndromic HI (OMIM, https://www.omim.
org/), illustrating the extreme genetic heterogeneity of HI. Mutations in GJB2 are the 
leading cause of NSHI, accounting for up to 50% of the NSHI population.13 Although a 
number of other genes are relatively frequently involved in HI (e.g. MYO6, MYO7A, MYO15A, 
SLC26A4, STRC and USH2A)14-21, many genes have been reported in only one or a few families, 
demonstrating that most types of hereditary HI are (extremely) rare.
 In this manuscript, we focus on monogenic (Mendelian) forms of HI, meaning that 
HI is caused by defect(s) in a single gene. Monogenic inheritance can be classified as 
autosomal recessive (70-80% of early onset NSHI cases), autosomal dominant (20-30% of 
NSHI), mitochondrial (1-2% of NSHI), X-linked (1-2% of NSHI) and Y-linked (rare in NSHI).22,23 
Nonsyndromic deafness loci and genes involved in monogenic forms of HI are named 
according to the DFN (DeaFNess) nomenclature: DFNA, autosomal dominant; DFNB, 
autosomal recessive; DFN, X-linked; DFNY, Y-linked inheritance; DFNM, modifier. 
Clinical aspects of hereditary hearing impairment
Worldwide, 360 million people suﬀer from disabling HI, of whom 32 million are children, 
making HI the most prevalent sensorineural disorder.24 One to two in every 1000 newborns 
has permanent HI; about half of the cases is assumed to be inherited.25 
 Very diverse genetic HI phenotypes are known. In most forms of monogenic HI, there 
is a congenital or childhood onset of HI, although onset can vary up to the 6th decade in 
patients with DFNA9.26 Hereditary HI can be syndromic or nonsyndromic, accounting for 
30% and 70% of cases, respectively.27 Syndromic HI is characterized by HI associated with 
one or more particular symptoms. The most common types of syndromic HI are Pendred, 
Usher, Waardenburg and Branchio- oto-renal syndrome. NSHI can be defined as isolated HI 
without additional symptoms. 
 Auditory phenotypes investigated in this thesis are described according to the 
recommendations of the GENDEAF study group.28 Vestibular characteristics in this thesis 
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are described in accordance with current standards29 and the international standard ANSI 
S3.45 2009. Tables 1 and 2 provide an overview of the audiological and vestibular terms 
and definitions. Although the auditory and vestibular phenotype can be objectively 
investigated and described, it is often impossible to predict the genotype based on the 
HI phenotype. Many monogenic types of NSHI have a similar phenotype, characterized 
by early onset HI with a downsloping audiogram configuration, making it impossible 
Table 1 Audiological terms and definitions, as described by the GENDEAF study group28 
Auditory characteristic Term Definition 
Type of HI Conductive Related to disease or deformity of outer/middle ear.  
Normal bone-conduction thresholds (<20 dB HL) 
and an air-bone gap >15 dB HL averaged over 0.5, 1 
and 2 kHz. 
 Sensorineural Related to disease/deformity of the inner 
ear/cochlear nerve. 
Air/bone gap <15 dB HL averaged over 0.5, 1 and 2 
kHz. 
 Mixed Related to combined involvement of the 
outer/middle ear and the inner ear/cochlear nerve. 
>20 dB HL in the bone conduction threshold 
together with >15 dB HL air-bone gap averaged 
over 0.5, 1 and 2 kHz. 
Severity of HI 
(applied to the better 
hearing ear, averaged 
over 0.5, 1, 2 and 4 kHz) 
Mild 20-40 dB HL 
Moderate 41-70 dB HL 
Severe 71-95 dB HL 
Profound in excess of 95 dB HL 
Audiometric 
configuration 
Low frequency ascending >15 dB HL diﬀerence from the poorer low 
frequency thresholds to the higher frequencies 
 Mid frequency U-shaped >15 dB HL diﬀerence between the poorest 
thresholds in the mid-frequencies, and those at 
higher and lower frequencies 
 High frequency gently 
sloping 
15-29 dB HL diﬀerence between the mean of 0.5 
and 1 kHz and the mean of 4 and 8 kHz 
 High frequency steeply 
sloping 
>30 dB HL diﬀerence between the mean of 0.5 and 
1 kHz and the mean of 4 and 8 kHz 
 Flat <15 dB HL diﬀerence between the mean of 0.25, 0.5 
kHz thresholds, the mean of 1 and 2 kHz and the 
mean of 4 and 8 kHz 
Frequency ranges Low frequencies ≤ 0.5 kHz 
 Mid frequencies >0.5 kHz ≤ 2 kHz 
 High frequencies >2 kHz ≤ 8 kHz 
 Extended high frequencies > 8 kHz 
Unilateral/bilateral  >10 dB HL diﬀerence between the ears in at least 
two frequencies. The average over 0.5, 1 and 2 kHz 
of the better ear should be worse than 20 dB HL. 
Progression  Deterioration of >15 dB HL in the average over the 
frequencies of 0.5, 1, and 2 kHz within a 10 year 
period.  
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to clinically diﬀerentiate them. There are, however, a few types of HI with a very distinct 
phenotype, such as HI in Pendred syndrome, Usher syndrome, and DFNA9. These types of 
HI are therefore easily recognized, enabling targeted diagnostic analysis. 
 Mutations in a specific deafness gene can lead to diﬀerent phenotypes, which has 
implications for counseling. Some deafness genes are involved in both syndromic and 
nonsyndromic HI, such as CDH23, which is known for DFNB12 and Usher syndrome type 
1D.30 Other deafness genes have been associated with both dominantly and recessively 
inherited forms of HI. Mutations in TECTA can, for example, lead to DFNA8/12 and DFNB21.31 
It is important to realize that even diﬀerences in phenotypes between patients with exactly 
the same genetic defect do exist. Therefore, counseling for these types of HI, particularly 
on prognosis, may be diﬃcult. In general, phenotypic diﬀerences can be due to the 
type or location of the mutation (such as in DNFA926,32), environmental factors (e.g. noise 
exposure33) or genetic modifiers34 (e.g. DFNM135). The penetrance of the mutation within a 
family can be complete or incomplete, but is usually complete.
Table 2 Vestibular terms and definitions in accordance with current standards29 and the international 
standard ANSI S3.45 2009 
Vestibular test Term Definition 
Caloric irrigation testa Hyporeflexia Slow phase velocities of the nystagmus <10°/sec cold water 
irrigation or <7°/sec warm water irrigation 
 Hyperreflexia Slow phase velocities of the nystagmus >52°/sec cold water 
irrigation or >31°/sec warm water irrigation  
Rotary chair test Hyporeactivity Gain <33% and maximum velocity at deceleration <30°/sec and 
decay time <11 sec 
 Hyperreactivity Gain >72% and maximum velocity at deceleration >65°/sec and 
decay time >26 sec 
vHIT Hyporeactivity Gain <82% 
cVEMP Hyporeactivity Thresholds >100 dB 
 Hyperreactivity Thresholds <82 dB 
sec, second; vHIT, video head impulse test; cVEMP, cervical vestibular evoked myogenic potentials. aCaloric 
irrigation tests were performed with water irrigation during 30 seconds. 
The impact of hereditary hearing impairment on life
HI can have a significant impact on social life and professional performance. Patients with 
HI may have to deal with feelings of shame and insecurity, lack of energy, depression, 
loneliness, isolation, dependence, and frustration.36-39 Parents sometimes experience 
feelings of guilt.40 It can be very diﬃcult for parents to cope with a (syndromic) diagnosis, 
especially (presymptomatic) Usher syndrome. Presymptomatic diagnosis of syndromic HI 
has become more frequent with the introduction of next generation sequencing (NGS), 
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targeting a panel of syndromic and nonsyndromic HI-related genes or the whole exome. A 
presymptomatic diagnosis can induce feelings of insecurity and lead to coping problems 
with unanswered questions, such as for parents when and how to tell their child, and what 
the future of their child will hold. A genetic diagnosis can also entail diﬃcult decisions on 
family planning and career. 
 It is essential to assist patients and their relatives, by counseling them on their 
diagnosis, recurrence risk, prognosis and rehabilitation options, and by providing 
aftercare.41 It has been shown that a genetic diagnosis positively impacts the psychological 
status of individuals and families aﬀected by HI.42 In addition, a genetic diagnosis can 
prevent further diagnostic testing and may identify possible medical comorbidities43 (e.g. 
hypothyroidism in Pendred syndrome). Knowledge on phenotype characteristics and 
genotype-phenotype correlations is crucial for proper counseling, however, evidence 
based information lacks for many types of HI.
Diagnostic work-up of patients with hereditary hearing impairment
In the Netherlands, patients suspected of hereditary HI can be referred to an (oto)genetic 
outpatient clinic in one of the eight university medical centers, where they are clinically and 
genetically examined. In the Radboud university medical center outpatient clinic, expertise 
center Hearing & Genes, a standardized protocol is used (see flowchart, Figure 2). Clinical 
evaluation has been described in detail before.44 In brief, patients and their relatives are 
seen by an otologist, clinical geneticist, and/or audiologists, who takes medical history and 
family history, and performs physical examination including otoscopy. Special attention is 
paid to possible acquired causes of HI12, such as cytomegalovirus infection45 and perinatal 
hypoxia/ asphyxia.46 Hearing is evaluated to determine the auditory phenotype. When 
indicated, additional examinations can be performed, such as high-resolution computed 
tomography, magnetic resonance imaging, cytomegalovirus test, full blood count, and 
additional audiometric or vestibular tests. 
 If a patient is clinically suspected of Usher syndrome type 2, Pendred syndrome or 
DFNA9, a single gene test is requested (USH2A, SLC26A4 or COCH, respectively). In patients 
with early-onset HI, gene tests for DFNB1 are performed (GJB2/GJB6). In all other cases, 
whole exome sequencing (WES) is performed and subsequently a panel of known (non)
syndromic HI-related genes is targeted and analyzed. This gene panel is constantly updated 
according to newest insights on genes involved in HI. Patients or their legal representatives 
are counseled by the clinician on potential findings related to syndromic HI, prior to 
testing. If gene panel analysis is negative, analysis of all WES data (open exome analysis) 
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can be performed. Open exome analysis is used for identification of (likely) pathogenic 
variants in candidate genes for HI. The risk of incidental findings47 (0.7%, unpublished 
data), the extremely low diagnostic yield of open exome analysis, and the importance 
to establish a genetic diagnosis, are carefully considered and counseled. If an incidental 
finding occurs, the results are discussed in a panel of independent specialists who decide 
whether the incidental finding is important for the patient to know, in accordance with 
the recommendations by the European Society of Human Genetics48, and the guidelines 
for diagnostic next generation sequencing as published by Eurogentest (http://www.
eurogentest.org/). The turnaround time for single gene tests is approximately 6 weeks, 
for gene panel analysis 4 months, and for open exome analysis 2 additional months. In 
the Netherlands, genetic tests are all reimbursed by the health insurance company of the 
patient. Genetic testing for nonsyndromic HI and the most common syndromic forms is 
centered in the Radboud university medical center, Nijmegen, and the Erasmus University 
Medical Center, Rotterdam; the Netherlands. 
 All patients seen in the outpatient clinic Hearing & Genes in the Radboud university 
medical center Nijmegen, are discussed in a multidisciplinary meeting with otologists, 
clinical geneticists, molecular geneticists, audiologists and social workers. Here, we discuss 
the interpretation of variants and whether the identified genetic defect is in accordance 
with the phenotype known to be associated with defects in a specific gene. If a genetic 
diagnosis can be established, we discuss who (otologist and/or clinical geneticist) should 
perform the counseling and whether patients or their parents may possibly need aftercare 
(e.g. in case of a presymptomatic Usher diagnosis). Patients are counseled on prognosis, 
recurrence risk, rehabilitation options and, if applicable, additional symptoms. 
Scientific research into hereditary hearing impairment
Molecular diagnostic results often raise questions regarding the causality of identified 
variants, because novel variants of uncertain significance have been identified in a known 
deafness gene, or because the identified genetic defect does not match with the phenotype 
of the patient. These questions can be answered by performing research into the eﬀect 
of the mutation on protein level. There can also be uncertainty about the associated 
phenotype due to insuﬃcient phenotype data, which hampers proper counseling. 
Therefore, studies into phenotype characteristics and genotype-phenotype correlations 
are essential. Negative results from diagnostic genetic tests can be a reason to investigate 
presence of variants in candidate genes for HI in a scientific research setting. Identification 
of novel (candidate) deafness genes and functional analysis of the encoded proteins 
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contribute to knowledge of the complex physiology of the hearing apparatus.11 When a 
novel deafness gene is identified in research, it can also be included in the diagnostic gene 
panel. Finally, there is high demand for development of genetic therapies and for data 
that enable personalized medicine in hearing rehabilitation. Worldwide, many research 
projects currently focus on these issues. In this thesis, we focused on the identification of 
novel deafness genes and characterization of genotype-phenotype correlations for known 
and novel deafness genes.
Several techniques can be used to identify novel genes associated with the disease 
of interest, such as homozygosity mapping, linkage analysis, WES and whole genome 
sequencing (WGS). 
 Homozygosity mapping is used to identify the genetic region, in which the causative 
variant of a disorder is located. It is only applicable in families with autosomal recessive 
disorders, and can determine disease haplotypes inherited from a common ancestor 
(founder eﬀect)50 or within consanguineous families51. This technique detects homozygous 
genotypes shared by aﬀected individuals, but not by unaﬀected individuals within a 
family. Genome-wide Single Nucleotide Polymorphism (SNP) arrays are used to determine 
individual genotypes. Subsequently, these genotypes are compared amongst aﬀected 
and/or unaﬀected individuals within the same family to identify large regions (usually >1 
Mb) of homozygosity. 
 Linkage analysis can be used for localization of the genetic defect located in a specific 
chromosomal region, in families with autosomal dominant52, recessive53, and X-linked54 HI. 
It can also provide statistical evidence that a chromosomal region is excluded to harbor the 
genetic defect.
 Whereas since 1977 Sanger sequencing has been used to sequence DNA55, the need 
for large-scale, rapid and inexpensive sequencing has increased exponentially over the 
years. With the advent of NGS, which is based on massively parallel sequencing, complete 
exomes (WES) or the whole genome (WGS) can be analyzed in one experiment. It is also 
possible to perform targeted sequencing of a gene panel using NGS methods, such as in 
OtoSCOPE.56 Many recently identified deafness genes have been discovered using WES, 
often in combination with homozygosity mapping or linkage analysis.57 However, the 
large number of variants identified with WES and WGS poses challenges for interpretation 
of variants, storage of data and managing of incidental findings. To reduce the risk of 
incidental findings, pathogenic variants in 59 genes associated with severe diseases, can 
be excluded from analysis.  For this purpose, the list of genes compiled and updated by the 
American College of Medical Genetics and Genomics, for reporting of secondary findings 
in clinical exome and genome sequencing, can be used.58
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For characterization of genotype-phenotype correlations in this thesis, the pathogenicity 
of the identified variant(s) was first classified according to the guidelines of the American 
College of Medical Genetics and Genomics.49 In this context, DNA of aﬀected and unaﬀected 
family members was collected for segregation analysis. Subsequently, audiovestibular 
phenotypes were investigated and described according to the recommendations of the 
GENDEAF study group.28 Need for investigation of additional symptoms was based on 
the phenotype of animal models, expression and function of the gene and complaints 
reported by the investigated individuals.
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Scope of this thesis
The research presented in this thesis has the aim to contribute to optimal diagnostics and 
counseling for patients with hereditary HI in the Netherlands and beyond, by identification 
of novel deafness genes and (further) characterizing phenotypes and correlations between 
types of HI and the underlying genetic causes. Ultimately, we aim to identify causative 
mutations and provide personal, evidence-based counseling in >90% of individuals with 
hereditary HI.
In chapter 2, the diagnostic yield of WES targeting a deafness gene panel has been 
investigated in 200 Dutch patients with HI. This chapter serves as the starting point of this 
thesis. It provides insight into the most frequent causes of HI in the Netherlands, the yield 
and (dis)advantages of WES targeting a deafness gene panel, the issues that are faced 
in the interpretation of genetic variants, and genotype-phenotype correlations in the 
Dutch population. In chapter 3, the phenotypes of two recessive types of HI, DFNB28 and 
DFNB77, are further characterized and genotype-phenotype correlations are extended. 
These chapters contribute to our knowledge on the phenotypic spectrum of DFNB28 
and DFNB77 and to our understanding of the relationship between specific mutations 
and the associated phenotype. The findings are particularly useful for counseling of 
patients. Both chapters emphasize the huge genetic and phenotypic heterogeneity of HI. 
In chapter 4, two novel deafness genes (MPZL2 and LMX1A) are described for autosomal 
recessive and autosomal dominant HI, respectively. A combination of thorough genetic 
research, phenotype characterization, and for MPZL2, localization studies and investigation 
of a mouse model, reveals that both genes are associated with NSHI and thus that both 
encoded proteins are essential for normal hearing. For patients with HI caused by defects 
of MPZL2 or LMX1A, the identification of these two novel genes enables establishment of a 
genetic diagnosis and subsequently genotype-based counseling.
As part of this thesis, a clinical and scientific collaboration with four university medical 
centers in the Netherlands was started, called “DOOFNL: Diagnostiek en Onderzoek Oto-
genotype Fenotype Nederland”, freely translated as: “DEAFNL: Diagnostics and Research 
Oto-genotype Phenotype the Netherlands”. The goal of this collaboration is fully in line 
with the aim of this thesis: contribute to the best diagnostics and information for patients 
with HI in the Netherlands. Participating centers are: Radboud university medical center, 
Erasmus University Medical Center, Leiden University Medical Center, Maastricht University 
Medical Center+, and University Medical Center Groningen. Genetic and phenotypic data 
obtained by this collaboration is shared in a national database.
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Abstract
Hearing impairment (HI) is genetically heterogeneous, which hampers genetic counseling 
and molecular diagnosis. Testing of several single HI-related genes is laborious and 
expensive. In this study, we evaluate the diagnostic utility of whole-exome sequencing 
(WES) targeting a panel of HI-related genes. Two hundred index patients, mostly of Dutch 
origin, with presumed hereditary HI underwent WES followed by targeted analysis of an 
HI gene panel of 120 genes. We found causative variants underlying the HI in 67 of 200 
patients (33.5%). Eight of these patients have a large homozygous deletion involving 
STRC, OTOA or USH2A, which could only be identified by copy number variation detection. 
Variants of uncertain significance were found in 10 patients (5.0%). In the remaining 
123 cases no potentially causative variants were detected (61.5%). In our patient cohort, 
causative variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were the leading causes 
for autosomal recessive and dominant HI, respectively. Segregation analysis and functional 
analyses of variants of uncertain significance will probably further increase the diagnostic 
yield of WES.
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Introduction
DNA diagnostics of any genetically heterogeneous disease based on single gene testing 
is highly ineﬃcient, laborious and expensive. High throughput sequencing technologies 
such as whole exome sequencing (WES) have coped with these disadvantages allowing 
the analysis of all protein-coding exons in a single cost-eﬀective attempt.1 
 Hearing impairment (HI) is the most common sensory disorder with an incidence of 
one in 750 newborns (> 40 dB hearing loss) in developed countries.2 About half of the 
cases are attributed to genetic factors with more than a hundred syndromic and non-
syndromic genes known to date (http://hereditaryhearingloss.org/). HI is most frequently 
manifested as non-syndromic (NSHI) accounting for about 70% of the hereditary cases. 
About 77% of hereditary NSHI cases exhibit autosomal recessive inheritance (arNSHI) with 
62 genes and 92 loci known to date, whereas it is dominant (adNSHI) in about 22% of the 
cases with 36 genes and 58 loci known. The remaining 1% shows an X-linked, a Y-linked 
or a mitochondrial type of inheritance pattern with seven loci and six genes known to 
date (http://hereditaryhearingloss.org/). Thus, NSHI is a perfect example of a genetically 
heterogeneous disorder. Many genes have been described to be involved in only one or a 
few families with HI.3-5 Some exceptions are known, for example, mutations in GJB2 followed 
by mutations in STRC and MYO15A are the most common causes for arNSHI worldwide.6-9 
 Since many genes contribute to hereditary HI, targeting all or a selection of protein-
coding exons in a single experiment, as in WES, might currently be the best option 
for a comprehensive genetic analysis of HI individuals. The implementation of WES in a 
diagnostic setting has been much slower than in scientific research due to the relatively 
low sensitivity of this method in detection of genetic variation in some exonic regions, 
for example, extremely GC-rich regions, as compared to Sanger sequencing.10 Despite 
this fact, the diagnostic yield in hereditary HI obtained by WES is expected to be higher 
compared with the approach of phenotype-based pretesting of one or two genes by 
Sanger sequencing.11 Therefore, the aim of this study is to evaluate the diagnostic utility 
of WES targeting a panel of HI-related genes in a group of 200 Dutch index patients with 
presumed hereditary HI. 
Patients and Methods
Patients
A retrospective cohort study was performed in 200 patients with HI, mainly of Dutch origin, 
who underwent WES in diagnostics in the period of 2011-2014. Only index cases were 
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included. Non-genetic causes of the HI were considered to be unlikely on basis of medical 
history and ENT examination. Type of inheritance, age of onset, and phenotype were based 
on family history, medical history and available audiogram(s) (Supplemental Tables S2-S4). 
The inheritance pattern indicated by the referring clinician was autosomal dominant in 66 
cases, autosomal recessive in 31 cases, X-linked in one case and the remaining 102 cases 
were isolated. In the majority of subjects, the age of onset of HI was congenital (n=79) or 
in the first decade of life (n=60). Patients with both nonsyndromic and syndromic HI were 
included. The audiometric phenotype was assessed according to the recommendations by 
the GENDEAF study group.12 Thirty-six patients have been previously reported in a study on 
the utility of WES,11 and one patient has been reported before in a publication on novel and 
recurrent CIB2 variants.13 Prior to WES, causative variants in one or more genes involved in 
HI had been excluded by Sanger sequencing in 137 patients. Prescreening was performed 
in these patients because WES was not available at that time or because the clinician had 
a high clinical suspicion for mutations in a specific gene. Diagnostic WES was approved by 
the medical ethics committee of the Radboud university medical center, Nijmegen, the 
Netherlands (registration number 2011-188). For all patients, written informed consent for 
WES was obtained after counseling by a clinical geneticist. 
WES and bioinformatics
Prior to sequencing, genomic DNA fragments of all patients were enriched for exome 
sequences using the Agilent SureSelectXT Human All Exon 50 Mb kit (n=30) or the version 
4 (V4) kit (n=170). For 44 patients (30 cases Agilent 50 Mb, 14 cases Agilent V4), WES was 
performed with a 5500xl SOLiD system (Life Technologies) at the department of Human 
Genetics, Radboudumc Nijmegen, and data were analyzed using LifeScopeTM software as 
previously reported.11 For the remaining patients (n=156, Agilent V4) WES was performed 
at BGI-Europe (Copenhagen, Denmark), employing an Illumina HiSeq2000TM machine. For 
these samples, ‘read alignment’ using BWA and ‘variant calling’ with GATK were performed 
at BGI.14 
 For all patients, variants were annotated with an in-house developed annotation and 
prioritization pipeline.11 Variants in genes associated with HI were selected and analyzed. 
In the first 44 patients, a panel of 98 HI genes was analyzed (gene list DGD07092012).11 In 
2014, the gene panel was updated to 120 genes: four genes were deleted from the gene 
list, because proof for the involvement of the gene in HI is questionable, and 26 published 
novel HI-related genes were added (gene list DGD20062014). The remaining 156 patients 
were analyzed with the updated list of 120 HI genes. In retrospect, the WES data of the first 
44 patients were analyzed for variants in the 26 genes added to gene list DGD20062014. 
Detailed information on both gene lists can be found in Supplemental Table S1. 
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 The coverage was determined for the HI-related genes. The targeted genes enriched 
with the Agilent 50 Mb and Agilent V4 were compared with the longest RefSeq transcript 
to identify untargeted exons (Supplemental Table S1). These exons were omitted from 
coverage calculations. The coverage was calculated per sample on a base pair resolution, 
using the coverage function of BEDtools (v2.19.1; PMID 20110278). Subsequently, the mean 
percentage of base pairs with at least 20 reads (≥20x coverage) was determined per sample, 
for each gene and technological WES condition. Finally, the median ≥20x coverage was 
calculated per gene and technological WES condition. For all patients ‘copy number variant 
calling’ was carried out using CoNIFER 0.2.0,15 and variant annotation was performed using 
an in-house developed strategy.16
Interpretation and classification of variants 
To systematically predict their pathogenicity, variants were classified according to the 
existing guidelines from the American College of Medical Genetics and Genomics: benign 
(class 1), likely benign (class 2), uncertain significance (class 3), likely pathogenic (class 
4) and pathogenic (class 5).17 Patients were grouped based on the variant classification, 
segregation analysis and associated phenotype known from literature. Three groups were 
distinguished: (1) patients with causative variants, that is, (likely) pathogenic variant(s) 
matching the phenotype and segregating with the HI in the family; (2) patients with 
variants of uncertain significance, that is, variants that could not be further classified by 
segregation analysis or not matching the phenotype; and (3) patients without detected 
causative variants. All detected variants were submitted to the Leiden Open Variant 
Database (LOVD, http://databases.lovd.nl/shared/genes, patient IDs 79876, 79998, 80001-
80064, 80136, and 80138-80147).
Validation of selected variants
All reported sequence variants have been validated by Sanger sequencing (primer 
sequences and PCR conditions are available upon request). Copy number variants (CNVs) 
were validated by MLPA (STRC, homemade MLPA kit s139; USH2A, MRC-Holland kits P361A1 
and P362A2 or deletion-specific PCR (OTOA, kindly provided by Guney Bademci, MD).
Results
The exomes of 200 individuals with presumed hereditary HI, mostly of Dutch origin, were 
sequenced in this study. Subsequently, targeted analysis of WES data was performed for a 
panel of 120 genes (DGD20062014) associated with HI. A median coverage of at least 20x 
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was reached for 72.0% and 97.8% of the targeted genes with the SOLiD system (n=44), for 
the Agilent 50 Mb and V4 enrichment kits, respectively (Supplemental Figure S1a and b, 
Supplemental Table S1). The median coverage was 97.5% with the HiSeq system (n=156; 
Supplemental Figure S1c). The percentage of identified causative variants did not increase 
with improvement of the technological WES conditions. In 31.8% (n=14) of the samples 
performed with the SOLiD system causative variants were identified, compared to 34.0% 
(n=53) of the samples performed with the Illumina HiSeq2000TM (Supplemental Table S3).
Diagnostic yield with WES in HI patients
We identified causative variants in 33.5% (67 cases) out of 200 cases with presumed 
hereditary HI (Table 1, Supplemental Tables S2 and S3). In 44 of these patients, homozygous 
or compound heterozygous variants in genes associated with autosomal recessive HI (arHI) 
were detected, being large homozygous deletions of several exons or complete genes in 
eight of these cases. No causative heterozygous CNVs were identified. GJB2 was found to be 
the most frequently mutated gene (13.4% of positive cases), followed by USH2A, MYO15A 
and STRC, together accounting for 34.3% of the positive cases (Figure 1a).
 In the remaining 23 cases heterozygous causative variants in 11 diﬀerent genes 
associated with autosomal dominant HI (adHI) were found (Supplemental Table S2, Figure 
1b). In four cases, the heterozygous variants were de novo. Causative variants in MYO6 were 
the leading cause in this cohort of presumed adHI cases (Figure 1b).
 The diagnostic yield was related to the type of inheritance and the age of onset of HI 
in the patients. For patients with suspected arHI, the diagnostic yield was 58.1%, of which 
16.7% (n=3) caused by variants in GJB2 (Table 1, Supplemental Table S3). In 30.4% of the 
cases without a (known) family history of HI (isolated cases), the molecular etiology could be 
identified, the majority harboring causative variants in genes associated with arHI. In 19.4% 
(n=6) of these cases causative variants in GJB2 were found (Table 1, Supplemental Table 
S3). For adHI, causative variants were found in 27.3% of the cases (Table 1, Supplemental 
Table S3). Causative variant(s) could be identified in 49.4% and 36.7% of the subjects with 
congenital and 1st decade onset HI, respectively (Supplemental Table S3, Supplemental 
Figure S2). This percentage strongly declines with the increase in age of onset. 
 We identified variants of uncertain significance in 10 cases (5.0%) (Supplemental 
Tables S3 and S4). In eight of these, segregation analysis of the variant(s) could not be 
performed, because DNA of family members was unavailable. Segregation analysis is 
essential in order to classify these variants as causative or non-causative. In the remaining 
two cases segregation analysis was performed, but the variants could neither be classified 
as the cause of the HI, nor could they be discarded as not disease causing. In one case 
(AD19), the reported phenotype (unilateral HI) is diﬀerent from the type of HI known to 
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Figure 1 Overview of HI genes and number of cases in which causative variant(s) were identified in these 
genes. (a) Cases with autosomal recessive HI. (b) Cases with autosomal dominant HI.
Table 1 List of patients with causative variants in HI-related genes  
Patient Gene, RefSeq 
transcript ID 
Variant 1 
nucleotide change 
(protein change) 
Variant 2 
nucleotide change 
(protein change) 
Zygositya Segre-
gating 
with HIb 
AD1c MYO6 NM_004999.3 c.1546+1G>T (p.?) - het yes 
AD2 WFS1 NM_006005.3 c.2051C>T (p.Ala684Val)c - het ND 
AD3 TECTA 
ENST00000392793.1 
c.6002G>T 
(p.Cys2001Phe) 
- het de novo 
AD4 MYO7A 
NM_000260.3 
c.1373A>T (p.Asn458Ile)c - het yes 
AD5c MYO6 NM_004999.3  c.1211del 
(p.Gly404Glufs*4) 
- het yes 
AD6c MYH9 NM_002473.5 c.2507C>T (p.Pro836Leu) - het yes 
AD7 POU4F3 
NM_002700.2  
c.828_829insT (p.Lys277*) - het ND 
AD8 MYO7A 
NM_000260.3 
c.652G>A (p.Asp218Asn) - het yes 
AD9 POU4F3 
NM_002700.2  
c.668T>C (p.Leu223Pro)c - het ND 
AD10 MYO6 NM_004999.3 c.3395del 
(p.Lys1132Serfs*12) 
- het yes 
AD11 SOX10 NM_006941.3 c.1195C>T (p.Gln399*) - het ND 
AD12 MITF NM_000248.3 c.649del 
(p.Arg217Aspfs*4)c 
- het yes 
AD13 MYO7A 
NM_000260.3 
c.2617C>T (p.Arg873Trp)c - het yes 
AD14 TECTA 
ENST00000392793.1 
c.5794A>C 
(p.Thr1932Pro) 
- het yes 
AD15 MYH14 
NM_001145809.1 
c.5176C>T 
(p.Arg1726Trp) 
- het yes 
AD16 WFS1 NM_006005.3 c.2032T>C (p.Trp678Arg) - het yes 
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Table 1 (continued)  
Patient Gene, RefSeq 
transcript ID 
Variant 1 
nucleotide change 
(protein change) 
Variant 2 
nucleotide change 
(protein change) 
Zygositya Segre-
gating 
with HIb 
AD17 MYO6 NM_004999.3 c.584C>A (p.Ala195Glu) - het yes 
AD18 TECTA 
ENST00000392793.1 
c.5597C>T 
(p.Thr1866Met)c 
- het yes 
AR1c USH2A NM_206933.2 c.(9371+1_9372-
1)_(9570+1_9571-1)del 
(p.?) 
c.(9371+1_9372-
1)_(9570+1_9571-1)del 
(p.?) 
hom ND 
AR2 OTOA 
ENST00000388958 
c.(?_-1)_(*1_?)delc c.(?_-1)_(*1_?)delc hom ND 
AR3c CIB2 NM_006383.3 c.97C>T (p.Arg33*) c.196C>T (p.Arg66Trp) compound 
het 
yes 
AR4 STRC NM_153700.2 c.(?_-1)_(*1_?)delc c.(?_-1)_(*1_?)delc hom yes 
AR5 USH2A NM_206933.2 c.(8845+1_8846-
1)_(9371+1_9372-1)del 
(p.?) 
c.(8845+1_8846-
1)_(9371+1_9372-1)del 
(p.?) 
hom yes 
AR6 TMC1 NM_138691.2 c.646del 
(p.Leu216Serfs*54) 
c.790C>T (p.Arg264*) ND ND 
AR7 CDH23 NM_022124.5  c.6442G>A 
(p.Asp2148Asn)c 
c.1545_1547del 
(p.Ile515del)c 
compound 
het 
ND 
AR8 USH2A NM_206933.2 c.1606T>C (p.Cys536Arg)c c.9815C>T 
(p.Pro3272Leu)c 
compound 
het 
yes 
AR9 GJB2 NM_004004.5 c.35del (p.Gly12Valfs*2)c c.71G>A (p.Trp24*)c ND ND 
AR10 GJB2 NM_004004.5 c.35del (p.Gly12Valfs*2)c c.35del (p.Gly12Valfs*2)c hom ND 
AR11 CDH23 NM_022124.5 c.2096A>G (p.Asp699Gly) c.4562A>G 
(p.Asn1521Ser) 
compound 
het 
yes 
AR12 GJB2 NM_004004.5   c.-23+1G>A (p.?)c c.35del (p.Gly12Valfs*2)c compound 
het 
ND 
   c.5227C>T 
(p.Arg1743Trp)c 
  
AR13 MYO7A 
NM_000260.3  
c.3289C>T (p.Gln1097*) c.3862G>C 
(p.Ala1288Pro)c 
compound 
het 
ND 
AR14 STRC NM_153700.2 c.(?_-1)_(*1_?)delc c.(?_-1)_(*1_?)delc hom ND 
AR15 PCDH15 
NM_033056.3 
c.3374-2A>G (p.?) c.4127C>A 
(p.Ala1376Asp) 
compound 
het 
yes 
AR16 STRC NM_153700.2 c.(?_-1)_(*1_?)delc c.(?_-1)_(*1_?)delc hom ND 
AR17 LOXHD1 
NM_144612.6 
c.1618dup 
(p.Thr540Asnfs*24) 
c.1730T>G 
(p.Leu577Arg) 
compound 
het 
yes 
AR18 USH2A NM_206933.2 c.5018T>C 
(p.Leu1673Pro) 
c.2299del 
(p.Glu767Serfs*21) 
compound 
het 
ND 
c.7871C>T 
(p.Pro2624Leu) 
ISO1c MYO15A 
NM_016239.3 
c.625G>T (p.Glu209*) c.1137del 
(p.Tyr380Metfs*64)c 
ND ND 
ISO2c USH2A NM_206933.2 c.5385T>A (p.Tyr1795*) c.6846_6849dup 
(p.His2284Asnfs*48) 
ND ND 
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Table 1 (continued)  
Patient Gene, RefSeq 
transcript ID 
Variant 1 
nucleotide change 
(protein change) 
Variant 2 
nucleotide change 
(protein change) 
Zygositya Segre-
gating 
with HIb 
ISO3 CDH23 NM_022124.5  c.8480_8481del 
(p.Leu2827Hisfs*23) 
c.8480_8481del 
(p.Leu2827Hisfs*23) 
hom ND 
ISO4c MYO15A 
NM_016239.3 
c.6764+2T>A (p.?) c.3844C>T 
(p.Arg1282Trp) 
ND ND 
c.5287C>T 
(p.Arg1763Trp) 
ISO5 GJB2 NM_004004.5  c.101T>C (p.Met34Thr)17 c.109G>A (p.Val37Ile)17 compound 
het 
ND 
ISO6 WFS1 NM_006005.3 c.2051C>T (p.Ala684Val)2 - het ND 
ISO7 MYO15A 
NM_016239.3  
c.6787G>A (p.Gly2263Ser)  c.7893+1G>A (p.?) compound 
het 
ND 
ISO8 TRIOBP 
NM_001039141.2 
c.2653del 
(p.Arg885Alafs*120) 
c.5014G>T (p.Gly1672*) compound 
het 
ND 
ISO9 USH2A NM_206933.2 c.2299del 
(p.Glu767Serfs*21) 
c.920_923dup 
(p.His308Glnfs*16) 
compound 
het 
ND 
ISO10 MYO7A 
NM_000260.3 
c.3476G>T 
(p.Gly1159Val)c 
c.5560G>A 
(p.Val1854Met)c 
compound 
het 
ND 
ISO11 GJB2 NM_004004.5 c.250G>C(p.Val84Leu) c.269T>C (p.Leu90Pro)c ND ND 
ISO12 GJB2 NM_004004.5  c.109G>A (p.Val37Ile)c c.109G>A (p.Val37Ile)c hom ND 
ISO13 TMPRSS3 
NM_024022.2 
c.916G>A (p.Ala306Thr)c c.1276G>A 
(p.Ala426Thr)c 
ND ND 
ISO14 STRC NM_153700.2 c.(?_-1)_(*1_?)delc c.(?_-1)_(*1_?)delc hom ND 
ISO15 GJB2 NM_004004.5 c.35del (p.Gly12Valfs*2)c c.101T>C (p.Met34Thr)c compound 
het 
ND 
ISO16 ACTG1 
NM_001199954.1 
c.773C>T (p.Pro258Leu) - het de novo 
ISO17 GJB2 NM_004004.5 c.35del (p.Gly12Valfs*2)c c.508_511dup 
(p.Ala171Glufs*40)c 
compound 
het 
ND 
ISO18 MYO15A 
NM_016239.3 
c.3311dup (p.Glu1105*) c.3311dup (p.Glu1105*) hom ND 
ISO19 TRIOBP 
NM_001039141.2 
c.3460_3461del 
(p.Leu1154Alafs*29)  
 c.3232dup 
(p.Arg1078Profs*6)c 
compound 
het 
ND 
ISO20 MYO7A 
NM_000260.3 
c.5618G>A 
(p.Arg1873Gln)c 
c.6028G>A 
(p.Asp2010Asn)c 
compound 
het 
ND 
ISO21 MYO6 NM_004999.3 c.3610C>T 
(p.Arg1204Trp)c 
- het de novo 
ISO22 SLC26A5 
NM_198999.2 
c.355C>T (p.Pro119Ser) c.355C>T (p.Pro119Ser) hom ND 
ISO23 GJB2 NM_004004.5 c.101T>C (p.Met34Thr)c c.109G>A (p.Val37Ile)c compound 
het 
ND 
ISO24 SOX10 NM_006941.3 c.482G>A (p.Arg161His)c - het de novo 
ISO25 MYO6 NM_004999.3 c.3335A>G 
(p.Tyr1112Cys) 
c.1897del 
(p.Gln633Lysfs*19) 
compound 
het 
ND 
ISO26 LARS2 NM_015340.3  c.683G>A (p.Arg228His) c.880G>A (p.Glu294Lys) compound 
het 
ND 
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be associated with mutations in the gene (MYO7A). In another patient (AR19), two class 
3 variants in USH2A were found. The patient was 14 years old and had no signs of retinitis 
pigmentosa. The significance of the (previously unreported) USH2A missense variants in 
this patient is unclear and they cannot be definitely classified as causative for the HI in this 
patient, although they are located in trans and co-segregate with the HI.
 In our study, 61.5% of the 200 exomes (123 cases) did not reveal causative or putative 
causative variants. In the majority of them (95 cases), no putative causative variants 
remained after the data-filtering procedure. In 24 cases, the variants were not segregating 
with the HI in the family. In three cases, only a single variant was identified in a gene known 
to underlie arHI. In two of these patients (ISO41 and ISO45), the genes were analyzed 
with Sanger sequencing and/or MLPA, which did not reveal a second variant. In the third 
patient (AD65) a heterozygous variant c.1322C>T (p.Ser441Leu) was found in SLC26A5. As 
the patient had autosomal dominant, profound, asymmetric HI with an onset in the sixth 
decade, the phenotype was not compatible with DFNB61. Therefore, the SLC26A5 gene was 
not further analyzed. Finally, in one case (ISO87), a class 3 variant was identified in NLRP3, 
a gene known to underlie autosomal dominant cryporin-associated periodic syndromes, 
for example, Muckle-Wells syndrome.18 Further clinical evaluation in the patient revealed, 
however, no evidence for this syndrome and the variant was therefore considered not to be 
the cause of the HI. 
Prescreening of single genes
In 137 patients (68.5%), one or more HI-related genes had been prescreened with Sanger 
Table 1 (continued)  
Patient Gene, RefSeq 
transcript ID 
Variant 1 
nucleotide change 
(protein change) 
Variant 2 
nucleotide change 
(protein change) 
Zygositya Segre-
gating 
with HIb 
ISO27 OTOA 
ENST00000388958 
c.(?_-1)_(*1_?)delc c.(?_-1)_(*1_?)delc hom ND 
ISO28c COL11A1 
NM_001854.3 
c.1630-2del (p.?) - het ND 
ISO29 LOXHD1 
NM_144612.6  
c.3061+1G>A (p.?) c.6353G>A 
(p.Gly2118Glu) 
ND ND 
ISO30 LOXHD1 
NM_144612.6  
c.3061C>T (p.Arg1021*) c.5885C>T 
(p.Thr1962Met) 
compound 
het 
ND 
ISO31 SLC26A4 
NM_000441.1  
c.505del 
(p.Thr169Leufs*3) 
c.1334T>G 
(p.Leu445Trp)c 
compound 
het 
ND 
AD, autosomal dominant; AR, autosomal recessive; HI, hearing impairment; het, heterozygous; hom, 
homozygous; ISO, isolated; ND, not determined or not conclusive. aZygosity, determined on basis of 
segregation analysis in the parents. bSegregating with HI, determined on basis of segregation analysis in 
aﬀected and/or unaﬀected family members. cMutations that have been described in literature before, the 
corresponding references are provided in Supplemental Table S2. 
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sequencing prior to WES (Tables 2a and b). On average, 1.5 genes were pretested per 
individual. The numbers of individuals with pretests and the number of pretested genes 
were comparable between the groups of inheritance and between the groups of patients 
with causative variants, variants of uncertain significance and without detected causative 
variants. GJB2 was most frequently tested (80 times), followed by TECTA (36 times). Although 
prescreening in these 137 patients was negative and therefore WES was performed, it is 
known that patients with a specific phenotype associated with mutations in one or a few 
genes (eg, Pendred syndrome) are quite often solved by targeted testing.19 
 To evaluate the utility of prescreening in individuals with HI, we made an overview of all 
in-house gene analysis requests for HI in 2013-2014 and the diagnostic yield (Supplemental 
Table S5). The vast majority of these tests were performed in patients of Dutch origin. The 
three genes with the highest diagnostic yield were COCH (36.8%), KCNQ4 (15.4%) and GJB2 
(7.2%). For these three genes, founder or hotspot mutations occur in the Dutch population 
explaining the high incidence of mutations found in DNA diagnostics.20-22 The diagnostic 
yield for COL11A1, DFNA5, EYA1, MYO7A, NDP, OTOF, SLC26A4 and USH2A was higher than 
10%, but the number of requests was less than 10 times. Therefore, the diagnostic yield for 
these genes is not reliable.
Table 2a Single gene tests prior to WES per category 
 Categories Subcategories No. of individuals with 
single gene test(s) (%) 
No. of single gene tests 
(per individual) 
No. of individuals with 
GJB2/GJB6 test (%) 
WES result  Causative variant(s)  45 (67.2%) 101 (1.5) 32 (47.8%) 
Variant(s) of 
uncertain 
significance 
8 (80.0%) 17 (1.7) 4 (36.4%) 
No detected 
causative variant(s) 
84 (68.3%) 188 (1.5) 44 (35.8%) 
Inheritance adHI 45 (68.2%) 106 (1.6) 11 (16.7%) 
arHI 24 (77.4%) 43 (1.4) 17 (54.8%) 
Isolated HI 67 (55.8%) 154 (1.5) 51 (50.0%) 
X-linked HI 1 (100.0%) 3 (3.0) 1 (100.0%) 
 
Discussion
In this study, we aimed to evaluate the diagnostic yield of WES-based targeted analysis 
of genes involved in HI. WES technology allowed the eﬃcient identification of single-
nucleotide variants, small insertions or deletions (indels) and large deletions that aﬀect the 
protein coding regions of HI genes in a single experiment.11 Our study underlines the great 
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genetic heterogeneity of HI, as causative variants were found in 26 diﬀerent genes (Table 
1, Figure 1). 
 In 61.5% of the cases, no causative variants were identified in the targeted HI-related 
genes. A part of these cases might be explained by variants that are not identified due 
to insuﬃcient enrichment or coverage.23 Although coverage has greatly improved over 
time (Supplemental Figure S1, Supplemental Table S1), the identification rate of causative 
variants has remained stable (Supplemental Table S3). This implies that part of the causative 
variants in known HI genes cannot be identified by WES, for example deep intronic variants 
aﬀecting splicing, variants in non-coding exons, repeat regions and regulatory regions. 
Table 2b Single gene tests prior to WES per gene 
Gene No. of requests Gene (continued)! No. of requests (continued) 
Total 306 COLL11A2 2 
GJB2/GJB6 80 POUF4F3 2 
TECTA 36 PTPRQ 2 
KCNQ4 18 TMC1 2 
COCH 16 CDH23 1 
COL11A2 15 DFNB59 1 
SLC26A4 15 EYA 1 
TMPRSS3 14 EYA1 1 
MYO6 10 FMR1 1 
POU4F3 10 KCNE1 1 
ACTG1 9 KCNQ 1 
WFS1 8 KCNQ1 1 
Asper array 6 POLR1C 1 
EYA4 6 POLR1D 1 
USH2A 6 POU3F4 1 
MITF 5 RP-R 1 
MYO7A 5 SIX1 1 
DFNA5 4 SIX5 1 
MYO15A 4 SMPX 1 
PAX3 4 SNAI2 1 
DIAPH1 3 SOS1 1 
OTOF 3 TCOF1 1 
Array 2 TIMM8A 1 
adHI, autosomal dominant hearing impairment; arHI, autosomal recessive hearing impairment.  
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Another part of the cases without detected causative variants may be explained by 
mutations in yet undiscovered genes. There are tens of HI-related loci known, of which 
the causative gene is still not identified (http://www.hereditaryhearingloss.org/). As de 
novo variants in known adNSHI genes were identified in four of the cases in our study, 
we hypothesize that novel genes for adNSHI can be identified by a de novo strategy (ie, 
sequencing aﬀected individuals and their unaﬀected parents).24 For the isolated cases, 
comprising about half of the subjects in this study, involvement of non-genetic causes 
cannot be fully excluded. Also, in subjects with late-onset HI non-genetic causes or a 
combination of (multiple) genetic and non-genetic factors cannot be discarded, despite 
the thorough patient evaluation. This could well explain why no variants were identified 
in the 16 subjects with an age of onset in the fifth or sixth decade (Supplemental Table S3, 
Supplemental Figure S2). 
 Variants of uncertain significance were mainly reported for patients without a family 
history of HI (isolated cases) or presumed adHI (Supplemental Tables S3 and S4). As in most 
of these cases no family members were available for segregation analysis, the causality 
of these variants remained unclear. This highlights the importance of taking an accurate 
family history and collecting clinical data and DNA samples of family members. In addition, 
it is essential to provide a thorough description of the phenotype of the patient in order to 
evaluate whether the gene with the identified variant has previously been associated with 
this specific phenotype.
 A subset of patients (36 cases) in the present study was previously reported by 
Neveling et al.11 In 16 out of these 36 cases likely causative variants were identified, leading 
to a diagnostic yield of 44.4% for WES in HI.11 However, in nine of these families segregation 
analysis was still needed to confirm the genetic diagnosis. This analysis was performed in 
the current study and in seven families the variants did not segregate with the HI. This 
lowers the diagnostic yield of the cases included in the study by Neveling et al. to 22%, 
which is comparable to the yield in our study and again underlines the importance of 
segregation analysis.
 The wide use of WES in routine diagnostics and research is producing large amounts 
of data on sequence variants in HI. Variants that have initially been reported as causative, 
based on the knowledge at that time, might be reclassified as benign due to increasing 
availability of allele frequency data.25 This highlights the importance of population-based 
allele frequency data to evaluate the causality of variants. However, rare variants can still 
be diﬃcult to classify. We identified novel missense variants in USH2A (AR19) and classified 
these as variants of uncertain significance, despite the fact that (1) they are predicted 
to be damaging, (2) they were not reported in any public database so far and (3) they 
segregated with the hearing impairment in the corresponding family. The patient did 
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not show symptoms of retinitis pigmentosa at the age of 14 years, but visual symptoms 
in Usher syndrome type 2 normally start in the second decade of life.26 Without support 
from functional studies, the pathogenicity of these missense variants will remain uncertain, 
since Petrovski et al.27 calculated a residual variation score of 4.18 for USH2A (75th percentile 
of scored genes, frequency data based on NHLBI Exome Sequencing Project) suggestive 
of a great tolerance of this gene to genetic variation. This is casting some doubt on the 
extensive variation in USH2A reported as likely pathogenic in public databases such as the 
LOVD. Importantly, these uncertainties are extremely diﬃcult for genetic counseling, as 
parents have to be informed about the possible development of Usher syndrome in their 
children.
 CNV detection in our cohort could identify large homozygous deletions in 4% of the 
cases, which is comparable to the 1.5-7.3% presented in the literature.28-34 A relatively high 
frequency of STRC deletions was found in our Dutch population (2%), as has also been 
reported in other populations.8,9 In one case (ISO31), we found causative variants in a 
gene that is associated with an identifiable phenotype and segregating with a recessive 
inheritance pattern. This patient had an incomplete partition of the cochlea and mutations 
in SLC26A4.35 We did not find other cases with an identifiable phenotype such as progressive 
HI with a downsloping audiogram caused by TMPRSS3 mutations,7,36 and the stable HI with 
a cookie-bite audiogram configuration caused by mutations in TECTA.7 This is most likely 
due to the fact that these genes are generally pretested in patients with these identifiable 
phenotypes.
 In our cohort, the diagnostic yield of WES targeting a panel of HI-related genes is 33.5%. 
Other studies using massively parallel sequencing have reported similar overall diagnostic 
rates, despite of using diﬀerent technologies and testing diﬀerent populations.32-34,37,38 
We found that causative variants in GJB2, USH2A, MYO6, STRC and MYO15A underlie HI in 
14.0% of the cases in our cohort. This is in agreement with previously published studies 
on the involvement of HI genes in other populations.6-9,32-34,36,38-40 The diagnostic yield of 
WES targeting a panel of HI-related genes is generally higher than that of single gene 
testing. Therefore, we recommend to reduce prescreening of single genes to a minimum. 
As the utility and yield of prescreening of single genes prior to WES is population specific, 
our recommendations apply in particular for the Dutch population. We suggest that for 
nonsyndromic congenital or 1st decade onset HI it would be cost-eﬀective to prescreen 
GJB2, because of its relatively frequent association with HI. For recognizable phenotypes 
(such as Pendred syndrome, Waardenburg syndrome and Usher syndrome) or for genes 
with a relatively common founder mutation in a specific population (such as mutations in 
COCH in the Dutch and Belgian population)20 prescreening of specific genes might still be 
useful. This is supported by the relatively high diagnostic yield of targeted sequencing of 
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GJB2 (7.2%) and COCH (36.8%). In all other cases, we recommend to perform WES targeting 
a panel of HI-related genes as a first diagnostic test.
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Figure S1 Percentage of ≥20x coverage per gene for each technological WES condition.
The boxplots show the percentage of base pairs covered by at least 20 reads per gene (DGD20062014, 120 
genes) and technological WES condition. Outliers are depicted as dots, representing individual samples. (a) 
Coverage of samples (n=30) enriched with the Agilent 50Mb kit and sequenced on the 5000xl SOLiD system. 
(b) Coverage of samples (n=14) enriched with the Agilent V4 kit and sequenced on the 5000xl SOLiD system. 
(c) Coverage of samples (n=156) enriched with the Agilent V4 kit and sequenced on the HiSeq2000TM 
system.
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Figure S2 Diagnostic yield of WES targeting a panel of HI-related genes, based on age of onset of HI. One 
individual with late-onset HI was ommited from this analysis, because the exact age of onset was unknown. 
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Table S5 Diagnostic yield for targeted sequencing of single genes 
Gene symbol No. of requests No. of positivea requests % of positivea requests per gene 
ACTG1 17 0 0 
BSND 1 0 0 
CLRN1 1 0 0 
COCH 19 7 36.8 
COL11A1 1 1 100 
COL11A2 35 0 0 
COL2A1 1 0 0 
DFNA5 5 1 20 
DFNB59 2 0 0 
DIAPH1 8 0 0 
EYA1 9 1 11.1 
EYA4 22 0 0 
GJB2 69 5 7.2 
GRXCR1 1 0 0 
HOXA2 1 0 0 
KCNQ4 26 4 15.4 
MITF 18 1 5.6 
MYO15A 3 0 0 
MYO6 16 0 0 
MYO7A 3 1 33.3 
NDP 1 1 100 
OTOF 4 2 50 
OTOG 3 0 0 
OTOGL 3 0 0 
PAX3 14 1 7.1 
POU3F4 1 0 0 
POU4F3 11 0 0 
PTPRQ 1 0 0 
SIX1 5 0 0 
SIX5 5 0 0 
SLC26A4 8 2 25 
SNAI2 10 0 0 
SOX10 2 0 0 
TECTA 47 2 4.3 
TMC1 2 0 0 
| Chapter 2
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Table S5 (continued) 
Gene symbol No. of requests No. of positivea requests % of positivea requests per gene 
TMPRSS3 36 2 5.6 
TSHZ1 3 0 0 
USH2A 5 1 20 
WFS1 17 1 5.9 
aPositive indicates that causative variants were identified. 
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Abstract
DFNB28 is characterized by prelingual, severe to profound sensorineural hearing impairment 
(HI). It is associated with mutations in exon 6 and 7 of TRIOBP and has not been reported 
in the European population. Here, we describe two isolated cases of Dutch origin with 
congenital, moderate HI and compound heterozygous mutations in TRIOBP. Three of the 
mutations are novel, one nonsense mutation (c.5014G>T (p.Gly1672*) and two frameshift 
mutations (c.2653del (p.Arg885Alafs*120) and c.3460_3461del (p.Leu1154Alafs*29). 
The fourth mutation is the known c.3232dup (p.Arg1078Profs*6) mutation. Longitudinal 
audiometric analyses in one of the subjects revealed that HI was stable over a period 
of 15 years. Vestibular function was normal. Predicted eﬀects of the mutations do not 
explain the relatively mild phenotype in the presented subjects, whereas location of the 
mutation might well contribute to the milder HI in one of the subjects. It is known that 
isoform classes TRIOBP-4 and TRIOBP-5 are important for stereocilia stability and rigidity. 
To our knowledge, p.Gly1672* is the first pathogenic variant identified in DFNB28 that 
does not aﬀect isoform class TRIOBP-4. This suggests that a single TRIOBP copy to encode 
wild-type TRIOBP-4 is insuﬃcient for normal hearing, and that at least one TRIOBP copy to 
encode TRIOBP-5 is indispensable for normal inner ear function. Furthermore, this study 
demonstrates that DFNB28 can be milder than reported so far and that mutations in TRIOBP 
are thus associated with a heterogeneous phenotype.
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Introduction
DFNB28 (MIM #609823) is a rare type of autosomal recessive hereditary hearing impairment 
(HI), caused by mutations in TRIOBP (MIM #609761). It was first described by Riazuddin et 
al. and Shahin et al. in 2006, who mapped DFNB28 to chromosome 22q13.1 and found that 
mutations in TRIOBP were segregating with HI in 15 families.1,2 To date, 22 families with 
(likely) pathogenic mutations in TRIOBP have been reported in literature, originating from 
the USA, China, India, Iran, Pakistan, Palestine, South Africa and Turkey. The majority of 
these families are consanguineous. All patients show prelingual, severe to profound HI.1-7 
To our knowledge, DFNB28 has not been described in the European population.
 TRIOBP encodes TRIO - and filamentous-actin-Binding Protein, which plays an 
important role in the stability and rigidity of hair cell stereocilia in the inner ear.8 Stereocilia 
are mechano-sensory structures, which are located on the apical surface of hair cells. 
Sound-induced deflections of the stereocilia bundle change the open probability of 
the mechanotransduction channel and thereby induce electrochemical signals that 
are transmitted via the cochlear nerve to the auditory cortex.9 Hair cell stereocilia need 
to endure an infinite number of sound-induced deflections. Especially the pivot point of 
stereocilia, which is located at its insertion point in the cuticular plate of the cochlear hair 
cell,10 needs to sustain the repeated mechanical stress. Rigidity and stability of stereocilia 
is secured by rootlets, flexible structures that anchor the base of the stereocilia into the 
cuticular plate.11,12 Rootlets are formed by densely packed, tapered actin filaments at the 
base of each stereocilium.13 It has been shown that the Triobp mouse mutant (Triobp∆ex8/
∆ex8) fails to form normal rootlets, although the remaining part of the stereocilia develop 
normally. Upon stimulation of stereocilia of the Triobp∆ex8/∆ex8 mouse, hyperflexibility 
of the stereocilia and decreased pivot stiﬀness was observed, followed by progressive 
degeneration of the stereocilia. As a result, Triobp∆ex8/∆ex8 mice are profoundly deaf from an 
early age.8 This mimics DFNB28 in human and explains the severity and prelingual onset of 
HI. 
 It has been shown that specific classes of TRIOBP isoforms are involved in the 
formation of stereocilia rootlets.8 According to Kitajiri et al. (2010), TRIOBP isoforms can be 
grouped into three classes: TRIOBP-5, TRIOBP-4 and TRIOBP-1.8 TRIOBP-5 (NM_001039141) 
is encoded by the longest transcripts (exons 1-24) with a translation start site in exon 3. 
TRIOBP-4 (DQ228004) is encoded by exons 2-7 (previously known as exons 1-6) and 
translation occurs from an alternative translation start site in exon 6. TRIOBP-1 (NM_007032) 
is encoded by exons 11a-24 and translated from a translation start site in exon 11a (Figure 2). 
TRIOBP-4 and TRIOBP-5 are preferentially expressed in the inner ear and the eye; TRIOBP-1 
is ubiquitously expressed. As already indicated, Triobp∆ex8/∆ex8 mice, which lack exon 8, are 
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deaf. Mouse exon 8 is orthologous to human exon 7, previously known as human exon 
6, and present in TRIOBP-4 and TRIOBP-5. Mice deficient for TRIOBP-1 are not viable. This 
indicates that TRIOBP-4 and/or TRIOBP-5 are essential for hearing, whereas TRIOBP-1 is 
indicated to be involved in processes essential for mouse development.8 This is in line with 
the fact that all known pathogenic mutations associated with DFNB28 are located in exon 7, 
and only aﬀect TRIOBP-4 and TRIOBP-5.1-4,8 Localization experiments by Kitajiri et al. (2010) 
revealed that TRIOBP-4 localizes along the length of the stereocilia actin filaments, whereas 
TRIOBP-5 is only detected in the rootlets. Further in vitro studies showed that TRIOBP-4 
alone is suﬃcient to organize filamentous-actin into dense bundles, which resemble 
stereocilia rootlets in vivo.8 The interfilament spacing of the bundles is unusually small, 
which might suggest that TRIOBP wraps around the actin filaments externally instead of 
cross-linking.8,14 The precise formation and maintenance of stereocilia rootlets and the role 
of TRIOBP-4 and/or TRIOBP-5 in this process is still elusive.
 The present study describes mutations in TRIOBP in two Dutch isolated cases with 
moderate, stable HI. This demonstrates that HI in DFNB28 can be milder than reported so 
far and also occurs in the European population. We provide an overview of the genotype-
phenotype characteristics of DFNB28 and seek to find a correlation between the severity of 
HI and the genotype.
Subjects and Methods
Subject evaluation
Medical history was obtained from the participants of the Dutch families 14-00692 and 
W15-2079, using a questionnaire focusing on hearing and balance. Ear, nose and throat 
examination was performed in all subjects to exclude acquired causes of HI. Pure-tone 
audiometry was performed in a sound-treated room according to current standards. Air 
conduction thresholds were determined at 0.25, 0.5, 1, 2, 4, and 8 kHz in dB HL. Bone 
conduction thresholds were determined at 0.5, 1, 2, 4, and 8 kHz in dB HL, to exclude 
conductive HI. In the proband (II:1) of family 14-00692, hearing was assessed at the age of 
one month, by use of Brainstem Evoked Response Audiometry (BERA) according to current 
standards. At the age of two years, visual reinforcement audiometry with a bone conductor 
and with headphones was performed by an experienced paediatric audiologist and 
hearing thresholds were determined at 0.5, 1, 2 and 4 kHz in dB of HL. For all participants, 
the 95th percentile threshold values of presbyacusis (p95) were calculated for each 
frequency and matched to the individual’s sex and age, according to the ISO 7029 standard. 
HI was described according to the recommendations by the GENDEAF study group.15 In 
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the index case (III:1) of family W15-2079, speech-recognition and vestibular function were 
assessed. Speech audiometry was performed in quiet, using standard monosyllabic Dutch 
word lists.16 Vestibular function was assessed by electronystagmography, including a video 
head impulse test, rotary, and caloric tests.17 This study was approved by the medical ethics 
committee of the Radboud university medical center. Informed consent was obtained from 
all participants or their legal representatives. 
Mutation analysis
Genomic DNA was isolated from peripheral blood using standard techniques. In the index 
cases (family 14-00692, II:1 and family W15-2079, III:1) whole exome sequencing (WES) 
was performed. First, the exome was enriched using the Agilent SureSelect version 4 kit. 
Subsequently, WES was performed on an Illumina HiSeq system by BGI-Europe (Denmark). 
A panel of 120 HI-related genes (Supplemental Table S1) was analyzed and variants were 
selected based on variant classification guidelines,18 for short description also see Neveling 
et al. (2012).19 A potential eﬀect of the TRIOBP variants was predicted with Alamut Visual 
(Interactive Biosoftware). Allele frequencies of the identified variants were obtained from 
the Exome Aggregation Consortium (ExAC) database and our in-house database that 
contains whole exome sequencing data of 13314 individuals, the vast majority of Dutch 
origin, aﬀected by a large number of diﬀerent diseases (including 810 patients with hearing 
impairment) and also non-aﬀected individuals. Exons of TRIOBP that were not completely 
covered in WES were Sanger sequenced. The identified variants in TRIOBP (NM_001039141) 
were confirmed by Sanger sequencing. Segregation analysis in family members was 
performed to determine compound zygosity and co-segregation of the mutation with the 
HI in the family. Primer sequences and PCR conditions are available upon request.
Results
Moderate HI in family 14-00692
The index case (II:1) of family 14-00692 (Figure 1a) presented with congenital, bilateral 
HI, detected during neonatal hearing screening and confirmed by BERA at the age of one 
month. This BERA revealed hearing thresholds of 70 dB HL in the lower frequencies and 
80 dB HL in the higher frequencies with slight total wave delay, indicating a conductive or 
mixed HI. Repeated visual reinforcement audiometry with a bone conductor, performed 
at the ages of 1 and 2 years, showed moderate HI on the left side. Visual reinforcement 
audiometry with headphones, performed at the age of 2 years, showed a conductive 
component of the hearing impairment (Figure 1b). Repeated tympanometry displayed 
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a flat curve, indicating otitis media with eﬀusion. Hearing thresholds on the right ear 
were not determined during these examinations. There were no associated symptoms, 
such as dysmorphology, vestibular problems, delayed motor development or intellectual 
disability. Acquired causes of HI could most certainly be excluded by history taking, 
physical examination and a negative cytomegalovirus test. The parents (I:1 and I:2) had 
normal hearing. There were no other family members with HI and there was no history of 
consanguinity in the family.
 With HI gene-panel analysis, a heterozygous mutation was detected in TRIOBP, 
c.3232dup (p.Arg1078Profs*6) in exon 7 (Figure 2). This mutation has been reported 
homozygously in two Indian families with profound HI (Table 1).1 Sanger sequencing of 
the exons that were not completely covered in the WES data resulted in detection of a 
second variant, c.3460_3461del (p.Leu1154Alafs*29) in exon 7 (Figure 2). This variant 
was novel and considered to be pathogenic as it is predicted to introduce a premature 
stop codon, and because it is very rare (Table 1). Segregation analysis in the unaﬀected 
parents demonstrated that the father carried the c.3232dup mutation (Figure 1a). The 
second mutation could not be traced in the parents. A common SNP (rs5756795, C/T) is 
located in proximity to the c.3460_3461del mutation. Segregation analysis of this SNP 
and the c.3460_3461del mutation revealed that this mutation occurred de novo on the 
maternal allele or that germline mosaicism existed in the mother (Supplemental Figure 
S1). No potentially pathogenic variants were identified in other HI-related genes that were 
targeted in our analysis.
Moderate, stable HI in family W15-2079
The proband (III:1) of family W15-2079 suﬀered from congenital, symmetric, moderate, high 
frequency sensorineural HI (Figure 1). Longitudinal analyses of audiograms over a period 
of 15 years revealed no progression of HI up to the age of 28 years. Speech audiometry 
showed a maximum phoneme score of 100% without hearing aids. Acquired causes of HI 
could be excluded by medical history and ear, nose and throat examination. There were no 
complaints of balance problems and electronystagmography showed normal vestibular 
function. Audiological evaluation of family members I:2, II:1, III:2 and III:3 demonstrated 
normal hearing. The father (II:2) of the proband was physically not able to participate in the 
study. Family history was negative for HI and consanguinity.
 HI gene-panel analysis revealed two novel variants in TRIOBP: c.2653del 
(p.Arg885Alafs*120 in exon 7 and c.5014G>T (p.Gly1672*) in exon 9 (Figure 2). The variants 
were considered to be causative, because 1) they are damaging (a premature stop codon is 
predicted to be introduced), 2) they have a very low global and population-specific minor 
allele frequency (Table 1), 3) they are located in trans, and 4) they co-segregate with the HI 
Broadening the phenotype of DFNB28 |
73
3.1
in the family (Figure 1a). No possibly pathogenic variants were identified in other HI-related 
genes that were targeted in our analysis.
Figure 1 Family 14-00692 and W15-2079
(a) Pedigrees and segregation analyses of the identified mutations in TRIOBP. (b) Pure-tone audiograms of the 
aﬀected individuals, showing moderate HI (14-00692, II:1 measured with visual reinforcement audiometry, 
besides the sensorineural HI there is a conductive component due to otitis media with eﬀusion). HI in W15-
2079, III:1 was stable over a period of 15 years.
Figure 2 Pathogenic mutations in TRIOBP
Schematic representations of the genomic structure and alternative transcript classes of TRIOBP: TRIOBP-5 
(NM_001039141, RefSeq), TRIOBP-4 (DQ228004, GenBank) and TRIOBP-1 (NM_007032, RefSeq). Previously 
published (likely) pathogenic mutations (depicted in grey) and novel mutations identified in this study 
(depicted in black) are shown. 
, alternative translation start site; * (alternative) stop codon.
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3.1
Discussion
In this study, we present two isolated cases of Dutch origin with hereditary moderate HI 
caused by compound heterozygous mutations in TRIOBP. The three novel and one known 
truncating mutations were identified by WES targeting a panel of HI-related genes and 
Sanger sequencing, and segregated with HI in the family. Table 1 represents an overview of 
the TRIOBP variants that have been reported in this and previous studies. DFNB28 displays 
allelic heterogeneity, as many other types of genetic HI. To date, 21 (likely) pathogenic 
mutations have been reported in homozygous or compound heterozygous state, viz. 
14 nonsense, 6 frameshift and 1 missense mutations, all located in exons 6 and 7, which 
were previously described as exons 5 and 6 (Table 1, Figure 2).1-4,8 We assumed the 4 
mutations described by Kitajiri et al. (2010) to be present in homozygous state although 
this is not clearly indicated by the authors. In addition, 13 missense variants of uncertain 
significance have been published.4,20 The pathogenicity of these variants is unclear, 
because no mutations of the second allele were identified, prediction programs were 
inconclusive about the pathogenicity of the variant, and/or segregation analysis has not 
been performed. In addition, some of these missense variants are relatively frequent found 
in control populations, which casts doubt on their pathogenicity  (Table 1, minor allele 
frequency ExAC database).
 Published phenotypic data of DFNB28 families showed that aﬀected individuals 
suﬀered from prelingual, severe to profound HI (Table 1).1,2,4-7,22 One case reported by Gu et 
al. (2015) had asymmetric, moderate (right ear) to severe (left ear) HI.4 Another case reported 
by Sloan-Heggen et al. (2016) suﬀered from mild to moderate HI. However, in both cases the 
identified missense variants are of uncertain significance. In this study, sensorineural HI in 
both cases is moderate. The reliability of the thresholds determined in visual reinforcement 
audiometry could be questioned as the index case of family 14-00692 is only 2 years old. 
However, the thresholds measured with headphones are comparable to those measured 
with BERA. In addition, repeated measurements with a bone conductor show comparable 
sensorineural thresholds. Until now, repeated audiometry shows no hearing deterioration 
of the subject, although future progression of HI cannot be excluded. Importantly, HI in 
the aﬀected subject of family W15-2079 was stable over a period of 15 years and remains 
moderate at the age of 28 years. This indicates that the moderate HI is not related to an 
early stage of disease. Our results therefore provide evidence that mutations in TRIOBP can 
be associated with moderate, stable HI. 
 All but two previously reported (likely) pathogenic mutations are predicted to result 
in premature protein truncation as are the mutations presented in this study (Table 1). 
Therefore, we conclude that the relatively mild phenotype observed in the subjects 
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presented here is unlikely to be explained by the type of mutations.
 The TRIOBP mutations in family W15-2079 are located in exon 7 (c.2653del) and exon 
9 (c.5014G>T). The latter exon is only present in the mRNA for isoform class TRIOBP-5. 
Since the isoform classes TRIOBP-4 and TRIOBP-5 have a diﬀerent distribution along the 
stereocilia and their rootlets,8 it may well be that the location of the mutations and thus the 
aﬀected isoform(s) explain the milder HI in this family. However, the mutations identified 
in family 14-00692 are both located in exon 7, and aﬀect both isoform classes TRIOBP-4 
and TRIOBP-5, as is the case in all previously published mutations associated with DFNB28 
and severe to profound HI. In this family, therefore the location of the mutations is unlikely 
to explain the milder DFNB28 phenotypes. This implies that diﬀerent genetic factors may 
underlie or contribute to the milder phenotype in the two families. Candidate factors are 
variants in other proteins that function in the stereociliary rootlet or variation in their level 
of expression and diﬀerences in eﬃcacy of nonsense mediated decay of the mutated 
TRIOBP mRNA. 
 To our knowledge, c.5014G>T is the first pathogenic TRIOBP variant identified in a 
patient with DFNB28 that does not aﬀect TRIOBP-4. This implies that a single gene copy to 
encode wild-type TRIOBP-4 is insuﬃcient for the formation of normal stereocilia rootlets, 
and/or that at least one gene copy to encode wild-type TRIOBP-5 is required for normal 
hearing. This is in line with the diﬀerential localization of the protein isoforms, showing that 
TRIOBP-4 was detected along the entire length of the stereocilia, whereas TRIOBP-5 was 
only found to be located at the rootlets of stereocilia.8
 We assessed the vestibular function to extend the insight in the DFNB28 phenotype. 
The lack of complaints of imbalance and normal motor development in the presented 
subjects in combination with normal electronystagmography in family W15-2079 
suggested vestibular function to be normal. This is in line with previous research by 
Riazuddin et al. (2006), who described that subjects with DFNB28 have no vestibular 
symptoms and normal vestibular function.1 Whether the vestibular organ is dysfunctioning 
in Triobp mouse mutants has not been reported.
 Our findings highlight the importance of providing an extensive description of the 
phenotype when mutations underlying HI are reported in literature, including audiometric 
data, vestibular symptoms and/or function and presence of syndromic features. Such 
descriptions were not available for a number of the published TRIOBP mutations. 
Phenotypic characterizations are essential for expanding our knowledge on genotype – 
phenotype correlations for HI. This enables clinicians to provide adequate counseling on 
prognosis and rehabilitation options.
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3.1
Conclusions
DFNB28, caused by mutations in TRIOBP, was known to be associated with prelingual, 
severe to profound HI. We identified three novel mutations and one known mutation in 
TRIOBP in two Dutch isolated cases with moderate HI. Longitudinal audiometric analysis 
in one of these subjects demonstrated that the HI is stable over a period of 15 years. These 
data indicate that DFNB28 can be less severe than reported so far and that the phenotype 
associated with mutations in TRIOBP is heterogeneous. Predicted eﬀect of the mutations 
does not explain the less severe phenotype in the presented subjects, whereas location of 
the mutations could probably explain the milder HI in only one of the subjects. Vestibular 
function was found to be normal.
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Supplemental data
Figure S1 Segregation analysis family 14-00692.
(a) Sequence analysis showed that both the index patient and the father carry the c.3232dup mutation in 
TRIOBP. (b) Sequence analysis demonstrated that the index case and the father carry a heterozygous SNP 
(rs5756795, C/T), which lies in proximity to the c.3460_3461 del mutation. (c) Analysis of the WES paired-
reads demonstrated that the second variant c.3460_3461del was located in reads that do not harbor the 
SNP (indicated by the red boxes), revealing that this mutation occurred de novo on the maternal allele or that 
germline mosaicism existed in the mother.
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Table S1 Analyzed panel of 120 HI-related genes 
Gene name RefSeq transcript 
ID 
Gene name 
(continued) 
RefSeq transcript 
ID (continued) 
Gene name 
(continued) 
RefSeq transcript 
ID (continued) 
ACTB NM_001101.3 GPR98 NM_032119.3 SLC17A8 NM_139319.2 
ACTG1 NM_001199954.1 GPSM2 NM_013296.4 SLC26A4 NM_000441.1 
ADCY1 NM_021116.2 GRHL2 NM_024915.3 SLC26A5 NM_198999.2 
ATP6V1B1 NM_001692.3 GRXCR1 NM_001080476.2 SLC33A1 NM_004733. 
BDP1 NM_018429.2 GRXCR2 NM_001080516.1 SLITRK6 NM_032229.2 
BSND NM_057176.2 HARS NM_002109.5 SMPX NM_014332.2 
CABP2 NM_016366.2 HARS2 NM_012208.2 SNAI2 NM_003068.4 
CACNA1D NM_000720.3 HGF NM_000601.4 SOX10 NM_006941.3 
CCDC50 NM_178335.2 HSD17B4 NM_001199291.1 STRC NM_153700.2 
CDH23 NM_022124.5 ILDR1 NM_001199799.1 SYNE4 NM_001039876.2 
CEACAM16 NM_001039213.3 KARS NM_001130089.1 TBC1D24 NM_001199107.1 
CIB2 NM_006383.3 KCNE1 NM_000219.4 TECTA NM_005422.2 
CLDN14 NM_144492.2 KCNJ10 NM_002241.4 TIMM8A NM_004085.3 
CLIC5 NM_001114086.1 KCNQ1 NM_000218.2 TMC1 NM_138691.2 
CLPP NM_006012 .2 KCNQ4 NM_004700.3 TMIE NM_147196.2 
CLRN1 NM_001195794.1 LARS2 NM_015340.3 TMPRSS3 NM_024022.2 
COCH NM_001135058.1 LHFPL5 NM_182548.3 TNC NM_002160.3 
COL11A1 NM_001854.3 LOXHD1 NM_144612.6 TPRN NM_001128228.2 
COL11A2 NM_080680.2 LRTOMT NM_001145309.3 TRIOBP NM_001039141.2 
COL2A1 NM_001844.4 MARVELD2 NM_001038603.2 TSPEAR NM_144991.2 
COL4A3 NM_000091.4 MIR96 NR_029512.1 USH1C NM_153676.3 
COL4A4 NM_000092.4 MITF NM_198159.2 USH1G NM_173477.4 
COL4A5 NM_033380.2 MSRB3 NM_198080.3 USH2A NM_206933.2 
COL4A6 NM_001287758.1 MYH14 NM_001145809.1 WFS1 NM_006005.3 
COL9A1 NM_001851.4 MYH9 NM_002473.5   
COL9A2 NM_001852.3 MYO15A NM_016239.3   
CRYM NM_001888.4 MYO3A NM_017433.4   
DFNA5 NM_004403.2 MYO6 NM_004999.3   
DFNB31 NM_015404.3 MYO7A NM_000260.3   
DFNB59 NM_001042702.3 NLRP3 NM_001079821.2   
DIABLO NM_019887.5 OPA1 NM_130837.2   
DIAPH1 NM_005219.4 OTOA NM_144672.3   
DIAPH3 NM_001042517.1 OTOF NM_194248.2   
DSPP NM_014208.3 OTOG NM_001277269.1   
EDN3 NM_207034.2 OTOGL NM_173591.3   
EDNRB NM_001201397.1 P2RX2 NM_170683.3   
ELMOD3 NM_032213.4 PAX3 NM_181459.3   
EPS8 NM_004447.5 PCDH15 NM_033056.3   
ESPN NM_031475.2 PDZD7 NM_001195263.1   
ESRRB NM_004452.3 PNPT1 NM_033109.4   
EYA1 NM_000503.5 POU3F4 NM_000307.4   
EYA4 NM_001301013.1  POU4F3 NM_002700.2   
FGF3 NM_005247.2 PRPS1 NM_002764.3   
FOXI1 NM_012188.4 PTPRQ NM_001145026.1   
GIPC3 NM_133261.2 RDX NM_002906.3   
GJB2 NM_004004.5 SERPINB6 NM_001271823.1   
GJB3 NM_024009.2 SIX1 NM_005982.3   
GJB6 NM_001110219.2 SIX5 NM_175875.4   
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Abstract
This study focuses on further characterization of the audiovestibular phenotype and on 
genotype-phenotype correlations of DFNB77, an autosomal recessive type of hereditary 
hearing impairment (HI). DFNB77 is associated with disease-causing variants in LOXHD1, 
and is both genetically and phenotypically highly heterogeneous. So far, a clear correlation 
between variant- and phenotypic characteristics has not been established. Heterozygous 
deleterious missense variants in LOXHD1 have been associated with late-onset Fuchs 
corneal dystrophy (FCD). However, up to now screening for FCD of heterozygous 
carriers in DFNB77 families has not been reported. Enhanced knowledge on phenotype 
characteristics, potential genotype-phenotype correlations and the involvement of FCD 
will lead to improved care and personal counseling of patients and their relatives. This study 
describes the genotype, and audiometric and vestibular phenotypes of nine families with 
HI, caused by pathogenic variants in LOXHD1. In addition, carriers within the families were 
screened for FCD. Fifteen pathogenic missense and truncating variants were identified, 
of which twelve were novel. The hearing phenotype showed high inter- and intrafamilial 
variation in severity and progression, which could not be related to the type or location of 
the variant. There was no evidence for involvement of the vestibular system. None of the 
carriers showed (preclinical) symptoms of FCD. Our findings expand the genotypic and 
phenotypic spectrum of DFNB77, but a clear correlation between the type or location of 
the variant and the severity or progression of HI could not be established. We hypothesize 
that environmental factors or genetic modifiers are responsible for phenotypic diﬀerences. 
No association was found between heterozygous pathogenic variants in LOXHD1 and the 
occurrence of FCD in carriers.
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Introduction
Nonsyndromic hereditary hearing impairment (HI) is clinically and genetically very 
heterogeneous. Currently, more than 100 genes (http://hereditaryhearingloss.org/) have 
been associated with this disorder and for many of the genes only a single or a few families 
have been described. As a result, knowledge on genotype-phenotype correlations for many 
forms of hereditary HI is limited. This hampers evidence-based counseling on prognosis 
and rehabilitation options.1 The introduction of massive parallel sequencing approaches, 
such as whole exome sequencing (WES), has enabled eﬃcient molecular diagnosis for 
hereditary HI.2,3 The number of families or patients with a genetic diagnosis will thus 
increase, allowing the determination of novel and more detailed genotype-phenotype 
correlations.
 DFNB77 (MIM #613079) is an example of an autosomal recessive type of nonsyndromic 
HI, of which knowledge on its genotype-phenotype correlation is limited due to its rareness. 
It is known to be caused by deleterious truncating and missense variants in LOXHD1 
(MIM #613072).4 LOXHD1 encodes lipoxygenase homology domain 1, which consists of 
15 PLAT (polycystin-1, lipoxygenase, alpha-toxin) domains. PLAT domains are thought 
to target proteins to the plasma membrane and mediate protein interactions.5-7 Based 
on studies in mice, it is known that Loxhd1 is mainly expressed in stereocilia of cochlear 
hair cells and plays an important role in maintaining normal hair cell function. Mice with 
homozygous Loxhd1 missense variants are profoundly deaf from an early age.4 To date, 41 
cases with DFNB77 from 22 families have been reported worldwide, harboring 27 diﬀerent 
disease-causing variants.4,8-18 In 17 of these families the auditory characteristics have been 
described, showing diﬀerent audiometric phenotypes, varying from mild to profound and 
stable to progressive sensorineural HI.4,8,9,11,12,14-17 So far, a clear correlation between variant- 
and phenotypic characteristics has not been established. 
Variants in LOXHD1 have not only been linked to HI; Riazuddin et al. (2012) associated 
heterozygous pathogenic missense variants in LOXHD1 with dominantly inherited late-
onset Fuchs corneal dystrophy (FCD).19 FCD is a genetic disorder of the corneal endothelium 
and is characterized by an increasing number of central corneal guttae, which are 
excrescences of Descemet’s membrane. In more advanced stages of the disease it can be 
accompanied by corneal edema.20 The onset of FCD is generally in the fourth or fifth decade 
of life. Over time, corneal edema and endothelial loss lead to deterioration of visual acuity 
and can eventually lead to painful epithelial bullae.20 Riazuddin et al. (2012) demonstrated 
that a heterozygous pathogenic variant in LOXHD1 segregated in a multiplex family with 
autosomal dominant late-onset FCD. Subsequent screening of sporadic cases with late 
| Chapter 3.2
88
onset FCD and unaﬀected, unrelated control samples revealed that in both groups rare 
missense variants occur, which were predicted to be damaging. However, the variant load 
in aﬀected individuals was significantly higher (7.5% versus 2.7%, p = 0.003).19 Expression of 
LOXHD1 was demonstrated in human corneal endothelium and in mouse corneal epithelial 
and endothelial cells. Results of corneal immunohistochemistry led to the hypothesis that 
allelic deleterious variants of LOXHD1 lead to protein aggregation in the endothelium and 
Descemet membrane, which might have long-term cytotoxic eﬀects.19
 It is essential to determine whether family members who carry a heterozygous 
pathogenic variant in LOXHD1 are at risk of FCD. Besides, further characterization of 
the audiovestibular phenotype and investigation of potential genotype-phenotype 
correlations of DFNB77 is needed in order to enable personal and evidence-based 
counseling of patients and their relatives with deleterious variants in LOXHD1. The present 
study evaluated the audiovestibular phenotype of nine families with DFNB77, mainly of 
Dutch origin, with novel and known compound heterozygous pathogenic variants in 
LOXHD1. Characterization of the phenotype was established by otoscopic evaluation, 
audiometric analyses and vestibular testing. Heterozygous carriers of pathogenic variants 
in LOXHD1 were evaluated for presence of FCD.
Subjects and methods
Subject evaluation
Medical history was obtained from all participants, using a questionnaire focusing on 
hearing and balance, and otoscopic examination and external ear inspection was performed 
in all subjects. Special attention was paid to possible causes of acquired deafness. 
 Pure-tone audiometry was performed in a sound-treated room according to the ISO 
8253-1:2010 standard. Air conduction thresholds were determined at 0.25, 0.5, 1, 2, 4, and 
8 kHz in dB HL. Bone conduction thresholds were determined at 0.5, 1, 2, 4, and 8 kHz in 
dB HL, to determine if the HI had a conductive component. The better hearing ear was 
defined using the mean air conduction thresholds averaged over the frequencies of 0.5, 
1, 2 and 4 kHz. HI characteristics were described according to the recommendations of 
the GENDEAF study group.21 In the index cases of families 5 and 7, hearing was evaluated 
by click-evoked Brainstem Evoked Response Audiometry (BERA) because of young age, 
according to current standards22, and severity of HI was based on the BERA thresholds, 
displaying hearing thresholds at about 3 kHz. Individual progression of HI was calculated 
with longitudinal linear regression analyses, using all available audiograms for the better 
hearing ear. Audiograms were used only if they were obtained after the age of 5 years. The 
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onset level of HI (threshold intercept, in dB HL at age 0 years) and progression of HI (slope 
in dB/year) were determined for each frequency (0.25, 0.5, 1, 2, 4 and 8 kHz). Progression of 
HI was considered to be significant, if the regression coeﬃcient diﬀered significantly (p ≤ 
0.05) from 0 for at least two of the six evaluated frequencies, and if the slopes were positive. 
 Vestibular function was assessed with cervical vestibular evoked myogenic potentials 
(cVEMP; Interacoustics EP25, Denmark), video head impulse test (Ulmer vHIT, Synapsys, 
France) and electronystagmography (ENG; BalanceLab, Ekida, Germany) in one aﬀected 
individual per family and in both aﬀected siblings of family 8. ENG consisted of rotary 
chair testing (trapezium stimulated velocity step test: acceleration of 2°/s2, deceleration 
of -200°/s2, with an adaptation time of 60 seconds and a velocity of 90°/s) and caloric tests 
with water irrigation (cold 30°C and warm 44°C, 30 seconds irrigation).23 Prior to vestibular 
testing, oculomotor testing was performed to exclude central lesions. Vestibular function 
was defined as abnormal when slow phase velocities of the nystagmus elicited by caloric 
irrigation was less than 10°/s or 7°/s (hyporeflexia) or more than 52°/s or 31°/s (hyperreflexia) 
for warm and cold water irrigation, respectively. Rotary chair testing was considered to be 
significantly deviant when the gain was less than 33% (hyporeactivity) or more than 72% 
(hyperreactivity), maximum velocity at deceleration less than 30°/s or more than 65°/s, and 
decay time less than 11 seconds or more than 26 seconds. cVEMP responses were elicited 
using 500 Hz tone burst stimuli with 6 ms duration (1 cycle rise/fall, 1 cycle plateau) at a 
presentation rate of 5.1 Hz. EMG responses were band pass filtered between 10 Hz and 
750 Hz, and typical P13/N23 peaks were obtained in steps of 2 dBnHL down to threshold 
level. Peak-to-peak (P-P) amplitudes of the P13/N23 component were used to determine 
cVEMP thresholds. To compare cVEMPs from both sides, P-P amplitudes were corrected 
and normalized for interaural diﬀerences in background EMG activity. cVEMP responses 
were defined as abnormal when thresholds were lower than 82 dBnHL or higher than 100 
dBnHL.24 Responses to the video head impulse tests were defined as abnormal when the 
gain of the vestibulo-ocular reflex (i.e. head/ eye movement) was less than 0.72 for each of 
the three semicircular canals.
 Parents of aﬀected individuals, who carry a heterozygous deleterious variant in 
LOXHD1, were assessed for presence of FCD. They were asked to fill out a questionnaire 
focusing on vision problems. Slit lamp biomicroscopy was performed to evaluate the 
presence of FCD. To support the diagnosis, specular microscopy was performed in order 
to visualize corneal endothelial cells and assess the endothelial cell density. All hearing 
impaired individuals were younger than the described age of onset of FCD and were 
therefore not examined.
 This study was approved by the medical ethics committee of the Radboud university 
medical center and is in accordance with the principles of the World Medical Association 
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Declaration of Helsinki. Written informed consent was obtained from all participants or 
their legal representatives. 
Whole Exome Sequencing
Genomic DNA was isolated from peripheral blood using standard techniques. In the 
index cases of families 1, 2, 4–7 and 9, whole exome sequencing (WES) was performed. 
First, the exome was enriched using the Agilent SureSelect version 4 kit. Subsequently, 
WES was performed on an Illumina HiSeq system by BGI-Europe (Denmark). A panel of 120 
(DGD_200614), 123 (DGD_250214) or 127 (DGD_141114) HI-related genes was analyzed 
and variants were selected based on variant classification guidelines.25 A list of analyzed 
genes can be found at https://www.radboudumc.nl/Informatievoorverwijzers/Genoom-
diagnostiek/en/Pages/Hearingimpairment.aspx. The index cases of families 1, 6 and 7 
have been reported previously.3 The identified variants in LOXHD1 (NM_144612.6 and 
NM_001145472.2) were confirmed using PCR and sequence analysis, as described below. 
STR-marker analysis for LOXHD1
Short Tandem Repeat (STR) markers flanking LOXHD1, D18S1145, D18S1143, D18S970, and 
D18S470, were genotyped under standard PCR conditions and analyzed on an ABI Prism 
3730 Genetic Analyzer. The alleles were assigned with GeneMapper software (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s protocol.  
PCR and sequence analysis
Amplification of all exons and exon-intron boundaries of LOXHD1 was performed using 
standard PCR conditions. PCR fragments were purified with Exonuclease I and FastAPTM 
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. 
Sequence analysis was performed with the ABI PRISM BigDye Terminator Cycle Sequencing 
V2.0 Ready Reaction kit and analyzed with the ABI PRISM 3730 DNA analyzer (Applied 
Biosystems Foster City, CA, USA).  For all families in which the index patient carried putative 
pathogenic variants in LOXHD1, segregation analysis in available family members was 
performed to determine zygosity and co-segregation of the variant with the HI in the 
family using PCR and sequence analysis as described above. Primer sequences and PCR 
conditions are available upon request.
Minigene Construction and Splicing Assay 
To determine the eﬀect of the synonymous c.5934C>T variant on splicing, a 
minigene was constructed and a splicing assay was performed, as described 
previously.37 A PCR amplified fragment of wild-type LOXHD1 exons 38 and 
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39, along with flanking intronic sequences, was generated with the following 
primers: 5’- GGGGACAAGTTTGTACAAAAAAGCAGGCTTCatctccattttgcatctcacc-3’ 
and 5’- GGGGACCACTTTGTACAAGAAAGCTGGGTCcagatggaccattggattacc-3’. This 
fragment was inserted in a pCI-NEO vector between exons 3 and 5 of RHO. The 
c.5934C>T variant was introduced with site-directed mutagenesis using primers 
5’-ggctcatcctggagggtaggaagaaccgatcc-3’ and 5’- ggatcggttcttcctaccctccaggatgagcc-3’, 
and using Q5® High-Fidelity DNA Polymerase (New England Biolabs, Ontario, Canada). 
Recombinant vectors were employed for transfection of HEK293T cells, which were incubated 
at 37 oC for 24 hours. RNA was isolated from transfected cells and reverse transcribed into 
cDNA. Primers 5’-cggaggtcaacaacgagtct-3’ and 5’-aggtgtaggggatgggagac-3’ were used to 
amplify and sequence the amplified cDNA fragments of exon 38-39 of LOXHD1, along with 
flanking RHO sequences as present in the vector. The RT-PCR fragments were excised from 
gel and purified using a Qiaquick gel extraction kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s protocol prior to sequencing. 
Results
LOXHD1 variants
Nine families with DFNB77, comprising of 14 aﬀected individuals, were included in this 
study (Figure 1). LOXHD1 variants that were predicted to be damaging were identified in 
seven families by WES targeting a HI gene panel. In a parallel approach a panel of seven 
families with progressive HI was tested for possible linkage to the DFNB77 locus. In five 
families linkage to LOXHD1 could not be excluded and LOXHD1 variant analysis of the 
index case was performed. This resulted in the identification of variants in two additional 
families  (Figure 1 and Table 1). All variants were detected in a compound heterozygous 
state and all segregated with HI in the families. In total, fifteen missense and truncating 
variants were identified, of which twelve were novel. All patients carried a missense variant 
in one LOXHD1 allele. The type of variant on the second allele varied; nonsense (3 families), 
canonical splice site (2 families), missense (2 families), frameshift (1 family) and synonymous 
(1 family) variants were identified. The synonymous variant was predicted to introduce 
a novel splice donor site (Supplemental Figure 1a). Usage of this splice site would lead 
to a frameshift and a premature stop codon. To determine the eﬀect of this synonymous 
variant a minigene approach was used. This showed correct splicing of the wild-type exon 
38, while the c.5934C>T variant indeed abolished normal splicing (Supplemental figure 1b) 
by usage of the predicted novel splice donor site. 
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Figure 2 Deleterious variants in LOXHD1 associated with DFNB77 and FCD
Schematic representations of two of the five LOXHD1 protein isoforms (NP_653213.6, known as isoform 
1; and NP_001138944.1, known as isoform 2) and identified pathogenic variants in LOXHD1. Two variants 
(L635P and splice site variant K646K), only aﬀect the shorter isoform 2; the L635P variant has also been 
reported in a subject with FCD.19 PLAT protein domains are predicted with Pfam 29.0 (http://pfam.xfam.org/) 
and are numbered. Previously published variants associated with DFNB77 are depicted in grey, published 
variants associated with FCD are depicted in italic, and novel variants identified in this study are underlined.
Figure 1 Families and identified pathogenic variants in LOXHD1
Pedigrees of nine families with DFNB77 and segregation analyses of the identified variants in LOXHD1. 
Only those family members are depicted who were relevant for the study. I:1 and II:2 of family 7 did not 
participate in genetic analysis. Index cases are indicated by arrows. + means wild-type. 
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Clinical history
HI was diagnosed in the aﬀected subjects between 0 and 5 years. The aﬀected sibling (II:2) 
of family 7 did not participate in clinical evaluation, but had congenital HI, according to 
information provided by the parents. In the individuals with a congenital onset (n=8), HI 
was discovered after failed neonatal hearing screening. The subjects who were diagnosed 
in the first years after birth did not have neonatal hearing screening (family 2 and 3), or 
the results of the screening were inconclusive (index cases of family 1 and 4). There were 
no known causes of acquired hearing loss identified by history or physical examination of 
the aﬀected subjects. Otoscopic examination and external ear inspection were normal in 
all subjects. The index cases of families 5, 7 and 8 had a negative cytomegalovirus test; the 
other aﬀected individuals could not be tested because of age or because the parents did 
not give consent. There were no associated symptoms, such as dysmorphology, delayed 
motor development or intellectual disability. All parents had normal hearing sensitivity. In 
family 1, there is a positive family history of Usher syndrome type 2, but variants in USH2A 
were ruled out previously in the aﬀected subjects of family 1. In all other families, there were 
no additional relatives with childhood onset HI and there was no history of consanguinity. 
Audiometric analysis
In all subjects, HI was sensorineural and symmetric. In most cases, the audiogram 
configuration was downsloping (Figure 3). Families 2–5 and 7 showed mild to moderate 
HI; in family 6 HI was severe. In families 1, 8 and 9, severity of HI varied between aﬀected 
individuals. Hearing in the index cases of families 5 and 7 was assessed by click-evoked 
BERA (data not shown). The index case of family 5 demonstrated binaural sensorineural HI, 
with hearing thresholds of 30 dB HL at the age of 6 months. BERA in the index case of family 
7 was performed at the age of 6 weeks, 5 months, 1 year and 3 years; all showed bilateral 
sensorineural HI, with thresholds of about 60 dB HL. 
 To determine whether HI was progressive, longitudinal linear regression analyses of 
hearing thresholds were performed in the aﬀected individuals of families 1-4, 6, 8 and 9. 
On average, 6 audiograms per individual were available. In four of the families (2, 4, 6 and 
8) HI was stable, which means that less than two out of six frequencies showed significant 
progression. In the index cases of families 1, 3 and 9, significant progression of HI was 
observed. The siblings (II:2) of families 1, 3 and 9 all demonstrated stable HI. However, the 
follow-up time in the cases with stable hearing loss was on average 8 years (3-17 years); 
hence deterioration of hearing over a longer period of time cannot be excluded in all cases 
(Figure 3). 
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Figure 3 Hearing thresholds of aﬀected individuals
Air conduction thresholds of the better hearing ear of all hearing impaired participants, except for the index 
cases of families 5 and 7, because hearing in these individuals was investigated with click-evoked BERA. The 
better hearing ear was determined by calculating the mean air conduction thresholds averaged over the 
frequencies of 0.5, 1, 2 and 4 kHz of the last audiogram. First-visit and last-visit audiograms are shown. Pure 
tone average (PTA) was calculated over frequencies 0.5, 1, 2 and 4 kHz of the last-visit audiogram. R, right 
ear; L, left ear; PTA, pure tone average. 
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Assessment of vestibular function
None of the aﬀected subjects reported vestibular symptoms, including vertigo, dizziness, 
instability or motoric developmental delay, except for the index case of family 1 who 
reported motion sickness. Vestibular function of the index cases of families 1-4 and 6, and 
both aﬀected siblings of family 8 was examined with ENG and cVEMP. These showed normal 
or slightly higher vestibular reactivity, the latter one based on higher gains measured with 
ENG and lower cVEMP thresholds (Table 3). There was slight asymmetry of the cVEMPS in 
the index cases of families 2 and 8, also after correction for muscle tone. All responses to 
the video head impulse test showed normal gains, demonstrating that all subjects have a 
normal vestibulo-ocular reflex (data not shown).
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Ophthalmological evaluation
The parents of families 1–4, 8 and the mother (I:2) of family 6 (n=11) were examined for 
symptoms of FCD (Table 4). The age of the parents ranged from 39 to 56 years, with a median 
age of 48 years. None of the parents had symptoms of blurred vision, glare, distorted vision 
or pain in the eye. Ophthalmological examination with slit lamp biomicroscopy in all 
parents was normal, and did not show any signs of FCD. Specular microscopy of endothelial 
cells showed normal appearance and density. History taking revealed that also none of the 
grandparents suﬀered from FCD or symptoms resembling FCD.
Table 4 Evaluation of pathogenic LOXHD1 variant carriers for FCD 
Family Subject nucleotide change 
(protein change) 
Type of 
variant 
Age at time of 
assessment for 
FCD (years) 
Endothelial 
cell count 
(cells/mm2) 
1 
 
I:1 c.1730T>G 
(p.Leu577Arg) 
missense 44 OD 3091 
OS 3055 
I:2 c.1618dup 
(p.Thr540Asnfs*24) 
frameshift 44 OD 2744 
OS 2593 
2 I:1 c.1828G>T 
(p.Glu610*) 
nonsense 50 OD 3138 
OS 2870 
I:2 c.2641G>A 
(p.Gly881Arg) 
missense 50 OD 3099 
OS 2556 
3 I:1 c.4678T>C 
(p.Cys1560Arg) 
missense 48 OD 2541 
OS 2716 
I:2 c.1904T>C 
(p.Leu635Pro)a 
missense 48 OD 2400 
OS 2827 
4 I:1 c.2696G>C 
(p.Arg899Pro) 
missense 39 OD 3234 
OS 3375 
I:2 c.3834G>C 
(p.Trp1278Cys) 
missense 40 OD 3081 
OS 3451 
6 I:2 c.3061C>T 
(p.Arg1021*) 
nonsense 56 OD 3328 
OS 3882 
8 I:1 c.3169C>T 
(p.Arg1057*) 
nonsense 52 OD 2458 
OS 2300 
I:2 c.6353G>A 
(p.Gly2118Glu) 
missense 49 OD 3231 
OS 2808 
Endothelial cell density (cells/mm2) determined with specular microscopy. The healthy endothelium has a 
hexagonal cell pattern and normal endothelial cell density in adults ranges from 2000 to 4000 cells/mm2.31,32 In 
FCD, variation in endothelial cell size and shape can be seen, as well as a decreased endothelial cell density. 33,34 
aThe c.1904T>C (NM_001145472.2) variant only aﬀects two of the five LOXHD1 isoforms (transcript variants 2 and 
5, UCSC Genome Browser). 
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Discussion
In this study, we present nine families with hereditary HI caused by compound 
heterozygous deleterious variants in LOXHD1. Diﬀerent types of pathogenic variants 
were identified, namely truncating, splice site and missense variants, which is in line with 
previously published LOXHD1 genotypes.9,14-17 Twelve of the identified variants were novel. 
The c.1904T>C (NM_001145472.2) variant identified in family 3 only aﬀects two of the five 
LOXHD1 isoforms (transcript variants 2 and 5, UCSC Genome Browser). The pathogenicity 
of this variant is therefore uncertain, however the allele frequency in control populations 
is very low (EXAC, http://exac.broadinstitute.org/) and the variant co-segregates with 
another missense variant in this family. 
 Table 2 presents an overview of the (likely) causative LOXHD1 variants that have 
been reported in this study and previous studies. The causality of several published 
variants could be questioned, as in some studies segregation analysis was not performed 
and consequently the bi-allelic origin of the variants and segregation with the HI in the 
family is not proven. In addition, three of these variants (c.2825_2827delAGA, c.4217C>T 
and c.4526G>A) are found relatively frequently in control populations (EXAC database, 
all populations 2.70%, 0.79% and 0.61%, respectively), which makes it unlikely that these 
variants are pathogenic (Table 2). 
 The aﬀected individuals were diagnosed with HI at birth or in the first years of life. It is 
not unlikely that the individuals with non-congenital HI in fact have congenital HI, but that 
delayed diagnosis occurred due to lack of neonatal hearing screening or inconclusive test 
results. In literature, the reported onset of HI is mainly congenital, but varies from congenital 
to 8 years old (Table 2).4,8,12-17 One individual, described by Eppsteiner et al. (2012), had 
progressive HI that started at the age of 40 years.9 However, the pathogenicity of one of the 
reported variants in this individual can be questioned, because the minor allele frequency 
of the c.4526G>A variant is rather high (ExAC database, all populations 0.61%, 3 times 
homozygous). Moreover, the two reported variants might reside on the same allele, as both 
variants have been reported before in homozygous state in another individual (Table 2).15 
Audiometry performed in our study demonstrated that mainly the high frequencies are 
aﬀected, although in some cases the mid frequencies and/or low frequencies are equally 
aﬀected. Audiometric analyses revealed interfamilial and intrafamilial variation in severity 
and progression of HI. Severity varied from mild to profound and progression varied from 
stable to progressive HI in some frequencies. This phenotypic variability and audiogram 
configuration is in line with previous research on DFNB77 (Table 2).4,8-14,16,17
 To explain the variation in phenotype, we sought to identify genotype characteristics 
that correlate with the severity of HI. First of all, the type of variant (truncating versus 
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missense variant) does not seem to explain the severity of HI. Comparing families 2, 3 and 
4 shows that the combination of a truncating and a missense variant can be associated 
with the same audiometric phenotype as two missense variants (Table 2, Figure 3). Besides, 
the combination of a truncating and a missense variant can lead to diﬀerent audiometric 
phenotypes. This is illustrated by the aﬀected individuals from family 2 and 8, who all have 
a nonsense and a missense variant, but show mild versus severe HI, respectively (Table 2, 
Figure 3). Second, the location of the missense variants (i.e. in or outside a PLAT domain) 
does not correlate with the severity of the phenotype. This is illustrated by families 2, 8 
and 9, who all have a truncating variant and a missense variant in a PLAT domain, but 
demonstrate a completely diﬀerent phenotype with mild stable versus severe versus 
moderate progressive to severe HI, respectively (Figure 2, Figure 3).
 Even between aﬀected individuals from the same family large variation is seen in 
the HI phenotype (e.g. family 1). The same deleterious variants can thus lead to diﬀerent 
phenotypes, indicating that other factors are probably underlying the phenotypic 
diﬀerences. These could be genetic factors (e.g. genetic modifiers) or environmental factors. 
Almost all of the missense variants are located within the PLAT domains of the LOXHD1 
protein. These domains are known to be mostly involved in lipid binding, but also protein 
binding and protein localization have been described.5,7,35,36 Possibly, variants in other 
genes encoding proteins that interact with the PLAT domains influence the phenotype 
of DFNB77. Identification of these “modifiers” would require studies in large cohorts of 
patients with deleterious LOXHD1 variants.
 Previous studies on the DFNB77 phenotype reported no vestibular symptoms4,11,12, 
however, objective evaluation of vestibular function was not reported. In the present study, 
ENG and cVEMP were performed in seven aﬀected individuals and revealed normal or even 
increased vestibular reactivity (Table 3). These findings, in combination with the lack of 
complaints, suggests that the vestibular organ is not aﬀected by disease-causing variants 
in LOXHD1. 
We could not find an association between heterozygous pathogenic variants in LOXDH1 
and FCD. In none of the parents, who are carriers of a deleterious heterozygous missense 
or truncating variant in LOXHD1, was FCD present. This is in contrast to previous research by 
Riazuddin et al. (2012), who showed that pathogenic heterozygous missense variants are 
associated with dominantly inherited late-onset FCD.19 At the time of our ophthalmological 
examination, the median age of the parents was 48 years (Table 4). Since the first signs of 
late-onset FCD generally appear in the fourth or fifth decade of life, it could be expected 
that (preclinical) symptoms of FCD would be detectable at the age of the examined 
individuals, if FCD was present. In addition, none of the grandparents suﬀered from FCD or 
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had symptoms resembling FCD. 
 Since eye abnormalities nor FCD have been reported in previous research on DFNB77 
and could also not be confirmed in this study, monogenic involvement of deleterious 
LOXHD1 variants in FCD is unlikely. As described by Riazuddin et al. (2012), LOXHD1 variants 
were found in both individuals with FCD and unaﬀected subjects, with a significantly higher 
variant load in aﬀected subjects (7.5% versus 2.7%, respectively).19 This could suggest that 
heterozygous pathogenic variants in LOXHD1 are a risk factor for FCD. However, we cannot 
exclude that the association between rare allelic variants in LOXDH1 and FCD are related to 
specific variants in LOXHD1. There is no overlap between the missense variants identified 
by Riazuddin et al. and the variants identified in this study, except for the c.1904T>C 
(p.Leu635Pro) variant, which only aﬀects two smaller isoforms of LOXHD1 (transcript variant 
2 and 5). This pathogenic variant was found in family 3, and was inherited from the mother 
(I:2) who carried the variant heterozygously. Although the mother was already 48 years 
during the time of examination no symptoms of FCD were found. This strengthens the 
hypothesis that rare LOXHD1 alleles are a risk factor for FCD, rather than a monogenic cause. 
 Based on type and location of variants, we could not find clear diﬀerences between 
variants associated with FCD and with DNB77 (Figure 2). However, since homozygous 
truncating variants of LOXHD1 have been associated with DFNB77, it could be argued 
that all LOXHD1 variants associated with HI, including missense variants, are null variants. 
Riazuddin et al. (2012) described that subjects with FCD and mono-allelic missense 
variants of LOXHD1 have multiple corneal aggregates, most likely due to the increased 
LOXHD1 protein levels in FCD subjects.19 This could indicate a gain-of-function eﬀect of 
these variants. Therefore, one could hypothesize that bi-allelic loss-of-function variants 
cause HI, whereas mono-allelic gain-of-function variants are a risk factor for FCD. Further 
research into the eﬀect of the variants on protein function is needed to confirm or reject 
this hypothesis.
In conclusion, our study confirms that the HI phenotype associated with deleterious variants 
in LOXHD1 can diﬀer in onset, type and severity. No clear genotype-phenotype correlation 
could be established based on type or location of the variant and severity or progression 
of HI. Extensive vestibular examination confirmed that vestibular function is not aﬀected in 
DFNB77. In addition, no association was found in this study between pathogenic LOXHD1 
variants and FCD.
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Figure S1 (a) The synonymous variant c.5934C>T (p.(Gly1978Gly)) introduces a novel splice donor site. 
Splice site prediction scores and figure were obtained from Alamut (Interactive Biosoftware, Rouen, 
France). (b) An agarose gel containing RT-PCR products detected from HEK293T cells transfected with the 
wild-type and mutant minigene construct, and a schematic representation of the identified splicing 
products (the two bands with the highest intensity). All of the RT-PCR products were verified by sequence 
analysis. The c.5934C>T variant leads to a shortened exon 38 due to usage of the predicted splice donor 
site. Two RT-PCR products are visible in the wild-type (wt) samples. The larger product is the expected RT-
PCR product containing both wild-type exon 38 and 39 of LOXHD1 (566 bps). The smaller RT-PCR product 
only contains exon 39 of LOXHD1; exon 38 is not present in this product. Also in the mutant samples two 
RT-PCR products seem to be present. However, sequence analysis of both bands showed products of the 
same length and sequence with a shortened exon 38, due to use of the novel predicted splice donor size, 
and a wild-type exon 39 (502 bps). It seems that the two bands represent the same product with a 
diﬀerent migration pattern. 
566 bps
502 bps
600 bps
400 bps
M      1       2      3      4      5
M   = 100 bp marker
1-2 = wt
3-4 = mutant
5    = negative control
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Abstract
In a Dutch consanguineous family with recessively inherited nonsyndromic hearing 
impairment (HI), homozygosity mapping combined with whole exome sequencing 
revealed a homozygous truncating variant of MPZL2, c.72del (p.Ile24Metfs*22). By screening 
a cohort of phenotype-matched subjects and a cohort of HI subjects in whom WES was 
performed previously, we identified two additional families with biallelic truncating variants 
of MPZL2. Aﬀected individuals demonstrated symmetric, progressive, mild to moderate, 
sensorineural HI. Onset of HI was in the first decade and high-frequency hearing was more 
severely aﬀected. There was no vestibular involvement. MPZL2 encodes Myelin protein 
zero-like 2, an adhesion molecule that mediates epithelial cell-cell interactions in several 
(developing) tissues. Involvement of MPZL2 in hearing was confirmed by audiometric 
evaluation of Mpzl2ko/ko mice. These displayed early-onset progressive sensorineural HI 
that was more pronounced in the high frequencies. Histological analysis of adult Mpzl2ko/
ko mice demonstrated an altered organization of outer hair cells and supporting cells and 
degeneration of the organ of Corti. In addition, mild degeneration of spiral ganglion 
neurons was observed, most pronounced at the cochlear base. Although MPZL2 is known 
to function in cell adhesion in several tissues, HI is so far the only phenotype associated with 
MPZL2 defects. This indicates MPZL2 to have a unique function in the inner ear. The present 
study suggests that deleterious variants of Mplz2/MPZL2 aﬀect adhesion of the inner ear 
epithelium resulting in loss of structural integrity of the organ of Corti and progressive 
degeneration of hair cells, supporting cells, and spiral ganglion neurons.
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Introduction
The identification of novel genes for hereditary nonsyndromic hearing impairment (NSHI) 
has accelerated in the last decade with the introduction of next generation sequencing. 
But despite the fact that currently more than 100 deafness genes are known (Hereditary 
Hearing loss Homepage), over 60 percent of subjects with hereditary NSHI can still not 
be genetically diagnosed.1-6 These individuals and their relatives receive suboptimal care, 
because of insuﬃcient counseling on prognosis and recurrence risk. In addition, syndromic 
features can be overlooked, or in the opposite case, unnecessary and costly tests are 
performed to screen for additional symptoms that are not present. 
 Given the number of deafness loci for which the causative gene is not known yet 
(Hereditary Hearing loss Homepage), it is estimated that still many monogenic forms of 
NSHI await identification. Discovery of these NSHI-associated genes will contribute to the 
full understanding of the complex physiology of hearing. However, the search for novel 
deafness genes has become more challenging, as most frequently involved genes are 
already known and those that remain are most likely involved in less than 1 percent of the 
cases, or even in only one or a few families with NSHI. Also, identification of deleterious 
variant(s) in a novel deafness gene in one family with NSHI alone is insuﬃcient proof for 
causality. Functional studies and animal models are important tools to provide evidence 
for involvement of the identified gene in hearing.7,8 
 In this study, we report on the identification of a novel gene for recessive NSHI, MPZL2, 
by combining homozygosity mapping and whole exome sequencing (WES) in a family of 
Dutch origin. Subsequent screening of a phenotype-matched cohort and analysis of WES 
data of genetically undiagnosed individuals with NSHI led to the identification of two 
additional families of Turkish origin with truncating variants in MPZL2. We characterized 
the phenotype of aﬀected individuals and of mice with an intragenic deletion of Mpzl2.9 In 
addition, we observed histological abnormalities in the cochleae of the mutant mice. 
Subjects And Methods
Subject evaluation
This study was approved by the medical ethics committee of the Radboud University 
Medical Center and is in accordance with the principles of the World Medical Association 
Declaration of Helsinki. Written informed consent was obtained from all participants or 
their legal representatives. 
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 Medical history was obtained from all participants, using a questionnaire focusing 
on hearing and balance, and possible acquired causes of HI. Otoscopy was performed in 
all subjects to assess the tympanic membrane and aeration of the middle ear. Pure-tone 
audiometry was performed in a sound-treated room according to current standards. Air 
conduction thresholds were determined at 0.25, 0.5, 1, 2, 4, and 8 kHz in dB HL. Bone 
conduction thresholds were determined at 0.5, 1, 2, 4, and 8 kHz in dB HL, to exclude 
conductive HI. HI was described according to the recommendations of the GENDEAF study 
group.10 Progression of HI was evaluated by cross-sectional linear regression analysis of 
last-visit audiograms of the better hearing ear and used to construct Age Related Typical 
Audiograms (ARTA), as described previously.11 Individual progression of HI was calculated 
for each frequency with longitudinal linear regression analyses, using GraphPad Prism 6.0 
(GraphPad, San Diego, CA, USA). Tympanometry was performed, and click-evoked ABR and 
otoacoustic emissions (OAEs) were obtained, according to current standards. Contralateral 
and ipsilateral acoustic reflexes were measured at 0.5, 1, 2 and 4 kHz up to loudness 
discomfort level. Speech perception thresholds and maximum speech recognition scores 
were determined using speech audiometry, which was performed in a sound-treated room 
with standard monosyllabic consonant-vowel-consonant Dutch word lists.12
 Vestibular function was assessed using electronystagmography (ENG) rotary chair 
stimulation and caloric irrigation testing, according to current standards. Additionally, 
cervical vestibular evoked myogenic potentials (cVEMP) and video head impulse tests 
(vHIT) were performed to assess sacculus and vestibulo-ocular reflex (VOR) functionality, 
respectively. To assess the presence of polyneuropathy, standardized neurological screening 
was performed in accordance with a predefined protocol (Supplemental Methods). 
Immunological screening was performed to evaluate presence of immunodeficiencies 
by asking participants about symptoms of allergies, autoimmune diseases, and frequent, 
prolonged or severe infections or inflammations. In addition, the numbers of CD4- and CD8-
expressing human T cells were analyzed, using flow cytometry, as indicated in the legend 
of Figure S12. Screening for corneal abnormalities and vision problems was performed by 
history, slit lamp biomicroscopy and evaluation of visual acuity using a Snellen chart.
Description of subject cohorts
Two cohorts were screened for the presence of MPZL2 variants, a phenotype-based 
cohort and a WES cohort. The phenotype-based cohort consisted of 138 individuals 
with a phenotype comparable to that of individuals of family W05-682, demonstrating 
sensorineural NSHI and a flat, cookie-bite or downsloping audiogram configuration. 
Of these, 70 subjects were Dutch and displayed stable, mild to severe NSHI; 68 subjects 
were Spanish and displayed mild to profound NSHI. Only isolated cases and subjects with 
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suspected autosomal recessive inheritance were included. All subjects were previously 
tested for a phenotype-based selection of single genes. 
 The WES cohort consisted of 270 subjects with presumed recessive HI for whom 
WES was performed previously. In these subjects, pathogenic variants in known deafness 
genes (Table S1) were excluded by targeted analysis of WES data, as described previously.6 
Subjects were not preselected based on theirHI phenotype.
Homozygosity mapping 
Genomic DNA was isolated from peripheral blood lymphocytes by standard procedures. 
The samples of subjects II:1 and II:3 of family W05-682 (Figure 1) were genotyped using 
the Aﬀymetrix mapping 250K SNP array, according to the manufacturer’s protocol (Santa 
Clara, CA, USA). Genotype calling was performed with the Genotyping Console software 
(Aﬀymetrix) with default settings. Homozygosity mapping was performed with the 
online tool HomozygosityMapper13 to identify significant shared homozygous regions. 
Other shared homozygous regions larger than 1 Mb and regions of shared heterozygous 
genotypes were identified manually.
VNTR marker analysis
Genotyping of variable number of tandem repeats (VNTR) markers was performed by DNA 
amplification with touchdown PCR and analysis on an ABI Prism 3730 Genetic Analyzer 
(Applied Biosystems). Primers for amplification of VNTR loci were designed with Primer3Plus. 
Genetic location of the markers was derived online from the Marshfield genetic map and 
marker order was confirmed in the human genome assembly GRCh37/hg19. Alleles were 
assigned with GeneMapper v.4.0 software, according to the manufacturer’s protocol 
(Applied Biosystems, Foster City, CA, USA).
Whole Exome Sequencing
Exome DNA was enriched using the Agilent SureSelect version 4 or version 5 kits. WES 
was performed on an Illumina HiSeq system by BGI-Europe (Denmark). Variants in genes 
associated with hearing impairment (HI) were selected and analyzed.14 A list of the analyzed 
HI-related genes and their coverage is provided in Table S1. Mean ≥20x coverage per 
sample was 95.9% to 96.5% of the enriched regions. The eﬀect of identified variants on the 
protein and on splicing was predicted with Alamut (Interactive Biosoftware, Rouen, France). 
To predict the pathogenicity of variants, they were classified according to the guidelines 
from the Association for Clinical Genetic Science and the Dutch Society of Clinical Genetic 
Laboratory Specialists.15
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Sanger sequencing 
Primers for amplification of exons and exon-intron boundaries of MPZL2 (NM_005797.3) 
and TECTA (ENST00000392793), and for mRNA analysis of TECTA were designed with 
Primer3Plus and Oligo Primer Analysis Software. Amplification by PCR was performed 
under standard conditions. For TECTA mRNA analysis, total RNA was isolated from Epstein–
Barr virus-transformed lymphoblastoid cells of aﬀected subjects II:1 and II:3 of family W05-
682, using the NucleoSpin RNA II kit (Machery Nagel,) according to the manufacturer’s 
protocol. Poly A+ RNA was isolated from total RNA using the OligoTEX mRNA Spin Column 
kit (Qiagen), according to the manufacturer’s protocol. Subsequently, cDNA synthesis was 
performed with 0.5 μg poly A+ RNA as starting material by using the iScript cDNA Synthesis 
Kit (Bio-Rad Laboratories), according to the manufacturer’s protocol. PCRs were performed 
on 2 μl cDNA with Taq DNA polymerase (Roche). PCR fragments were purified with ExoI/
FastAP or ExoSAP-IT (Thermo Fisher Scientific), in accordance with manufacturers’ protocols. 
Sequence analysis was performed with the ABI PRISM BigDye Terminator Cycle Sequencing 
v.2.0 Ready Reaction kit and analyzed with the ABI PRISM 3730 DNA analyzer or the 3130 
Genetic Analyzer (Applied Biosystems). Possibly deleterious eﬀects of the identified variants 
on the MPZL2 and TECTA proteins and on splicing was predicted with Alamut (Interactive 
Biosoftware). Primer sequences and PCR conditions are provided in Table S2. 
Quantitative PCR (qPCR) analysis for identification of intragenic deletions 
We quantified copy numbers of MPZL2 exons 2, 3 and 5 by using genomic qPCR. Specific 
primers (Table S2) were designed with Primer3Plus and reference sequence NM_005797.3. 
qPCRs were performed with 5 μg genomic DNA and reaction mixtures were prepared with 
the GoTaq qPCR Master Mix (Promega) in accordance with the manufacturer’s protocol. 
qPCRs were performed with the Applied Biosystem Fast 7900 System in accordance with 
the manufacturer’s protocol (Applied Biosystems). SLC16A2 (MIM: 300095) was employed 
as a reference gene. All reactions were performed in duplicate.
MPZL2 expression in human tissues
Total RNA derived from fetal heart, skeletal muscle, lung, brain, colon, kidney, stomach, 
spleen and thymus, and from adult skeletal muscle, liver, duodenum, stomach, spleen, 
thymus and testis, was purchased from Stratagene (La Jolla, CA, USA). Adult heart, lung, 
brain, kidney, bone marrow and placenta total RNA was purchased from Bio-chain (Newark, 
CA, USA). In addition, total RNA was isolated from fetal cochlea (8 weeks of gestation) as 
described previously.16 Subsequently, cDNA synthesis was performed with 2 μg total RNA 
as starting material by using the SuperScript cDNA Synthesis Kit (Thermo Fisher Scientific, 
Waltham, MA, USA), according to the manufacturer’s protocol. Specification on primer 
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design, qPCR system and reaction mixtures are mentioned above. Primer sequences and 
conditions are provided in Table S2. The human beta glucuronidase gene (GUSB, MIM 
611499) was employed as a reference gene. All reactions were performed in duplicate. 
Relative gene expression levels were determined with the delta-delta Ct method17. 
Audiometric characterization of Mpzl2ko/ko mice
Hearing was evaluated in C57BL6J wild-type (WT) and Mpzl2ko/ko mice.9 In the Mpzl2ko/ko 
mice, exons 2 and 3 were deleted by standard gene targeting methods.9 This is predicted 
to result in an in-frame deletion of the coding sequences for amino acid residues 20-145, 
encompassing part of the signal sequence and the majority of the extracellular region of 
the 215-residue MPZL2 protein (cf. Figure S1). Auditory brainstem responses (ABR) were 
registered in 4, 8 and 12 week-old mice (n=5 per genotype and age group), essentially as 
reported by Cediel et al. (2006)18 with the modifications reported by Murillo-Cuesta et al. 
(2015).19 Briefly, ABR recordings were obtained under anesthesia with ketamine (75 mg/
kg, Imalgene, Merial) and xylacine (5 mg/kg, Rompun, Bayer). Click (0.1 ms, 30 pps rate) 
and tone burst stimuli (8, 16, 20, 28 and 40 kHz, 5 ms, 50 pps rate) were generated with 
SigGenRP™ software (Tucker-Davis Technologies, Alachua, FL, USA). Stimuli were presented 
from 90 to 10 decibels, relative to sound pressure level (dB SPL) in 5–10 dB SPL steps with 
a MF1 speaker (TDT). The electrical responses were amplified, recorded and averaged, and 
hearing thresholds were determined in the ABR recordings. Amplitudes of ABR waves I, II, 
and IV and interpeak latencies of peaks I-II, II-IV, and I-IV were analyzed for 70 dB SPL click 
stimuli.  
 Statistical analysis was performed with IBM SPSS 23.0 software. Nonparametric Mann-
Whitney U-tests were used to compare ABR parameters between genotypes because of the 
small sample sizes. Diﬀerences were considered significant if p<0.05.
Animal experiments were conducted in accordance with Spanish and European legislation, 
and approved by the local bioethics committees.
Histology and immunohistochemistry of wild-type and Mpzl2ko/ko cochleae
Cochleae from 12 weeks old mice (n=3 per genotype) were dissected, decalcified and 
embedded in paraﬃn or Tissue-Tek OCT (Sakura Finetek). Deparaﬃnized cochlear sections 
(5 mm) were stained with hematoxylin and eosin, and images for general cytoarchitecture 
evaluation were taken with 10x, 20x and 40x magnification objectives with an Olympus 
DP70 digital camera as described previously.20 For immunofluorescence assays of 12-week 
cochleae, cryosections (10 mm) were treated overnight at 4ºC with the following primary 
antibodies: rabbit anti-Kir4.1 (1:200 AB5818 Chemicon),  rat anti-ZO-1 (1:200 sc-33725 
Santa Cruz); rabbit anti-KCNQ1 (1:200 sc-20816 Santa Cruz),  rabbit anti-Myosin VIIa (1:250 
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25-6790 Proteus), or goat anti-SOX2 (1:100 sc-17320 SantaCruz). After washing, sections 
were incubated with the corresponding secondary Alexa conjugated antibodies for 2 hrs at 
room temperature (RT), essentially as reported in Sanchez-Calderon et al. (2010).21
 Images were taken with epifluorescence (Nikon 90i, Tokyo, Japan) and/or confocal 
(Leica TCS SP2; Leica, Wetzlar, Germany) microscopes. SOX2 and Myosin VIIa positive cells 
were counted from base to apex in five serial cryosections (10 µm) per animal separated 
by 50 µm, prepared from 3 mice of each genotype. The intensities of KCNQ1, ZO-1, and 
Kir4.1 immunostainings were determined in areas of the stria vascularis, delimited by 
thresholding the marker’s fluorescent signal using Fiji software v1.51n (National Institutes 
of Health, Bethesda, MD, USA). The fluorescence optical density was thus determined from 
base to apex in 3-5 serial cryosections (10 µm) per animal separated by 50 µm, prepared 
from 3 mice of each genotype. Statistical significance was determined by Student’s t test 
for unpaired samples.
 For evaluation of early postnatal cytoarchitecture of the cochlea and for localization 
of MPZL2, inner ears of postnatal day four (P4) C57BL6J wild-type and Mpzl2ko/ko mice (n=3) 
were dissected, cryoprotected with 10% sucrose in PBS before embedding in Tissue-Tek OCT. 
For analysis of the cytoarchitecture, cryosections (7 µm) were fixed with paraformaldehyde 
(PFA) 4% (10 min), stained with hematoxylin and eosin, and analyzed on a Zeiss Axioskop 
light microscope. For immunofluorescence, cryosections were permeabilised with 0.01% 
Tween20 in PBS (20 min) and after rinsing with PBS and blocking with blocking buﬀer 
(ovalbumin 0.1% and fish gelatin 0.5% in PBS; 1 hr) incubated overnight at 4 ºC with 
primary antibodies diluted in blocking buﬀer. After rinsing with PBS, cryosections were 
incubated (1 hr) with secondary antibodies diluted in blocking buﬀer with DAPI (1:8000; 
D1306; Molecular Probes). After rinsing in PBS, sections were fixed in PFA 4% in PBS (10 
min), rinsed and mounted in anti-fade Prolong Gold (P36930; Molecular Probes). Analyses 
were performed on a Zeiss Axio Imager fluorescence microscope and for higher resolution 
on a Zeiss LSM880 confocal microscope. As primary antibodies were used: Rabbit anti-
MPZL2 (1:200 11787-1-AP Proteintech), rabbit anti-Myosin VIIa (1:200 25-6790 Proteus), 
goat anti-Collagen IV (1:200 1340-01 SouthernBiotech), and mouse anti-Na+-K+ATPase α1 
(1:5 α6F Developmental Studies Hybridoma Bank). As secondary antibodies were utilized: 
Alexa Fluor (AF) conjugated immunoglobulins (Molecular Probes): AF 568-goat anti-rabbit 
(A11011), AF 488-donkey anti-goat (A11055), AF 488-goat anti-mouse (A11029) and AF 
488-goat anti-rat (A11006), at a 1:800 dilution.
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Results
Homozygosity mapping and WES revealed loss-of-function variants of MPZL2
Homozygosity mapping in a Dutch consanguineous family with HI (W05-682; Figure1, 
Figure S2) revealed a single significant homozygous region of 23.8 Mb on chromosome 
11q23.1-q25, flanked by single nucleotide polymorphisms (SNPs) rs4936310 and 
rs10458997 (Figure S3). VNTR marker analysis confirmed homozygosity of the region and 
segregation of marker alleles in the family was compatible with linkage of the HI with a 
region flanked by D11S1893 at the centromeric side and including D11S2359 at the 
telomeric side (Figure 1a). D11S2359 is the most telomeric VNTR marker of chromosome 
11q (UCSC Genome Browser, GRCh37/hg19). By combining VNTR marker and SNP data, 
the critical region is delimited to Chr11:110,803,280-134,746,130. Two hundred and nine 
RefSeq genes have been annotated in this region (UCSC Genome Browser, GRCh37/
hg19), including TECTA, a known deafness gene. However, pathogenic variants in TECTA 
were excluded by Sanger sequencing of all exons and exon-intron boundaries and by 
mRNA analysis. The homozygous region did not contain or overlap with any other known 
deafness gene or locus. Fifteen additional homozygous regions larger than 1 Mb and 
shared by individuals II:1 and II:3 were identified (Table S3). There were no regions with 
shared heterozygous genotypes larger than 1 Mb.
 As a next step, WES was performed in the index case (II:1) of family W05-682. The 
mean ≥20x coverage of genes in the homozygous region of chromosome 11q23.1-q25 
was 98.1%. Variants within this region were filtered and classified as depicted in Figure 
S4. This revealed four rare homozygous variants in coding sequences and splice sites. 
Based on variant classification guidelines15, one of these variants was predicted to be likely 
benign (OR8G2 c.537C>G (p.Leu179Leu)). Two variants were predicted to be of uncertain 
significance (BSX c.263-5T>C (p.?) and GRAMD1B c.1111G>A (p.Val371Ile). The fourth variant 
was a homozygous one-base-pair deletion of MPZL2, c.72del (Figure S4) that is predicted 
to result in premature termination of protein synthesis (p.Ile24Metfs*22). As MPZL2 was 
known to be transcribed in the cochlea, it seemed the most promising candidate gene.22,23 
The MPZL2 variant c.72del has only been reported heterozygously in gnomAD, with a 
global minor allele frequency (MAF) of 0.00077, and is most common in the non-Finnish 
European population with a MAF of 0.00127. Segregation analysis by Sanger sequencing 
demonstrated co-segregation of the variant and HI in the family (Figure 1a). Targeted 
analysis of WES data for a panel of 120 HI-associated genes (Table S1) revealed no other 
(likely) pathogenic variants. 
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Identification of additional families with deleterious MPZL2 variants
We addressed further involvement of MPZL2 variants in recessive NSHI. A phenotype-based 
cohort of 138 unrelated probands with a phenotype similar to that of aﬀected individuals 
in family W05-682, was screened for variants of MPZL2. This revealed the variant c.72del 
(p.Ile24Metfs*22) in homozygous state in a family of Turkish origin, W16-0195. The variant 
was present heterozygously in the unaﬀected consanguineous parents (Figure 1b, Figure 
S5).  
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Figure 1 Pedigrees, VNTR genotypes and segregation of variants of MPZL2.
(a) Genotypes of VNTR markers and segregation of identified truncating variants of MPZL2 in family W05-
682. Besides MPZL2, TECTA (DFNB21) is also located within the homozygous region shared by the aﬀected 
individuals. Pathogenic variants in the coding and intronic regions of TECTA were excluded. (b) Pedigrees 
and segregation analyses of two additional families with deleterious variants in MPZL2. Index cases are 
indicated by arrows. Double lines indicate consanguinity (for extended pedigrees, see Figure S1).
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 In two other individuals of the phenotype-based cohort, rare heterozygous variants of 
MPZL2 were identified, namely c.268C>T (p.Arg90Trp) and c.544C>T (p.Arg182*). To identify 
possible intragenic deletions of the second allele, genomic qPCR was performed for exons 
in which no heterozygous SNPs were detected (Table S4). No deletions could be identified. 
Therefore, defects of MPZL2 are unlikely to be causative of HI in these subjects. However, a 
deleterious variant in non-coding regions of the gene cannot be excluded.
 Subsequently, data of a WES cohort of 270 genetically undiagnosed NSHI subjects was 
analyzed for rare MPZL2 variants. This unveiled a third family, W16-0451, of Turkish origin 
with truncating variants in MPZL2. Segregation analysis demonstrated that the c.72del and 
c.220C>T (p.Gln74*) variants were present in compound heterozygous state in the index 
case and that her aﬀected oﬀspring also carried biallelic truncating MPZL2 variants (Figure 
1b, Figure S5). The c.220C>T variant has been reported only heterozygously in gnomAD, 
with a global MAF of 0.00038 and 0.00003 in the non-Finnish population, which represents 
a significant part of the Turkish ancestry.24 The MAF of c.220C>T is 0.00515 in the East Asian 
population and 0.00016 in the South Asia as indicated in gnomAD. There is admixture of 
the Turkish population from Asia, mainly from West and Central Asia.24 The c.220C>T variant 
has not been observed in other populations represented in gnomAD. 
The c.72del MPZL2 variant is derived from a common founder
VNTR marker analysis was performed in families W05-682, W16-0195 and W16-0451 to 
determine the haplotypes in the MPZL2 region (Figure S6). All c.72del MPZL2 alleles shared 
a haplotype of at least 0.5 Mb, delimited by markers D11S1341 and D11S4104, suggesting 
that it is a founder variant rather than a recurrent variant due to a mutational hotspot. Since 
the families have a diﬀerent ethnic background, the c.72del variant is likely to be of ancient 
origin.
MPZL2 is expressed in human fetal cochlea
The relative expression of MPZL2 was determined in human fetal cochlea and various other 
fetal and adult human tissues (Figure 2). As the fetal tissues were not derived from embryos 
of the same gestational age, mRNA transcript levels are not directly comparable. Among 
the tested fetal tissues, MPZL2 expression was highest in inner ear, with 70-fold higher 
transcript levels compared to skeletal muscle, which displayed the lowest detectable 
expression. Also in all other fetal tissues, MPZL2 transcript levels were significantly lower 
as compared to that in the inner ear. In the analysis of MPZL2 expression in adult tissues, 
mRNA levels of MPZL2 in fetal inner ear were included for comparison. MPZL2 mRNA was 
detected in all analyzed adult tissues, with highest levels in thymus and lung, which were 
in the range of those in fetal inner ear. 
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Mpzl2ko/ko mice are hearing impaired
Mpzl2ko/ko mice showed early-onset progressive HI, with significantly increased ABR 
thresholds in response to click and tone burst stimuli along the ages studied, when compared 
to age-matched C57BL6J normal hearing wild-type mice.  Four-week-old Mpzl2ko/ko mice 
showed a mild HI, that aﬀected the detection of click stimuli and pure tone frequencies 
above 16 kHz  (Figures 3a and 3b) with statistically significant higher thresholds (P<0.05) 
as compared to wild-type mice. HI in Mpzl2ko/ko mice rapidly progressed to moderate and 
severe at the ages of 8 and 12 weeks, respectively, with statistically significant elevated 
thresholds for all tested stimuli as compared to wild-type mice. At 12 weeks of age, ABR 
thresholds in response to 16-40 kHz are above 70 dB SPL in the Mpzl2ko/ko, while wild-type 
mice maintained normal hearing with thresholds below 30 dB SPL. Accordingly, significant 
alterations in ABR peak amplitudes, latencies and interpeak latencies were observed in 
Mpzl2ko/ko mice. The maximum amplitudes of wave I, which represents cochlear activity, were 
approximately 30% lower in the knock-out animals than in the wild-type mice at all ages 
studied (Figure 3c), and diﬀerences reached significance in 4 week-old mice (Figure 3d). In 
addition, wave I peaks showed increased latencies in the Mpzl2ko/ko as compared to wild-
type mice which progressed over time. Peaks were increased in young animals (4 weeks-
old) at the level of intensity near the threshold, whereas in 12 weeks-old mice they were 
increased for all intensities tested (Figure 3e). Also, Mpzl2ko/ko showed significantly shorter 
interpeak latencies (IPL) I-II, II-IV and I-IV compared to wild-type mice (Figure 3f ). These 
data suggest a compensatory central response to the delayed peripheral transmission, as 
already shown in the Igf1 knock-out.25 
 
Figure 2 MPZL2 expression profile in human tissues.
Relative MPZL2 mRNA levels as determined by RT-qPCR in human fetal (a) and adult (b) tissues. The 
relative expression values were determined by the delta-delta Ct method with GUSB as a reference gene.17 
Expression levels are relative to those in skeletal muscle (a) and placenta (b), which displayed the lowest 
detectable MPZL2 expression of tested fetal and adult tissues, respectively. In fetal brain, no expression of 
MPZL2 could be detected.
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Figure 3 Hearing phenotype of Mpzl2ko/ko mice.
(a) Representative click-evoked ABR recordings at decreasing intensities (dB SPL) in 4, 8 and 12 week-old 
wild-type and Mpzl2ko/ko mice. Waves are labeled I to IV and reflect the evoked activity of the auditory nerve 
(I) and ascending points of the auditory pathway in the midbrain (II-IV). As the stimulus level is reduced, 
amplitudes of ABR waves decrease and latencies of waves increase. The lowest intensity at which the ABR 
wave profile is higher than the background noise signal is the threshold (bold line; WT, blue; Mpzl2ko/ko mice, 
green). (b) ABR thresholds in response to click and 8-40 kHz tone bursts, of the diﬀerent genotypes and age 
groups. (c,e) ABR wave I amplitude/intensity (c) and latency/intensity (e) curves in response to click stimuli 
of increasing intensities were determined in 4- and 12-week-old wild-type and Mpzl2ko/ko mice. (d, f) Peak 
amplitude of ABR waves I, II and IV (d), and interpeak latencies I-II, II-IV and I-IV (f), in response to a 70 dB SPL 
click stimulus in 4- and 12-week-old wild-type and Mpzl2ko/ko mice. Data are shown as mean±SEM. Statistical 
significance, *p<0.05; **p<0.01.
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Mpzl2ko/ko mice display alterations in cell organization and cell loss in the organ of Corti.
Evaluation of the general cochlear cytoarchitecture was performed in the basal, medial 
and apical turns of the cochlea of 12 week-old mice (Figure S7) to assess the integrity of the 
principal structures. Namely, the organ of Corti with inner and outer hair cells (IHCs and OHCs, 
respectively) responsible, respectively, for the mechanotransduction and amplification 
and tuning of the sound, and diﬀerent types of supporting cells.  Furthermore, the spiral 
ganglion neurons that connect the hair cells with the central auditory pathway; the stria 
vascularis in the lateral wall, involved in the formation of the high potassium containing 
endolymph, and the spiral ligament.  Loss of hair and supporting cells of the organ of Corti 
(asterisk in Figure S7d) and of neurons in the spiral ganglion (asterisks in Figure S7d-1) 
were observed in the basal cochlear turn of Mpzl2ko/ko, but not in wild-type mice. No evident 
structural abnormalities were seen in the stria vascularis and spiral ligament. Expression 
of markers of the stria vascularis was not altered in Mpzl2ko/ko mice, as compared to age-
matched wild-type animals (Figure S8).
 A closer evaluation of the organ of Corti (Figure 4) showed clear diﬀerences between 
wild-type and Mpzl2ko/ko mice at 12 weeks of age. At the basal turn of the cochlea, two 
Mpzl2ko/ko mice showed a flat epithelium at the basilar membrane with complete loss of hair 
and supporting cells (asterisks in Figure 4n and Figure 4o). At the medial and apical turns 
of the cochlea, hair and supporting cells were present in both genotypes, as were tunnel 
forming inner (IP) and outer pillar cells (OP) (Figure 4e). However, Mpzl2ko/ko mice showed 
an aberrant mosaic pattern of OHCs and supporting Deiters cells (DCs), with collapse of the 
spaces between OHCs and displacement of DC nuclei with respect to OHC nuclei (asterisks 
in Figure 4g, h, j-l, n-p). 
 Specific immunolabeling for Myosin VIIa and SOX2 evidenced that IHCs, OHCs and 
supporting cells were present (Figure 5). Also, this analysis confirmed Mpzl2ko/ko mice to 
display a disorganized arrangement of OHCs and DCs in the apical (asterisks in Figures 
5b and 5c) and middle turns (asterisk in Figure 5h), and absence or decreased numbers of 
all cell types in the basal turn of the cochlea (asterisks in Figure 5j-l), when compared to 
wild-type mice. Statistically significant diﬀerences were found in the number of OHCs in 
the basal turn only due to the diﬀerences in severity of the phenotype in Mpzl2ko/ko mice 
(Figure S9). At P4, no indications were obtained for an abnormal cellular organization in the 
developing organ of Corti (Figure S10). 
Mouse MPZL2 is expressed in the organ of Corti and the stria vascularis 
Cochlear expression and localization of MPZL2 was assessed in wild-type mice at P4 by 
immunofluorescence, which revealed a signal in DCs and most intensely in the basal region 
of DCs in all three cochlear turns (Figure 6a and Figure S11). Staining of serial sections with 
MPZL2 is essential for hearing in man and mouse |
127
4.1
Figure 4 Cochlear morphology of 12-week-old wild-type and Mpzl2ko/ko mice.
Microphotographs show representative midmodiolar cross sections of the cochlea from one representative 
wild-type mouse (a) and three Mpzl2ko/ko mice (b-d). The apical (A), middle (M) and basal (B) organs of Corti 
are boxed in image a. Close-ups of the organ of Corti from one wild-type mouse (e, i, m) and three Mpzl2ko/ko 
mice (f-h, j-l, n-p). Arrowheads point to inner hair cells (IHC), blackhead arrows to outer hair cells (OHC) and 
arrows to Deiters cells (DC). BM; basilar membrane, IP; inner pillar cell, OP; outer pillar cell. Asterisks mark 
abnormalities. Scale bar a-d: 500 mm, e-p: 25 mm.
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anti-collagen IV suggests that MPZL2 is present at the contact sites of DCs with the basilar 
membrane (Figures 6a and 6b). A weaker MPZL2 immunostaining is observed in both IHCs 
and OHCs (Figure 6a and Figure S11). In the stria vascularis, MPZL2 was detected in the 
basal cell layer as confirmed by co-staining with anti-Na+-K+ATPase that demarcates the 
intermediate cell layer (Figures 6c and 6d). Specificity of the anti-MPZL2 antibody was 
confirmed by analyzing cochleae of Mpzl2ko/ko mice in the same experiments (Figure S11). 
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Clinical characterization of individuals with pathogenic variants of MPZL2
All aﬀected and unaﬀected subjects of families W05-682, W16-0195 and W16-0451 
underwent clinical examinations. One of the siblings (II:1) of family W16-0451 was not able 
to participate in the current clinical evaluation; only retrospective data of this subject were 
used for analysis. History revealed that this individual previously underwent surgery for 
cholesteatoma of the left ear. Therefore, audiometric data of the right ear only were used 
for this study, which showed pure sensorineural HI. However, she also had osteogenesis 
imperfecta, which might contribute to her sensorineural HI. Nevertheless, her hearing 
thresholds were very similar to age-matched hearing thresholds of other aﬀected family 
members and therefore we decided to include her in the audiometric evaluations.
 None of the aﬀected subjects (family W05-682, II:1, II:3, III:2; family W16-0195, II:1; family 
W16-0451, I:2, II:1, II:2, II:3) demonstrated abnormalities on otoscopy and tympanometry 
Figure 5 Organ of Corti cytoarchitecture of wild-type and Mpzl2ko/ko mice.
Close-ups of the organ of Corti from representative frozen sections (10 µm) prepared from one 
representative wild-type mouse (a, e, i) and three Mpzl2ko/ko mice (b-d, f-h, j-l). Hair cells and supporting cells 
were immunolabeled for Myosin VIIa (green) and SOX2 (red), respectively, in the apical, middle and basal 
turns of the cochlea. Actin in the organ of Corti was stained with phalloidin (purple). Arrowheads point to 
inner hair cells (IHC), whitehead arrows to outer hair cells (OHC) and arrows to Deiters cells (DC). Asterisks 
mark abnormalities. Scale bar: 10 mm.
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(Table S5a). Pure tone audiometry of these individuals revealed no signs of conductive 
HI but did demonstrate a symmetric mild to moderate HI with a gently downsloping 
audiogram configuration for all of them (Figure 7a). The mean reported onset age of HI 
was 4 years (min-max: 3-9 years) (Table S5a). Four aﬀected individuals had a disturbed 
speech-language development, whereas this was normal in three cases and unknown in 
one case. Speech perception thresholds were lower than the pure tone average thresholds 
at 0.5, 1 and 2 kHz, and maximum speech recognition scores were 90-100% for the better 
hearing ear, both suggesting absence of retrocochlear pathology. Acoustic reflexes were 
present (both ipsi- and contralateral) without decay, which also suggested absence of 
Figure 6 Localization of MPZL2 in the organ of Corti and stria vascularis.
MPZL2 displayed a distinct localization in the cochlear organ of Corti and stria vascularis at P4 in wild-type 
mice.  (a) MPZL2 (red) localizes in the organ of Corti in the basal region of Deiters cells (DC) present below the 
three rows of outer hair cells (OHC) and diﬀusely in inner hair cells (IHC), OHCs and DCs. (b) In a serial section, 
collagen IV (green) immunostaining marked basement membranes including the basilar membrane (BM) 
thereby indicating the localization of MPZL2 at the DC-BM contact region. (c) In the stria vascularis, MPZL2 
(red) immunostaining was observed predominantly in the basal cell (BC) region. (d) Co-immunostaining of 
MPZL2 and Na+-K+ATPase (green), a marker for marginal cells (MC), confirms immunostaining of MPZL2 (red) 
in the basal cells. Cell nuclei were stained with DAPI (blue). Arrowheads point to IHC, whitehead arrows to 
OHCs and arrows to DCs. Scale bar a-d, 20 µm.
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retrocochlear pathology. OAEs could only be detected in individuals II:2 and II:3 of family 
W16-0451, for frequencies with hearing thresholds lower than 30 dB HL. This is indicative 
of residual function of cochlear OHCs in these subjects.26 OAEs were absent in all other 
aﬀected subjects. The index cases of families W05-682 and W16-0195 displayed normal ABR 
wave latencies, which indicated normal auditory neural processing. Additional information 
on otologic and audiometric evaluation of individual cases is provided in Table S5a.
 Individual longitudinal regression analyses of hearing thresholds revealed that 
HI was progressive in all aﬀected adults. No progression could be demonstrated in the 
aﬀected children, for whom follow-up time was probably too short (1-11 years) to establish 
significant progression. Cross-sectional linear regression analysis revealed progression of 
HI for all frequencies. The increase of hearing thresholds was significant at 1 kHz (0.8 dB/
year), 2 kHz (0.5 dB/year) and 4 kHz (0.6 dB/year). In Figure 7b, the ARTA is depicted, which 
demonstrates gradual progression of HI. 
Figure 7 Audiometric characterization of families aﬀected by pathogenic MPZL2 variants. 
(a) Air conduction thresholds of the better hearing ear of all aﬀected individuals. The better hearing ear was 
determined by calculating the mean of the pure-tone thresholds for 0.5, 1, 2 and 4 kHz of the last audiogram. 
First-visit and last-visit audiograms are depicted. Subject II:1 of family W16-0451 was not able to participate 
in the clinical evaluation; only retrospective data of this subject were used for analysis. R, right ear; L, left ear. 
(b) ARTA (Age Related Typical Audiogram) constructed by cross-sectional linear regression analysis of last-
visit audiograms of all aﬀected individuals (n=8).
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 None of the aﬀected subjects or their parents reported vestibular symptoms, such as 
vertigo, dizziness, instability or delayed motor development, except for the index case of 
family W16-0451 (I:2) who reported two periods of vertigo in the past without persisting 
complaints. Vestibular function was assessed in three of the hearing impaired individuals 
(family W05-682, II:1; family W16-0451, I:2 and II:2) and normal to slight hyperreactive 
vestibular responses were measured (Table S5b).
 Because MPZL2 is highly homologous to MPZ (MIM: 159440), which is associated with 
distinct types of hereditary motor and sensory neuropathy27-33, we performed neurological 
screening of the aﬀected individuals (family W05-682, II:1, II:3, III:2; family W16-0195, II:1; 
family W16-0451, I:2, II:2, II:3). No symptoms or signs of neuropathy were present. 
 Hearing-impaired subjects were also screened for immunological abnormalities, 
because MPZL2 is involved in early thymocyte development.34-36 None of them had 
symptoms of immunodeficiency, allergies or autoimmune disease. CD4 and CD8 T cell 
counts, including double positive (CD4+CD8+) cell counts, double negative (CD4-CD8-) 
cell counts, as well as the CD4/CD8 ratios, were normal (Figure S11), indicating normal CD4 
and CD8 expression on T cells. 
 As gene expression studies have shown that MPZL2 transcript levels are relatively high 
in the cornea of the eye (Ocular Tissue Database)37, aﬀected individuals were screened for 
corneal abnormalities. There were no eye problems, slit lamp biomicroscopy did not show 
abnormalities and visual acuity was normal.
Discussion
This study provides evidence for the association of biallelic defects of MPZL2 with 
recessively inherited sensorineural NSHI in man and mouse. Aﬀected human subjects 
displayed moderate to severe, slowly progressive HI from the first decade onwards, and 
intra- and interfamilial phenotypic similarity was high. The causal relationship between 
MPZL2 defects and HI in the families was confirmed by functional and morphological inner 
ear defects in Mpzl2ko/ko mice. HI of these mice and aﬀected family members was similar 
with regard to the early onset, the progressive nature and high-frequency hearing being 
most severely aﬀected. The latter is reflected by the decreasing severity of disorganization 
and loss of OHCs and DCs from cochlear base to apex.38 
 OHCs function as cochlear amplifiers that enhance hearing thresholds by more 
than 40 dB, and loss of the amplifying function leads to 40-60 dB HI.39,40 As subjects with 
deleterious MPZL2 variants displayed a 35 to 65 dB increase of hearing thresholds, the HI 
phenotype is compatible with predominant loss of OHCs. In addition, the remarkably good 
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speech discrimination compared to the hearing thresholds and absence of OAEs in the 
aﬀected individuals indicate abnormal OHC function.41,42 Given the only moderate HI of the 
aﬀected adult subjects of family W05-682 and subject I:2 of family W16-0451 at the age of 
about 40 years, we hypothesize that IHCs do not, or very slowly degenerate over time.
 MPZL2 (Myelin Protein Zero-like 2), alternatively called EVA1 (Epithelial V-like Antigen 
1), is a low-aﬃnity adhesion molecule and a member of the immunoglobulin superfamily, 
more specifically of the family of immunoglobulin-like cell adhesion molecules (Ig-CAMs).34 
Ig-CAMs form a large family of cell surface molecules broadly expressed in for example 
epithelial and endothelial cells and in the nervous system. Ig-CAMs are known to interact 
directly with other classes of cell surface molecules such as cadherins, integrins, tyrosine 
kinase receptors and intracellularly also with proteins of the cytoskeleton such as actin and 
ankyrin. (for review see 43,44)
 The biological function of MPZL2 is likely to be related to its ability to mediate both 
homophilic and heterophilic cell-cell adhesions. In mouse, Mpzl2 is already expressed early 
in embryogenesis in various epithelial tissues as well as in adult tissues.34,45 An adhesive 
function of MPZL2 has been indicated in thymus histogenesis and T-cell development34,35, 
placental morphogenesis46, blood-cerebrospinal barrier47, lymphocyte adhesion to choroid 
plexus epithelial cells48,  and in mammary epithelial cell diﬀerentiation.45 Upregulation of 
Mpzl2 in spermatogenic cells of cell adhesion molecule 1-deficient mice further supports 
the cell adhesive function.49 Also, MPZL2 was demonstrated to function in proliferation 
and tumorigenesis of glioblastoma-initiating cells.50 Despite these manifold indications 
of functional significance of MPZL2, HI is to our knowledge the first phenotype found to 
be associated with MPZL2 deficiency.50,51 However, more phenotypic eﬀects might emerge 
under stress conditions, as is suggested by increased severity of experimentally induced 
autoimmune encephalomyelitis and white matter tissue injury in MPZL2-deficient mice.51
 In the developing and adult inner ear, several CAMs, belonging to diﬀerent protein 
families including the Ig-CAM superfamily, display a specific spatiotemporal pattern of 
expression and several of these Ig-CAMs are critical for hearing and/or balance in both 
mice and humans.52-59 The Ig-CAMs nectin-1 and -3, for example, are critical for establishing 
the checkerboard-like organization of hair cells and supporting cells in the cochlea.60 The 
abnormal organization of DCs and OHCs, and their loss in Mpzl2ko/ko mice at 12 weeks of age 
indicate that MPZL2 is essential for maintenance of the DC-OHC organization and integrity. 
A role in maintenance is supported by the moderate transcript levels of MPZL2 in adult 
human cochleae.23 Although no structural abnormalities were detected in cochleae of 
Mpzl2ko/ko mice at P4, MPZL2 is likely to function in prenatal cochlear development as well, 
in both man and mouse, as transcription of the gene was demonstrated in human embryos 
at 8 weeks of gestation and in mouse developing hair cells and their surrounding cells from 
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embryonic day 16 (E16) to P16.61(See also the SHIELD database). From the present study 
it is unclear whether MPZL2-associated HI is congenital or has an early childhood onset. 
As speech-language development was disturbed in a number of cases, onset of HI was 
prelingual these individuals. If HI was congenital in the cases with prelingual HI, thresholds 
were below 35 dB HL as two of three individuals with prelingual HI had a neonatal hearing 
screening, which they passed. These tests are calibrated to pick up HI of more than 35 dB 
HL.62 
 To our knowledge, MPZL2 is the first CAM that is specifically expressed at the base of 
DCs where they contact the basilar membrane. DCs develop a narrow infranuclear region 
that ends in feet-like junctions with the basal membrane.63 The stripe-shaped signal in DCs 
in MPZL2-immunohistochemistry might represent the developing feet-like structures. It is 
tempting to speculate that MPZL2 is involved in the morphogenesis and/or maintenance of 
the characteristic structure of DCs by anchoring the actin-rich cytoskeletal core of the feet-
like structures or the surrounding microtubules to the basilar membrane.63 The relatively 
weak MPZL2 signal in immunohistochemistry at P4 in OHCs, IHCs and the cytoplasm of DCs, 
suggest that MPLZ2 (transiently) functions in homophilic or heterophilic cellular junctions 
of these cells and that absence of these junctions in Mpzl2ko/ko mice might contribute to the 
disorganization and degeneration of the organ of Corti. 
 Although not much is known about the adhesive function of MPZL2 at the molecular 
level, some hints towards molecular interactions have been obtained. A co-association of 
MPZL2 and CLCA2 with ZO-1 has been described.45 ZO-1 is an adapter protein that functions 
in the coupling of TJs and adherens junctions (AJs) to the cytoskeleton.64 Also, ZO-1 binds 
directly to occludin in vitro.58 Interestingly, an association of MPZL2 and occludin has been 
observed in a high-throughput human protein interaction study.65 Occludin is a tight 
junction (TJ) protein and essential for functional integrity of the reticular lamina of the 
organ of Corti.56 The organ of Corti of Occ-/- mice degenerates, starting in the OHC region. 
Because of these associations and the organ of Corti defects of Mpzl2ko/ko mice, it is tempting 
to speculate that MPZL2 is essential for (functional) integrity of cell junctions in the reticular 
lamina, especially in the OHC region, and thereby for ion homeostasis in the cochlea. The 
associations of MPZL2 with TJ and AJ proteins and their co-function in the cochlea have 
to be validated with other protein interaction assays, and co-localization assays in the 
inner ear. The latter assays were impaired by failure of antibodies to detect MPZL2 in the 
experimental conditions to be used in immunofluorescence of adult cochleae.
 Recently, it was demonstrated that MPZL2 can activate the NF-ĸB signaling pathway, 
likely by binding TRAF2, for which a consensus binding site is present in the cytoplasmic 
domain of MPLZ2.50 This pathway was indicated to be protective for hair cell loss by 
environmental factors such as noise and aminoglycosides.66,67 Therefore, defects of MPZL2 
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might lead to an increased sensitivity to noise and other environmental cues.
 Although MPZL2 was detected in the basal cell layer of the developing stria vascularis, 
no gross histological abnormalities were observed in this region of the cochlea in Mpzl2ko/
ko mice neither at the age of four days nor at 12 weeks of age. However, this does not fully 
exclude functional defects. A mild loss of spiral ganglion neurons was observed in the basal 
turn of the cochlea of Mpzl2ko/ko mice, which might be secondary to hair cell loss.
 In conclusion, we demonstrated that MPZL2 is essential for normal cochlear function 
in man and mouse. In the latter species, defects of MPZL2 resulted in disorganization of the 
OHCs and DCs that is likely to interfere with mechanical and other functional properties 
of that region of the cochlea and ultimately in loss of organ of Corti integrity. Humans 
aﬀected by biallelic truncating MPZL2 variants displayed slowly progressive NSHI, which is 
important in (genetic) counseling of subjects and their families.
Acknowledgements
We are grateful to the participating patients and their families. We thank Jeroen van 
Reeuwijk for discussions. The DOOFNL consortium consists of M.F. van Dooren, H.H.W. de 
Gier, E.H. Hoefsloot, M.P. van der Schroeﬀ (ErasmusMC, Rotterdam, the Netherlands), S.G. 
Kant, L.J.C. Rotteveel (LUMC, Leiden, the Netherlands), S.G.M. Frints, J.R. Hof, R.J. Stokroos, 
E.K. Vanhoutte (MUMC+, Maastricht, the Netherlands), R.J.C. Admiraal, I. Feenstra, H. Kremer, 
H.P.M. Kunst, R.J.E. Pennings, H.G. Yntema (Radboudumc, Nijmegen, the Netherlands) A.J. 
van Essen, R.H. Free and J.S. Klein-Wassink (UMCG, Groningen, the Netherlands). We also 
thank the technical assistance of the Histology facility (CNB, CSIC and CIBERER), and of the 
Non-invasive Neurofunctional Evaluation and Genomics facilities (IIBm, CSIC-UAM and 
CIBERER). This work was supported by a grant from the Heinsius Houbolt foundation [to 
H.K., R.J.E.P. and H.P.M.K.] and partially by grants from the Spanish Ministry of Economy 
and Competitiveness and the European Regional Development Fund FEDER/SAF2014-
53979-R and from FEDER/CIBERER ISCIII [to I.V.N.], and a grant from Spanish Instituto de 
Salud Carlos III (PI14/01162; Plan Estatal de I+D+I 2013-2016, with co-funding from the 
European Regional Development Fund) [to I.d.C.]. S.M., A.M.C., and E.G.R. hold CIBERER 
ISCIII researcher contracts.
MPZL2 is essential for hearing in man and mouse |
135
4.1
Web Resources
The URLs for data presented herein are as follows:
Alamut Visual, http://www.interactive-biosoftware.com/alamut- visual/
ExAC Browser, http://exac.broadinstitute.org/
GnomAD Browser, http://gnomad.broadinstitute.org/ 
Hereditary Hearing loss Homepage, http://hereditaryhearingloss.org/ 
HomozygosityMapper, http://www.homozygositymapper.org/
Marshfield Genetic Maps, http://research.marshfieldclinic.org/genetics/GeneticResearch/
compMaps.asp
Ocular Tissue Database, https://genome.uiowa.edu/otdb/
Oligo Primer Analysis Software, http://www.oligo.net/
OMIM, http://www.omim.org/
OMIM Phenotypic Series, http://www.omim.org/phenotypicSeriesTitle/all
Primer3Plus, http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi
SMART, http://smart.embl-heidelberg.de/
UCSC Genome Browser, https://genome.ucsc.edu
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Supplemental Data
Supplemental methods
Screening protocol for polyneuropathy in subjects with MPZL2 variants.
Medical history was obtained regarding sensory disturbances, muscle weakness, functional 
impairment (walking, walking stairs, cycling), and use of medication. Participants also 
underwent physical neurological examination.
Neurological examination included testing of:
• Cranial nerves, according to current standards
• Muscle strength using the Medical Research Council (MRC) scores (0-5) of 18 predefined 
muscle groups, including shoulder abduction, elbow flexion, wrist extension, hip 
flexion, knee extension, foot dorsiflexion (extension) and plantar flexion, and toe 
dorsiflexon (extension); muscle tone and bulk
• Muscle mass of the extensor digitorum brevis muscle (normal / atrophic)
• Vigorimeter grip strength, as described previously1
• Coordination with use of nose-finger test and tandem gait (normal / abnormal).
• Sensation, using the Modified INCAT Sensory Sum Score (mISSReflexes) and the 
Romberg test (1= abnormal; 0 = normal), according to the European Federation of 
Neurological Societies/Peripheral Nerve Society guideline on management of chronic 
inflammatory demyelinating polyradiculoneuropathy2
• Deep tendon reflexes (biceps, triceps, patellar and ankle jerks) bilaterally (absent / 
reduced / normal) 
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Supplemental figures and tables
Figure S1 Exonic and protein structure of MPZL2/MPZL2 and pathogenic variants.
Schematic representation of the genomic structure and the encoded protein domains of MPZL2 
(NM_005797.3). Identified pathogenic variants are indicated. Protein domain predictions were extracted 
from the SMART domain database (http://smart.embl-heidelberg.de/), using the PFAM domains setting.
Figure S2 Extended pedigrees of families aﬀected by MPZL2 variants.
Index cases are marked by arrows. Double lines indicate consanguinity.
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Figure S3 Homozygosity mapping in family W05-682.
Graphical representation of the genome-wide homozygosity scores in family W05-682, produced by 
HomozygosityMapper.3 Homozygosity mapping was performed by genotyping of subjects II:1 and II:3 
of family W05-682 with the Aﬀymetrix mapping 250K SNP array, and subsequent genotype calling with 
Genotype Console software (Santa Clara, CA, USA) and homozygosity mapping with the online tool 
HomozygosityMapper (http://www.homozygositymapper.org/). This revealed a single homozygous region 
of 23.8 Mb on chromosome 11q23.1-q25, flanked by rs4936310 and rs10458997. There were no other 
significant regions of homozygosity.
Figure S4 Filtering of WES variants in the largest homozygous region on chromosome 11q23.1-q25 of family 
W05-682.
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ExAC frequency 
(%) 
0.08 0 0.25 0.07 
In-house database 
frequency (%) 
0.33 0 0.57 0.10 
PhyloP - -0.36 5.61 -2.3 
Grantham - - 29 0 
CADD - 10.8 23.1 0.3 
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Figure S5 Sequences of MPZL2 c.72del and c.220C>T.
Analysis of the WES paired-reads demonstrated a homozygous point deletion, MPZL2 c.72del, in the index 
cases of families W05-682 (a) and W16-0195 (b). In the index case of family W16-0451, WES revealed the 
c.72del variant heterozygously (c) and the heterozygous missense variant MPZL2 c.220C>T (d). NM_005797.3 
was used as reference sequence. Figures were obtained using Alamut Visual (Interactive Biosoftware, Rouen, 
France).
Criteria of variant filtering and resulting number of variants of WES data for the index case (II:1) of family 
W05-682. The in-house database contains WES data of 13314 individuals, the vast majority of Dutch origin, 
aﬀected by a large number of diﬀerent diseases (including 810 subjects with HI) and also non-aﬀected 
individuals. The variants in BSX, GRAMD1B and OR8G2 were considered not to be (likely) pathogenic, based 
on variant classification guidelines.4 aNo compound heterozygous variants were resulting from the first 
three filtering steps.
a b
c
c.72del c.72del 
c.72del c.220C>T 
d
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Figure S6 Haplotype analysis of the genomic region harboring MPZL2.
MPZL2 haplotypes were determined by genotyping VNTR-markers in families W05-682, W16-0195 and W16-
0451. All c.72del MPZL2 alleles (depicted in red) shared a haplotype of at least 0.5 Mb, delimited by markers 
D11S1341 and D11S4104 (boxed), suggesting that it is derived from a common ancestor. Index cases are 
marked by arrows.
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Figure S7 Cochlear morphology of 12-week-old wild-type mice and Mpzl2ko/ko mice.
Representative microphotographs from the middle (a and b) and basal (c and d) cochlear turns from 
midmodiolar cross sections. The second and fourth rows include close-ups of the boxed areas, from left to 
right: spiral ganglion (1), and stria vascularis (2). Asterisks mark abnormalities. L.w., lateral wall; Ot.c., otic 
capsule; Sp.G., spiral ganglion; Sp.L., spiral ligament; St.V., stria vascularis. Scale bar a-d, 100 µm, close-ups 
25 µm.
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Figure S8 Normal cellular organization of the stria vascularis in wild-type mice and Mpzl2ko/ko mice. 
Close-ups of the stria vascularis (a-h) of the basal turn of the cochlea from representative cryosections (10 
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Figure S9 Quantification of MyoVIIa and SOX2 positive cells.
Cell numbers were evaluated for wild-type (blue) and Mpzl2ko/ko mice (green) for each turn of the cochlea. 
Data were obtained counting MyoVIIa and SOX2 positive cells in each cochlear region from 5 serial 
cryosections (10 µm) per animal (apex, n=3 mice per genotype in IHC and SC, n=2 wild-type, n= 3 KO in OHC; 
middle region, n= 2 wild-type, n=3 KO for each cell type; base, n=3 mice per genotype for each cell type). 
Data are expressed as the sum of each cell type per animal. Statistical analysis was performed by Student 
t-test between groups for each marker and level of the cochlea. **p<0.01 (KO versus WT). IHC, inner hair cells; 
KO, Mpzl2ko/ko; OHC, outer hair cells; SC, supporting cells.
µm) prepared from a wild-type mouse (a,e) and three Mpzl2ko/ko mice (b-d, f-h). Strial marginal (MC), basal 
(BC) and intermediate cells (IC) were immunostained for KCNQ1 (red), ZO-1 (green) (a-d) and Kir4.1 (green) 
(e-h) respectively. Actin in the stria vascularis was stained with phalloidin (purple). Scale bar a-h: 10 µm.
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Figure S10 Normal histology of the cochlear basal turn at  P4 in wild-type and Mpzl2ko/ko mice.
Overview of the basal turn of cochleae (a, b) and higher magnifications of organs of Corti (c, d), striae 
vascularis (e, f) and spiral ganglions (g, h). Arrowheads point to inner hair cells (IHC), blackhead arrows to 
outer hair cells (OHC) and arrows to Deiters cells (DC). BC, basal cells; MC, marginal cells; WT, wild-type. Scale 
bars a, b: 100 µm, c-f: 20 µm and g, h: 20 µm. 
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Figure S11 Specificity of immunostaining of MPZL2 in hair cells and Deiters cells of the organ of Corti and 
basal cells of the stria vascularis in P4 wild-type and Mpzl2ko/ko mice.
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Figure S12 CD4 and CD8 expression on human T cells.
The number of CD4 and CD8 expressing human T cells was analyzed in aﬀected individuals (family W05-
682, II:1, II:3, III:2; family W16-0195, II:1; family W16-0451, I:2, II:2, II:3), as described in detail before.5 In 
brief, peripheral blood was collected in EDTA-tubes, and after red cell lysis, leucocytes were stained with 
fluorochrome labelled antibodies against CD3 (UCHT-1 pe), CD4 (13B8.2 pacific blue), CD8 (B9.11 APC-
AF750) and CD45 (J33 Krome Orange) (all from Beckman Coulter, Brea, USA). Data was acquired on a Navios 
flow cytometer (Beckman Coulter) and analyzed using Kaluza® software version 1.3 (Beckman Coulter). 
Presented cell counts are a percentage of total CD45+ cells (CD4+ and CD8+), a percentage of total CD3+ 
cells (CD4-CD8- and CD4+CD8+) or a fold ratio. Data of 20 healthy individuals was used as control. Individual 
and median cell counts and ratios are shown. Numbers of cells and ratios are comparable between subjects 
and controls, indicating normal CD4 and CD8 T cell counts. Mann-Whitney U tests did not demonstrate 
significant diﬀerences. 
Immunostaining of MPZL2 (red) is observed diﬀusely in the hair cells and Deiters cells and with higher 
intensity at the basal part of the Deiters cells in the apical (a), middle (c) and basal (e) turns of the cochlea in 
wild-type mice. Antibody-specificity is confirmed by absence of immunostaining in these cells in the apical 
(b), middle (d) and basal (f) turns in Mpzl2ko/ko mice. Myosin VIIa (green) immunostaining shows the inner 
and outer hair cells of the organ of Corti in wild-type (g) and Mpzl2ko/ko (h) mice. In the basal cells of the stria 
vascularis immunostaining of MPZL2 (red) was observed in the wild-type (i) mice and not in Mpzl2ko/ko (j) 
mice.  Na+/K+-ATPase (green) immunostaining was employed for marking marginal cells (i, j). Cell nuclei were 
stained with DAPI (blue). IHC: inner hair cell, OHC: outer hair cell, DC: Deiters cell, MC: marginal cells, BC: basal 
cells. Scale bars a-h: 20 µm and i, j: 20 µm.
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Table S1 Details on analyzed panels of HI-related genes, and coverage 
 
Gene name RefSeq transcript 
ID 
Mean % covered ≥ 20x 
    HI panel DGD 
20062014 
family W05-682, II:1 
HI panel DG 2.4 
family W16-0195, II:1 
HI panel DG 2.5 
family  
W16-0451, I:2 
Total   120 genes 
coverage 95.9% 
132 genes  
coverage 96.5% 
138 genes 
coverage, 95.8% 
ACTB NM_001101.3 x x x 
ACTG1 NM_001199954.1 x x x 
ADCY1 NM_021116.2 x x x 
ADGRV1 NM_032119.3 x x x 
AIFM1 NM_004208.3 not included not included x 
APOPT1 NM_032374.4 not included x x 
ATP1A2 NM_000702.3 not included x x 
ATP6V1B1 NM_001692.3 x x x 
BDP1 NM_018429.2 x x x 
BSND NM_057176.2 x x x 
CABP2 NM_016366.2 x x x 
CACNA1D NM_000720.3 x x x 
CCDC50 NM_178335.2 x x x 
CD164 NM_006016.5 not included not included x 
CDH23 NM_022124.5 x x x 
CEACAM16 NM_001039213.3 x x x 
CIB2 NM_006383.3 x x x 
CLDN14 NM_144492.2 x x x 
CLIC5 NM_001114086.1 x x x 
CLPP NM_006012 .2 x x x 
CLRN1 NM_001195794.1 x x x 
COCH NM_001135058.1 x x x 
COL11A1 NM_001854.3 x x x 
COL11A2 NM_080680.2 x x x 
COL2A1 NM_001844.4 x x x 
COL4A3 NM_000091.4 x x x 
COL4A4 NM_000092.4 x x x 
COL4A5 NM_033380.2 x x x 
COL4A6 NM_001287758.1 x x x 
COL9A1 NM_001851.4 x x x 
COL9A2 NM_001852.3 x x x 
CRYM NM_001888.4 x x x 
DCDC2 NM_016356.4 not included x x 
DFNA5 NM_004403.2 x x x 
DFNB59 NM_001042702.3 x x x 
DIABLO NM_019887.5 x x x 
DIAPH1 NM_005219.4 x x x 
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Table S1 (continued) 
 
Gene name RefSeq transcript 
ID 
Mean % covered ≥ 20x 
    HI panel DGD 
20062014 
family W05-682, II:1 
HI panel DG 2.4 
family W16-0195, II:1 
HI panel DG 2.5 
family  
W16-0451, I:2 
DIAPH3 NM_001042517.1 x x x 
DSPP NM_014208.3 x x x 
EDN3 NM_207034.2 x x x 
EDNRB NM_001201397.1 x x x 
ELMOD3 NM_032213.4 x x x 
EPS8 NM_004447.5 x x x 
ESPN NM_031475.2 x x x 
ESRRB NM_004452.3 x x x 
EYA1 NM_000503.5 x x x 
EYA4 NM_001301013.1 x x x 
FAM65B NM_014722.3 not included x x 
FGF3 NM_005247.2 x x x 
FOXI1 NM_012188.4 x x x 
GIPC3 NM_133261.2 x x x 
GJB2 NM_004004.5 x x x 
GJB3 NM_024009.2 x x x 
GJB6 NM_001110219.2 x x x 
GPSM2 NM_013296.4 x x x 
GRHL2 NM_024915.3 x x x 
GRXCR1 NM_001080476.2 x x x 
GRXCR2 NM_001080516.1 x x x 
HARS NM_002109.5 x x x 
HARS2 NM_012208.2 x x x 
HGF NM_000601.4 x x x 
HOMER2 NM_004839.3 not included not included x 
HSD17B4 NM_001199291.1 x x x 
ILDR1 NM_001199799.1 x x x 
KARS NM_001130089.1 x x x 
KCNE1 NM_000219.4 x x x 
KCNJ10 NM_002241.4 x x x 
KCNQ1 NM_000218.2 x x x 
KCNQ4 NM_004700.3 x x x 
KITLG NM_000899.4 not included x x 
LARS2 NM_015340.3 x x x 
LHFPL5 NM_182548.3 x x x 
LOXHD1 NM_144612.6 x x x 
LRTOMT NM_001145309.3 x x x 
MARVELD2 NM_001038603.2 x x x 
MCM2 NM_004526.3 not included not included x 
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Table S1 (continued) 
 
Gene name RefSeq transcript 
ID 
Mean % covered ≥ 20x 
    HI panel DGD 
20062014 
family W05-682, II:1 
HI panel DG 2.4 
family W16-0195, II:1 
HI panel DG 2.5 
family  
W16-0451, I:2 
MIR96 NR_029512.1 x x x 
MITF NM_198159.2 x x x 
MSRB3 NM_198080.3 x x x 
MYH14 NM_001145809.1 x x x 
MYH9 NM_002473.5 x x x 
MYO15A NM_016239.3 x x x 
MYO3A NM_017433.4 x x x 
MYO6 NM_004999.3 x x x 
MYO7A NM_000260.3 x x x 
NARS2 NM_024678.5 not included x x 
NLRP3 NM_001079821.2 x x x 
OPA1 NM_130837.2 x x x 
OSBPL2 NM_144498.2 not included x x 
OTOA NM_144672.3 x x x 
OTOF NM_194248.2 x x x 
OTOG NM_001277269.1 x x x 
OTOGL NM_173591.3 x x x 
P2RX2 NM_170683.3 x x x 
PAX3 NM_181459.3 x x x 
PCDH15 NM_033056.3 x x x 
PDZD7 NM_001195263.1 x x x 
PET100 NM_001171155.1 not included x x 
PNPT1 NM_033109.4 x x x 
POU3F4 NM_000307.4 x x x 
POU4F3 NM_002700.2 x x x 
PRPS1 NM_002764.3 x x x 
PTPRQ NM_001145026.1 x x x 
RDX NM_002906.3 x x x 
S1PR2 NM_004230.3 not included not included x 
SERPINB6 NM_001271823.1 x x x 
SIX1 NM_005982.3 x x x 
SIX5 NM_175875.4 x x x 
SLC17A8 NM_139319.2 x x x 
SLC26A4 NM_000441.1 x x x 
SLC26A5 NM_198999.2 x x x 
SLC33A1 NM_004733. x x x 
SLITRK6 NM_032229.2 x x x 
SMPX NM_014332.2 x x x 
SNAI2 NM_003068.4 x x x 
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Table S1 (continued) 
 
Gene name RefSeq transcript 
ID 
Mean % covered ≥ 20x 
    HI panel DGD 
20062014 
family W05-682, II:1 
HI panel DG 2.4 
family W16-0195, II:1 
HI panel DG 2.5 
family  
W16-0451, I:2 
SOX10 NM_006941.3 x x x 
STRC NM_153700.2 x x x 
SYNE4 NM_001039876.2 x x x 
TBC1D24 NM_001199107.1 x x x 
TECTA NM_005422.2 x x x 
TIMM8A NM_004085.3 x x x 
TJP2 NM_004817.3 not included x x 
TMC1 NM_138691.2 x x x 
TMEM132E NM_001304438.1 not included x x 
TMIE NM_147196.2 x x x 
TMPRSS3 NM_024022.2 x x x 
TNC NM_002160.3 x x x 
TPRN NM_001128228.2 x x x 
TRIOBP NM_001039141.2 x x x 
TSPEAR NM_144991.2 x x x 
TYR NM_000372.4 not included x x 
USH1C NM_153676.3 x x x 
USH1G NM_173477.4 x x x 
USH2A NM_206933.2 x x x 
WBP2 NM_012478.3 not included not included x 
WFS1 NM_006005.3 x x x 
WHRN NM_015404.3 x x x 
YAP1 NM_001130145.2 not included x x 
Coverage was calculated per sample on a base pair resolution, using the coverage function of BEDtools 
(v2.19.1; PMID 20110278). Subsequently, the mean percentage of base pairs with at least 20 reads (≥20x 
coverage) was determined per sample, for the enriched regions of each gene. 
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Table S2 Primer sequences and PCR conditions 
 
Target Primer Oligonucleotides Amplicon 
size (bp) 
Annealing 
temperature 
(°C) 
MPZL2 exon 1 Forward cattcacttcccaggcaagc 552 58 
Reverse agagtgagcagtgaaggagg 
MPZL2 exon 1 Forward tggggtggtgctttgagaagtg 652 60 
Reverse gctcaggctcccaaacaaaagtc 
MPZL2 exon 2 Forward gtaagtttgggagatggggc 422 58 
Reverse ttccgagcttaaccttgtgc 
MPZL2 exon 2 Forward gatggggcatctcagtttcactttac 365 60 
Reverse ggaaaggagaaatggactggcttatt 
MPZL2 exon 3 Forward tttcacttccgctcccac 381 58 
Reverse tgtccctctctctcagcc 
MPZL2 exon 3 Forward ctgggtgctgagtaagaagacctttt 316 60 
Reverse gcccctttcttttctacaagctctc 
MPZL2 exon 4 Forward tggggcctaagatttccatg 542 58 
Reverse tctgtcctgcaaatgtgaattc 
MPZL2 exon 4 Forward cctattgctagtaggattcacaaggtaat 369 60 
Reverse caaaataccaagagtcgccataaga 
MPZL2 exon 5 Forward ggcaccagtttagctctgtg 366 58 
Reverse ctgacccagctcctctaatttc 
MPZL2 exon 5 Forward acccacttgcttcttgtcttgttca 555 60 
Reverse aagctctcctgtaaaaactgccagata 
MPZL2 exon 6 Forward ggtcatccaagtgtccatgc 694 58 
Reverse cgaggaggcttagctcacc 
MPZL2 exon 2  
(genomic qPCR ) 
Forward ctgtggaaatttatacctcccgg 84 60 
Reverse gggcaaagctggagaaagtg 
MPZL2 exon 3  
(genomic qPCR ) 
Forward atgggaatcctgagcggtac 110 60 
Reverse caccccatcaacatcaggtg 
MPZL2 exon 5  
(genomic qPCR ) 
Forward tcccaagtgcatgtaattcttcc 99 60 
Reverse tcaggtgaacaagacaagaagc 
MPZL2 mRNA exons 2-3 Forward gtgggtgatgctctaacagtg 115 60 
Reverse ccttaaaccgcccactcatg 
MPZL2 mRNA exons 3-4 Forward cagttcgacgacaatgggac 109 60 
Reverse cagagaagcgtacagtgtgc 
TECTA exon 2 Forward gttgaacttcggaggacctg 489 58 
 
 Reverse ggcaagctggtacatacaaatag   
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Table S2 (continued) 
 
Target Primer Oligonucleotides Amplicon 
size (bp) 
Annealing 
temperature 
(°C) 
TECTA exon 3 Forward accaagatgcatgaaagtgc 509 58 
Reverse gccaataaatcctcccttcc 
TECTA exon 4 Forward ggtgtttgggggttctaattc 576 58 
Reverse tttcctgcaaagtgggtagc 
TECTA exon 5 Forward aggagtcagagctggaggg 423 60 
Reverse tagcctcgtagtccacctgc 
TECTA exon 6 Forward acctagaatgctggcccc 455 58 
Reverse aaaattaccttgatctccattaccc 
TECTA exon 7 Forward gggtgaccatacctccctaac 645 58 
Reverse cagagacaaacagcagaaccag 
TECTA exon 8 Forward ttcctgatctctgctggaac 833 56 
Reverse tggttgtggtattaggtggg 
TECTA exon 9_1 Forward cctcaattctgtcttccccg 485 58 
Reverse gaagcagccctggtagcc 
TECTA exon 9_2 Forward caatgcctgtgcgaggag 499 58 
Reverse cagatcattagaaaacgctccc 
TECTA exon 10 Forward ggcagaccgtgtctttatcc 746 58 
Reverse cctggaagggaagtcctgag 
TECTA exon 11_1 Forward gcacgcacacttctgtctc 490 56 
Reverse agctggtctggaagtcaaag 
TECTA exon 11_2 Forward agtggcacagacaacaggg 495 58 
Reverse tctctagggcctctctctgc 
TECTA exon 12 Forward ctgctcaaacttccctctgg 754 58 
Reverse tctagggagttggaagactgg 
TECTA exon 13 Forward agacccaggctttctgtgag 565 58 
Reverse tgacactcagtgcccaagag 
TECTA exon 14 Forward gtttccccactgctgcc 679 58 
Reverse tttgattctttaaaacctggtcac 
TECTA exon 15 Forward gggacagaatggagtcgttg 623 58 
Reverse ttactggggtctctgatgtgc 
TECTA exon 16 Forward tggcacaatgcactagcttc 552 58 
Reverse ctgcagctcacagctctctac 
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Table S2 (continued) 
 
Target Primer Oligonucleotides Amplicon 
size (bp) 
Annealing 
temperature 
(°C) 
TECTA exon 17 Forward agctaatccaggcccacag 555 58 
Reverse aatgtggcctcagatggaac 
TECTA exon 18 Forward tggaggtcatttgcctcttc 551 58 
Reverse ccacagtaggcatcccaaac 
TECTA exon 19 Forward cccaagtaaatgctaagg 456 56 
Reverse tggttgaaagcatttaggctc 
TECTA exon 20 Forward cccatgtggctagcagg 600 58 
Reverse cttgattgtctgtaaaatgaggc 
TECTA exon 21 Forward atgcagtccaggggtcac 456 58 
Reverse tcactgtcccatcaaagatgac 
TECTA exon 22 Forward ccagtggattcaatgatcaag 391 56 
Reverse ctttaaggaagcaggtgatg 
TECTA exon 23 Forward gatctcctgaccgcgtg 443 58 
Reverse aattccttgggcatgttcc 
TECTA exon 24 Forward gctgccttagggccatttag 398 58 
Reverse ctggtttctggaccttggac 
TECTA mRNA exons 1-4 Forward ttattggcaacaagttgaggag 572 57 
Reverse cttcctcccatgtcacaatg 
TECTA mRNA exons 1-4 
nested 
Forward actcagttcctccagcctctac 447 57 
Reverse gaaggttgccatgtctttgaag 
TECTA mRNA exons 4-7 Forward cttcaaagacatggcaaccttc 477 57 
Reverse tcattgttgaaatccagacagc 
TECTA mRNA exons 6-8 Forward gaccacaaacgtcaatgttcc 589 57 
Reverse tgtttccacggcagtagatatg 
TECTA mRNA exons 7-9 Forward agtggaggtgaatggctacaag 672 57 
Reverse cacacggagtagtggctgaag 
TECTA mRNA exons 9-10 Forward caggcctatgctcttgtgtg 747 57 
Reverse ccactgtcgtactgtttttgtttc 
TECTA mRNA exons 9-11 Forward aggtcaagataggaggcatcg 723 57 
Reverse gacatccctcagagcagctatc 
TECTA mRNA exons 10-12 Forward aacagctccttcctggagtg 896 57 
Reverse acaaccttcaggccaaaatc 
TECTA mRNA exons 10-12 
nested 
Forward gagtgggggcaatgagtcag 786 57 
Reverse acgtggaagccaaaggaaaag 
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Table S2 (continued) 
 
Target Primer Oligonucleotides Amplicon 
size (bp) 
Annealing 
temperature 
(°C) 
TECTA mRNA exons 11-13 Forward ctctttccccaagtttgttgtc 785 57 
Reverse agtcactcttcaggcggatg 
TECTA mRNA exons 12-15 Forward aagaactgcctgtttgactcttgc 781 57 
Reverse tgctgtagattttggttgccaaac 
TECTA mRNA exons 14-16 Forward gcttatcatcaacttcgacaagtg 494 57 
Reverse agtagccatcaccctgcatc 
TECTA mRNA exons 15-18 Forward ttaaaatcagcatcagcgagag 597 57 
Reverse tcacctctgcatcgataatgtc 
TECTA mRNA exons 17-20 Forward agtggttgaagatccctgtgtg 556 57 
Reverse atgtttgtaggaggcgtttttg 
TECTA mRNA exons 19-22 Forward caacactggcaacatcatcac 599 57 
Reverse taggtcccactgaaatgatctg 
TECTA mRNA exons 21-24 Forward tcaccgtctttaaattcataggg 476 57 
Reverse ttaagggcacacactttttatcc 
For primer design to amplify MPZL2, reference sequence NM_005797.3 was used, and for TECTA, 
ENST00000392793. 
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Abstract
We identified heterozygous pathogenic missense variants of LMX1A in two families of 
Dutch origin with nonsyndromic hearing impairment (HI), using whole exome sequencing. 
One variant, c.721G>C (p.Val241Leu), occurred de novo and aﬀected an amino acid of 
LMX1A’s homeodomain, which is essential for DNA binding. The second variant, c.290G>C 
(p.Cys97Ser), aﬀected a zinc binding residue of the second LIM domain that is involved 
in protein-protein interactions. Bi-allelic deleterious variants of Lmx1a are associated with 
a complex phenotype in mice, including deafness and vestibular defects, due to early-
stage arrest of inner ear development. Although Lmx1a mouse mutants demonstrate 
neurological, skeletal, pigmentation and reproductive system abnormalities, no syndromic 
features were present in the participating subjects of either family. LMX1A has previously 
been suggested as a candidate gene for intellectual disability, but our data do not support 
this, as aﬀected subjects displayed normal cognition. Phenotype characterization of the 
aﬀected individuals revealed large phenotypic variability in the age of onset (congenital to 
35 years), (a)symmetry, severity (mild to profound) and progression rate of HI. About half 
of the aﬀected individuals displayed vestibular dysfunction and experienced symptoms 
thereof. The late-onset progressive phenotype, and absence of cochleovestibular 
malformations on computed tomography scans indicate that heterozygous defects of 
LMX1A do not result in severe developmental abnormalities in humans. We hypothesize 
that a single LMX1A copy encoding wild-type protein causes minor cochleovestibular 
developmental abnormalities that eventually lead to a progressive phenotype, or that it 
is suﬃcient for normal development but insuﬃcient for maintenance of cochleovestibular 
function. 
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Report
Hereditary nonsyndromic hearing impairment (NSHI, MIM: 500008) is genetically very 
heterogeneous. Currently, more than 100 deafness genes have been identified, and still 
every year novel ones are discovered (Hereditary Hearing Loss Homepage). Since 2010, 
whole exome sequencing (WES) and targeted next generation sequencing have enabled 
the rapid and cost-eﬃcient identification of deafness genes.1 However, we need to beware 
of seemingly causative variants that segregate in small families or occur in several unique 
individuals with HI by coincidence, especially in dominant NSHI. This is illustrated by 
the recent disqualification of MYO1A (MIM: 601478) as a deafness gene.2,3 Ideally, unique 
pathogenic variants are identified in several families with a similar phenotype and not in a 
significant number of controls. Genetic studies are preferably supported by functional and 
animal studies that prove the deleterious eﬀect of a variant and demonstrate the function 
of a gene in hearing. As this is often very time- and money-consuming, (homology) protein 
modeling or existing data on studies in mice can be supportive in the discovery of novel 
deafness genes, as has recently been the case for KITLG (MIM: 184745)4 and S1PR2 (MIM: 
605111).5 
In the present study, we identified pathogenic missense variants of LMX1A (MIM: 600298), 
a gene associated with a complex phenotype in mice, including recessive deafness and 
vestibular defects6-8, as a cause of dominant NSHI and vestibular dysfunction in human. 
This study was approved by the medical ethics committee of the Radboud university 
medical center and is in accordance with the principles of the World Medical Association 
Declaration of Helsinki. Written informed consent was obtained from all participants or 
their legal representatives. 
 A family of Dutch origin (W15-0551, Figure 1a), was investigated to identify the 
underlying genetic defect of the dominant NSHI segregating in the family. We performed 
WES in the index case (III:8). The exome was enriched with the Agilent SureSelect version 
4 kit (Santa Clara, CA, USA), and WES was performed on an Illumina HiSeq system by BGI 
Europe (Denmark)9. As a first step, variants in genes associated with hearing impairment (HI) 
were selected (gene list DGD20062014) and classified according to the existing guidelines 
from the American College of Medical Genetics and Genomics10, as described previously.9 
Mean ≥20x coverage was obtained for 96% for the enriched regions. No (likely) pathogenic 
variants were identified. As a next step, all WES variants were analyzed. To reduce the 
number of candidate variants, WES was performed in subject II:7 as well, under the same 
conditions and using the Agilent SureSelect version 5 kit. After filtering for shared, rare 
(≤0.5%), and missense, nonsense, indels, and splice site variants, 186 variants remained 
| Chapter 4.2
168
(Table 1). One of these variants was a heterozygous missense variant of LMX1A, c.721G>C 
(p.Val241Leu) (Figure S1). This variant has not been reported in ExAC and segregated with 
the HI in the family (Figure 1a). As it was unknown whether the grandmother (subject I:2) 
was hearing impaired, based on conflicting subjective information provided by family 
members, we investigated whether the variant of LMX1A was inherited or occurred de novo 
in subject II:7. Haplotypes in the LMX1A region were determined by genotyping variable 
number of tandem repeats (VNTR) markers, as described previously4. This revealed that the 
c.721G>C containing haplotype was also present in individuals in the second generation, 
who did not carry this variant (Figure 1a). This indicates that the variant occurred de novo in 
subject II:7. LMX1A c.721G is highly conserved (PhyloP 5.53) and p.Val241 is fully conserved 
in the LIM-homeodomain protein family (Figure 2). Defects of Lmx1a have been associated 
with HI and vestibular defects in mouse.6-8 All together, we considered the identified LMX1A 
variant a promising candidate to underlie the HI in family W15-0551.
Figure 1 Pedigrees, VNTR genotypes and segregation of LMX1A variants.
(a) Genotypes of VNTR markers and segregation of the identified missense variant of LMX1A in family W15-
0551. Genetic locations of the markers were derived online from the Marshfield genetic map and maker 
order was confirmed in the human genome assembly GRCh37/hg19. As the variant resides on an allele 
(depicted in red) that is shared by non-aﬀected siblings of subject II:7, the variant was concluded to be de 
novo in subject II:7. It remained unclear whether subject I:2 was aﬀected only at high age or earlier, based on 
conflicting subjective information provided by her family members. (b) Pedigree and segregation analyses 
of a missense variant in LMX1A in family 63136. Index cases are indicated by arrows. +, wild-type.
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 To exclude other candidate DNA variants (n=185) shared by individuals II:7 and III:8, 
linkage analysis was performed by genotyping of all subjects of family W15-0551, using 
the 700K SNP Global Screening Array (Illumina, San Diego, CA, USA). Superlink online SNP 
1.1 software was employed for approximate multipoint LOD score calculations, and a 
window size of 20 SNPs was used.11 The inheritance pattern was assumed to be autosomal 
dominant with a disease allele frequency of 0.001. The penetrance of the disease allele 
was set at 99%. There were 54 regions in which linkage could not be excluded by a LOD 
score ≥ -2. (Figure S2, Table S1). DNA variants in these regions were filtered and classified 
as described above, which resulted in seven candidate variants (Table S1). None of them 
segregated with the HI in the family, as determined by Sanger sequencing. As ten of the 
54 regions not excluded by linkage analysis harbored known deafness genes (Table S1), 
coverage of all exons and exon-intron boundaries of these genes, including MYO6 (MIM: 
600970), was manually checked to be at least 10x. Subsequently, Sanger sequencing was 
performed for regions with a lower coverage, which did not reveal any rare variants (allele 
frequency ≤ 0.5%).  Since the HI associated with dominant defects of MYO6 is similar to that 
in the aﬀected subjects of family W15-055112,13, this gene was also excluded by segregation 
analysis of SNPs located in and flanking MYO6 (Figure S3). 
We addressed further involvement of deleterious LMX1A variants in dominant NSHI. WES 
data of genetically undiagnosed individuals with NSHI were evaluated for rare variants of 
LMX1A. Only subjects with suspected dominant inheritance or without family history of HI 
were included (n=405) This revealed a heterozygous variant c.290G>C (p.Cys97Ser) in the 
index case of family 63136 (Figure S1), which segregated with the dominantly inherited HI in 
the family (Figure 1b). LMX1A c.290G>C is highly conserved (PhyloP 5.45) and has not been 
reported in the ExAC database. Residue Cys97 is located within the second LIM domain, 
and is fully conserved in the LIM-homeodomain protein family (Figure 2). Screening of 
WES data also revealed a heterozygous variant c.376G>A (p.Gly126Lys) in the index case of 
family W05-233, but this variant was inherited from the normal hearing mother. As can be 
seen in Figure 2, p.Gly126 is not conserved in the LIM-homeodomain protein family.
Table 1 Filter steps applied on variants identified in WES for family W15-0551 
Filter steps No. of variants 
Shared by subjects II:7 and III:8 85798 
≤0.5% in ExAC, dbSNP database and in-house databasea 1039 
Exonic missense, nonsense, indels, and splice site variantsb 186 
aIn-house database contains WES data of 13314 individuals, the vast majority of Dutch origin, aﬀected by a 
large number of diﬀerent diseases (including 810 subjects with HI) and also non-aﬀected individuals. 
bSplice site variants up to +8/-20 nucleotides were selected 
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The aﬀected subjects of family W15-0551 (II:7, III:8 and IV:2) were clinically examined to 
characterize their audiovestibular phenotype. Medical history was obtained; otoscopy, 
tympanometry and pure-tone audiometry were performed, and otoacoustic emissions 
and acoustic reflexes were assessed, according to current standards. Family 63136 did not 
participate in our clinical evaluation; only retrospective data from the aﬀected subjects (I:2, 
II:2, II:3 and II:4) were analyzed. There was no evidence of acquired causes of HI. All aﬀected 
subjects had sensorineural HI except for individual II:7 of family W15-0551, who had 
bilateral fenestral otosclerosis and mixed HI of the left ear. We assume that the sensorineural 
HI was unlikely to be caused by otosclerosis, because there were no radiological signs of 
cochlear otosclerosis and her vestibular test results fit with the defect in LMX1A. There were 
no preoperative audiograms available before stapedectomy of the right ear in 1973 for 
comparison of the pre- and postoperative bone conduction thresholds of the right ear.
LIM HOXLIM
Figure 2 Domains and conservation of (mutated) residues in the LIM-homeodomain protein family.
Domain architecture of the LIM-homeodomain protein family. All ~600 members of the family were 
extracted from the SMART domain database and aligned. Sequence logos for the second LIM domain and 
the homeodomain within this family were created with WebLogo14, which shows the perfect conservation 
of the mutated residues Cys97 and Val241 (indicated by arrows). Within the second LIM domain, the residues 
that together bind two zinc atoms are indicated with black lines above the amino acid sequence.
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 The reported age of onset varied from congenital to 35 years (Table S3). Aﬀected 
subjects had mild to profound HI, with overall a downsloping audiogram configuration 
(Figure 3). Subject IV:2 of family W15-0551 and subject II:2 of family 63136 displayed 
asymmetric HI, whereas the other aﬀected individuals demonstrated symmetric HI. 
Longitudinal linear regression analysis of hearing thresholds revealed significant 
progression in all aﬀected subjects of both families, except for subject IV:2 of family W15-
0551, probably because follow-up time was too short (3 years) to measure significant 
deterioration of hearing in this individual. Progression of HI was not analyzed in subject II:7 
of family W15-0551, as we cannot exclude deterioration of hearing due to her otosclerosis. 
The progression rate and severity of HI varied widely among the aﬀected subjects (Table 
S3). Speech reception thresholds were lower than or comparable to pure tone average 
thresholds at 0.5, 1 and 2 kHz for the better hearing ear, indicating absence of retrocochlear 
pathology (Table S3). This is confirmed by results from acoustic reflex measurements in 
all aﬀected subjects and brainstem evoked response audiometry in subject II:2 of family 
63136, which showed no indications of retrocochlear pathology (data not shown). CT scans 
in subject II:7 of family W15-0551 and the index case (II:3) of family 63136 did not show 
cochleovestibular malformations, except for known fenestral otosclerosis in the former 
individual.
Figure 3 Audiometric characterization of families aﬀected by deleterious LMX1A variants.
Air conduction thresholds of both ears of the aﬀected individuals are shown of first-visit and last-visit 
audiometry. The 95th percentile threshold values of presbyacusis (p95) were calculated for the last-visit 
audiogram, and matched to the individual’s sex and age, according to the ISO 7029 standard. (a) Family 
W15-0551. For subject II:7, also bone conduction thresholds of the left ear are depicted, because of mixed 
HI due to fenestral otosclerosis (conductive HI) and the LMX1A variant (sensorineural HI). (b) Family 63136. 
Subjects did not participate in our clinical evaluation; only retrospective data were used for analysis. R, right 
ear; L, left ear. 
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 Four of the aﬀected individuals reported sudden episodes of vertigo in the past that 
lasted minutes to days, with or without tinnitus, but without simultaneous deterioration 
of hearing (Table S3). Individuals could not identify triggers for the vertigo episodes. 
Vestibular function was assessed in subjects II:7 and III:8 (family W15-0551) and the index 
case of family 63136, using electronystagmography rotary chair stimulation and caloric 
irrigation testing, according to current standards. The vestibular tests revealed bilateral 
symmetric hyporeflexia in subject III:8 of family W15-0551 (42 years old), asymmetric 
severe hyporeflexia to areflexia to the detriment of the left vestibulum in subject II:3 of 
family 63136 (52 years old), and bilateral areflexia in subject II:7 of family W15-0551 (73 
years old). Subjects II:7 and III:8 of family W15-0551 also underwent a video head impulse 
test (vHIT) and cervical vestibular evoked myogenic potential (cVEMP) recordings. The 
vHIT displayed bilateral weakness of the posterior semicircular canals in individual II:7 and 
normal function in individual III:8. cVEMPs showed no responses up to 100 dBnHL in both 
subjects, indicating dysfunction of the saccule. Since vestibular abnormalities are more 
severe in the older individuals, we hypothesize that there is progressive deterioration of 
vestibular function. There were, however, no longitudinal data available to confirm this. 
Apart from the vestibular abnormalities, the observed HI phenotype fits with DFNA7, for 
which the underlying defect has been localized to chromosome 1q21-q23 encompassing 
LMX1A.15 Therefore, LMX1A is a candidate gene for DFNA7.
LMX1A is a transcription factor that belongs to the highly conserved LIM-homeodomain 
protein family. LIM-homeodomein proteins are characterized by two cysteine-rich zinc-
binding LIM motifs that are known to be involved in protein-protein interactions16, and a 
homeodomain that is known to bind DNA.17 The mutated LMX1A residues identified in this 
study are located within the second LIM domain and the homeodomain. The p.Cys97Ser 
aﬀects one of the two zinc binding residues, which is highly likely to be deleterious for 
protein folding and function. LIM-homeodomain transcription factors play a pivotal role in 
various developmental processes, and can be divided into subgroups based on sequence 
similarities. The vertebrate Lmx subgroup consists of paralogs LMX1A and LMX1B that have 
identical homeodomain sequences (Figure S4).17 
 Bi-allelic loss-of-function variants of the murine Lmx1a gene cause congenital deafness, 
vestibular defects, and neurological, skeletal, pigmentation, and reproductive system 
abnormalities.6-8 However, upon screening (Supplemental Methods), none of the aﬀected 
individuals of families W15-0551 and 63136 displayed any cutaneous abnormalities, signs 
of cognitive dysfunction, or peripheral or central nervous system involvement. History 
taking did not indicate fertility problems. In contrast to humans, there is no auditory 
phenotype in heterozygous Lmx1a mouse mutants, but occasionally mild pigmentation 
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abnormalities are seen.8,18 Normal hearing thresholds have been measured up to 16 weeks8 
and 3 months (unpublished data, kindly provided by Dr. Johnson, Jackson Laboratory, Bar 
Harbor, Maine, concerning heterozygous Lmx1adr-J mice). Interestingly, the genetic defect 
in the well-studied mouse model Lmx1adr-J  is p.Cys82Tyr and aﬀects one of the zinc-binding 
cysteine residues of the LIM1 domain19, which supports the pathogenicity of the identified 
p.Cys97Ser variant.
 Heterozygous loss-of-function variants in LMX1B (MIM: 602575), a paralog of LMX1A, 
have been associated with nail-patella syndrome in human (NPS, MIM: 161200).20-22 NPS 
is characterized by dysplastic nails, absent or hypoplastic patellae, elbow dysplasia, and 
iliac horns, and may be accompanied with nephropathy and/ or glaucoma.23,24 There are 
important similarities between genetic defects in LMX1A and LMX1B. The mutated residues 
Cys97 and Val241 identified in LMX1A, are in the sequence alignments at the same 
positions as the amino acids Cys118 and Val265 in LMX1B  (Figure S4). Amino acid variant 
p.Val265Leu of LMX1B is known to be disease-causing and aligns with p.Val241Leu of LMX1A 
in the present study.25 The equivalent of LMX1A variant p.Cys97Ser has not been identified 
in LMX1B, but other substitutions at this position that would also impair the binding of 
a zinc atom, p.Cys118Phe22 and p.Cys118Tyr26, and the equivalent Cysteine to Serine 
substitution in LIM domain 1 (p.Cys59Ser), have been associated with NPS. Resemblance of 
the identified LMX1A variants with disease-causing variants in LMX1B supports the former’s 
pathogenicity.
We hypothesize that the identified deleterious LMX1A variants lead to haploinsuﬃciency, 
which is also the proposed pathogenic mechanism of NPS, caused by variants of LMX1B.27-29 
A number of LMX1B variants have been tested for a dominant-negative eﬀect, including 
p.Val265Leu, the equivalent of LMX1A p.Val241Leu, but no inhibitory eﬀect on wild-type 
protein function was found.28,29 Mono-allelic Lmx1b loss-of-function mice do not have a 
phenotype, except mice with the heterozygous Lmx1b variant p.Val265Asp, for which a 
dominant-negative eﬀect has been suggested.30 Our hypothesis that heterozygous LMX1A 
variants result in haploinsuﬃciency is strengthened by the fact that sensorineural HI and 
impaired speech development were diagnosed in a subject with a heterozygous interstitial 
1q23.3q24.1deletion encompassing LMX1A.31 Additional cases with heterozygous deletions 
of this region are reported to have impaired speech development.31,32 However, it remains 
unclear whether impaired speech development in these cases was associated with HI or 
with the determined intellectual disability (ID). Our data do not support the suggested 
involvement of LMX1A in ID31,32, as aﬀected subjects of families W15-0551 and 63136 
displayed normal cognition. Based on our findings and those of Chatron et al. (2015) and 
Mackenroth et al. (2016), we recommend screening for HI in subjects with mono-allelic loss 
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of LMX1A. The fact that a single copy of LMX1A encoding wild-type protein does not lead to 
a phenotype in mouse, whereas it does in man, suggests a diﬀerence in dosage sensitivity 
for this gene.27 However, it cannot be excluded that heterozygous Lmx1a mouse mutants 
develop HI later in adulthood, as mice have only been measured up to 3 months, whereas 
some subjects developed HI in the third decade of life. 
 In mouse, Lmx1a expression in the inner ear starts at the otocyst stage (from E10.5 
onwards) and is later restricted to non-sensory epithelia of the developing cochlea and 
vestibular system.8,33-35 Bi-allelic Lmx1a defects lead to disorganization of the inner ear and 
lack of diﬀerentiation and separation of sensory, non-sensory and neurogenic domains of 
the vestibulocochlear system. As a result, Lmx1a mouse mutants have a short and malformed 
cochlear duct, no endolymphatic duct and sac, no semicircular canals, and the sacculus 
and utriculus remain rudimentary.8,34,35 Hair cells in the basal part of the cochlea display 
severe disorganization, whereas hair cells in the apical turn are only mildly disorganized.35 
Although expression of Lmx1a in the inner ear is reduced from E16.5 onwards33, Lmx1a has 
been suggested to function in the maintenance of hair cells, as there is progressive hair cell 
loss in adult mutant mice.35 
There is large phenotypic variability within families W15-0551 and 63136, regarding age 
of onset, (a)symmetry, severity and progression rate of HI. Large intrafamilial phenotypic 
variation has also been reported for NPS.36 The variable HI phenotype suggests involvement 
of environmental and/or genetic factors in the expression of the phenotype. The expression 
level of the wild-type LMX1A allele might well be one of the genetic factors. The overall 
downsloping audiogram configuration observed in the aﬀected subjects corresponds to 
the abnormal development of the sensory epithelium in the organ of Corti in homozygous 
Lmx1a mouse mutants, displaying severe abnormalities of this epithelium in the basal part 
of the cochlea compared to mild defects in the apical regions.34 
 The onset of HI caused by LMX1A defects was in the 2nd or 3rd decade in most of the 
cases, which suggests that one LMX1A copy is suﬃcient for normal cochlear development. 
As homozygous Lmx1a mutant mice displayed loss of cochlear hair cells in the adult stage, 
the gene has been suggested to be essential for long-term maintenance of hair cells.35 It is 
therefore tempting to speculate that the deterioration of HI over time is due to progressive 
loss of hair cells. Since vestibular complaints occurred during adulthood and vestibular 
dysfunction seemed progressive, we speculate that LMX1A is also critical for maintenance 
of the adult vestibular organs. Interestingly, it has been demonstrated that both Lmx1a 
and Lmx1b not only function in the developing mouse brain, as expression of both genes 
was found to be sustained in the adult midbrain and to be essential for survival of adult 
dopaminergic neurons in the midbrain.37 A function in the regulation of genes with a 
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mitochondrial function was indicated. It remains to be determined whether LMX1A has 
a similar function in the adult inner ear. So far, there are no indications for LMX1A/Lmx1a 
expression in the adult inner ear.33,38 An   explanation for the HI in the presented families is 
that a single copy of LMX1A causes minor cochleovestibular developmental abnormalities 
that eventually lead to a progressive disease-phenotype. Currently, the recessive phenotype 
of deleterious LMX1A variants in humans remains unclear. As suggested by Steﬀes et al. 
(2012), bi-allelic loss-of-function variants of LMX1A might well be lethal in human.8
In conclusion, mono-allelic missense variants of LMX1A were found to underlie 
nonsyndromic HI and vestibular defects. The HI phenotype has a variable age of onset, 
severity and progression rate. Haploinsuﬃciency is the most likely pathogenic mechanism. 
Like in LMX1B, we expect that both truncating and missense variants can lead to the 
identified phenotype, with a preferential presence of missense variants in the conserved 
residues of the LIM domains and homeodomain of LMX1A. 
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Supplemental data
Supplemental methods
Screening protocol for syndromic abnormalities in subjects with LMX1A variants.
Medical history was obtained from all aﬀected subjects of families W15-0551 and 63136, 
regarding neurological, cognitive and dermatological abnormalities, and sub/infertility. 
Special attention was paid to symptoms related to ataxia. Participants of family W15-0551 
also underwent physical neurological and dermatological examination.
Neurological examination included testing of:
• Mental status, language and articulation
• Cranial nerves 
• Muscle strength using the Medical Research Council (MRC) scores (0-5) of 18 predefined 
muscle groups, including shoulder abduction, elbow flexion, wrist extension, hip 
flexion, knee extension, foot dorsiflexion (extension) and plantar flexion, and toe 
dorsiflexon (extension); muscle tone and bulk
• Sensory function including pain and light touch sensation, vibration sense and 
position sense (absent; reduced; normal)
• Coordination with use of nose-finger test, diadochokinesis, heel-shin slide, and 
tandem gait (normal / abnormal)
• Deep tendon reflexes (biceps, brachioradialis, triceps, patellar, ankle jerks and plantar 
reflex) bilaterally (absent / reduced / normal)
• Posture and gait, including heel and toe walking (normal / abnormal)
• SARA Score (Scale for the Assessment and Rating of Ataxia)1
  
Cognitive screening of II:7 and III:8 included:
• Montreal cognitive assessment2
• National adult reading test3
• Rey auditory verbal learning test4
Cognitive screening of IV:2 included:
• Wechsler Intelligence scale for children, similarities subset5
• Wechsler Intelligence scale for children, coding subtest5
• Beery-Buktenice developmental test of visual motor integration, visual motor 
integration subset6
• Rey auditory verbal learning test
| Chapter 4.2
180
Dermatological screening included evaluation of skin type (I–VI), skin depigmentation, 
hypopigmentation, and hyperpigmentation, number of naevi, allergic reactions, other 
observed skin abnormalities, and treatment of skin abnormalities in the past. The 
whole body was examined and a Wood’s lamp was used to analyze hypo-, hyper-, and 
depigmentations. If necessary, skin abnormalities were reviewed with a dermatoscope.
Supplemental figures and tables
Figure S1 Sequences of LMX1A c.721G>C and c.290G>C.
Analysis of the WES paired-reads demonstrated a heterozygous missense variant in the index cases of family 
W15-0551, c.721G>C (p.Val241Leu) (a) and of family 63136, c.290G>C (p.Cys97Ser) (b). NM_177398.3 was 
employed as reference sequence. Figures show reverse sequences and were obtained using Alamut Visual 
version 2.7.1 (Interactive Biosoftware, Rouen, France). 
a b
c.721G>C c.290G>C 
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Figure S2 Genome wide LOD scores per chromosome of family W15-0551.
Linkage analysis was performed in family W15-0551 and LOD scores were calculated using SuperLink 
online SNP 1.1 software. The blue lines define the customary LOD score range, with a LOD score of ≥3.3 
indicating significant linkage and a LOD score <-2 indicating exclusion of linkage. The green line indicates 
the maximum LOD score (2.4) measured in family W15-0551. In the calculations, window size was set at 20 
SNPs, disease allele frequency at 0.001 and penetrance at 99%. There were 54 regions in which linkage could 
not be excluded (LOD score ≥ -2), but none of them had a significant maximum LOD score. The region with 
the highest LOD score of 2.4 was located on chromosome 6 and delimited by rs16883199 and rs2143437 
(chr6:73,739,831-96,400,830; GRCh37, hg19). 
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Figure S3 Haplotype analysis of the genomic region harboring MYO6.
MYO6 haplotypes were determined by genotyping SNPs in and flanking MYO6 using Sanger sequencing and 
WES data of family W15-0551. As subject IV:2 does not inherit the grandmaternal haplotype, the causative 
variant does not reside in the coding or regulatory regions of MYO6. Black arrow indicates the index case.
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Figure S4 Alignment of LMX1A and LMX1B.
Protein alignment of LMX1A (NP_796372.1) and LMX1B (NP_002307.1) performed with Clustal Omega 
version 1.2.4 (EMBL-EBI, http://www.ebi.ac.uk/Tools/msa/clustalo/). An asterisk (*) indicates positions which 
have a single, fully conserved residue; a colon (:) indicates conservation between groups of strongly similar 
properties, a period (.) indicates conservation between groups of weakly similar properties. There is a high 
percentage of similarity between the two proteins and the homeodomain of the two proteins is identical. 
The mutated residues identified in LMX1A (Cys97 and Val241) are boxed and indicated by a red arrow 
head, and demonstrate that the amino acids at these positions are identical in LMX1B (Cys118 and Val265, 
respectively). LIM, LIM domain; HOX, homeodomain.
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Table S2 Primer sequences and PCR conditions 
Target Primer Oligonucleotides Size (bp) Annealing 
Temperature (°C) 
LMX1A exon 3 Forward gttctttcccaggagtgcg 299 58 
Reverse tgtatgaagaggggcgctag 
LMX1A exon 4 Forward tggttgattagcaggagttcc 461 58 
Reverse ctgaagggaagttctgctcg 
LMX1A exon 5 Forward tgaatgactcaactgaatgcttc 500 58 
Reverse agggaagaaacaatgcagacag 
LMX1A exon 6 Forward tgctctcatacataaagccatcc 376 58 
Reverse caatgcccactgagatccca 
LMX1A exon 7 Forward aggcaagagaggagaccaag 576 58 
Reverse acctggcagcaagtacaatg 
LMX1A exon 8 Forward tggccactgttgctccttta 395 58 
Reverse ccctctcacaagttcctcgt 
LMX1A exon 9 Forward ggaatcaggacccagggaaa 347 58 
Reverse tggaacttcggtgagcatct 
LMX1A exon 10 Forward cagctgaatatcctagcactga 395 58 
Reverse GGAAATGCTGAGCTACACCA 
LMX1A mRNA exons 3-4 Forward AGAACTTCCAAAGCGCGATC 105 60 
Reverse TCCAAGATGACCCGCTGAC 
LMX1A mRNA exons 4-5 Forward TCTACCGGGACAAGAAGCTG 111 60 
Reverse GGGCCCGCATAACAAACTC 
LMX1A mRNA exons 6-7 Forward CTCAACAGAGGCGAGCATTC 97 60 
Reverse ACACTCAGCCCTGTCTCTG 
MYO6  c.2417-1758T>G  Forward ccattcatttgtggactgtg 283  58 
Reverse tgaaatgtgaataggtatgtcctg 
NR5A2 exon 8 Forward AATGTGTAACTACCCGCAGC 396 58 
Reverse AGCCTTTGATTCACAGTTTGC 
NRXN1 exon 2 Forward CCAGCTCAAGACTCGCAGC 300 58 
Reverse CCGACGAAAAGGCCGCTG 
PEX13 exon 1 Forward GTTGTGTCTTACGCTCCAGG 294 58 
Reverse ggttgggtattggttaaagggg 
CD164 exon 3 Forward tttgggtttgatttcatagagc 264 58 
Reverse ctgaaacaaggctttctgagg 
FZD1 exon 1 Forward CTTCGTGGGGCTTAACAACG 273 58 
Reverse CTGCGTTCCCACTGGTCC 
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Table S2 (continued)  
Target Primer Oligonucleotides Size (bp) Annealing 
Temperature (°C) 
RAVER1 exon 11 Forward acaaagggctgggtactaca 280 58 
Reverse ggttacagagccccggtg 
BCOR exon 8 Forward CACCGTGATCCCTTTGAAGC 248 58 
Reverse ggctcacCTTTAGAGACTCGT 
COL11A1 exon 26 Forward tgaattgaagccagtgactcag 370 58 
Reverse agtttccacaaaagccaccg 
COL11A1 exon 56 Forward tgctgtttttcagtattctaagagg 657 58 
Reverse gaaagtaaaatatgggagcacattag 
PNPT1 exon 7 Forward tacaaagcccctgcttttagc 397 58 
Reverse gccatatgccattgctgtaac 
PNPT1 exon 9 Forward gaaatcaaggtggatctatcactaag 398 58 
Reverse tccatgggaagtttctctcc 
COCH exon 2 Forward ATCAGTCACCATGTCCGCAG 497 58 
Reverse cttcctcgacctcctgctg 
GIPC3 exon 1 Forward cctgtccctgtccttatttg 746 58 
Reverse gctagtcctaagacctgccc 
Primers for amplification of exons and exon-intron boundaries were designed with Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). The following reference sequences 
were used: LMX1A, NM_177398.3; MYO6, NM_004999.3; NR5A2, NM_205860.2; NRXN1, NM_004801.5; 
PEX13, NM_002618.3; CD164, NM_006016.5; FZD1, NM_003505.1; RAVER1, NM_133452.2; BCOR, 
NM_001123385.1; COL11A1, NM_001854.3; PNPT1, NM_033109.4; COCH, NM_001135058.1; GIPC3, 
NM_133261.2. Amplification by PCR was performed under standard conditions. PCR fragments were 
purified with ExoI/FastAP (Thermo Fisher Scientific, Waltham, MA, USA), in accordance with manufacturers’ 
protocols. Sequence analysis was performed with the ABI PRISM BigDye Terminator Cycle Sequencing 
v.2.0 Ready Reaction kit and analyzed with the ABI PRISM 3730 DNA analyzer or the 3130 Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA). A possibly deleterious eﬀect of the identified variants on the 
proteins and splicing was predicted with Alamut Visual version 2.7.1 (Interactive Biosoftware, Rouen, 
France). 
 
| Chapter 4.2
188
Ta
bl
e 
S3
 In
di
vi
du
al
 re
su
lts
 o
f o
to
sc
op
y,
 p
ur
e-
to
ne
 a
ud
io
m
et
ry
, H
I p
ro
gr
es
si
on
 a
na
ly
si
s,
 s
pe
ec
h 
di
sc
rim
in
at
io
n 
an
d 
ve
st
ib
ul
ar
 c
om
pl
ai
nt
s 
Fa
m
ily
 
Su
bj
ec
t 
Ag
e 
at
 
ev
al
ua
tio
n 
(y
rs
) 
Re
po
rt
ed
 
ag
e 
of
 
H
I 
on
se
t (
yr
s)
 
O
to
sc
op
ic
 
ex
am
in
at
io
n 
PT
A 
(d
B 
H
L)
 
Si
gn
ifi
ca
nt
 p
ro
gr
es
si
on
 o
f 
H
Ia 
SR
T 
 
(d
B)
c 
M
ax
. 
SR
S 
(%
)c 
Ve
st
ib
ul
ar
 c
om
pl
ai
nt
s 
 
 
 
 
 
R 
L 
R 
L 
ra
te
b 
YO
F 
 
 
 
W
15
-0
55
1 
II:
7 
73
 
27
 
R+
L 
m
yr
in
go
-
sc
le
ro
si
s 
73
 
65
d 
no
 
no
 
- 
17
 
67
 
58
 
no
 
 
III
:8
 
44
 
pu
be
rt
y 
R+
L 
hy
pe
rm
ob
ile
 
ea
rd
ru
m
 
57
 
53
 
ye
s 
ye
s 
1.
2 
20
 
51
 
92
 
ve
rt
ig
o 
ep
is
od
es
 a
t 
ag
e 
of
 3
2 
an
d 
40
 y
ea
rs
 la
st
in
g 
fo
r d
ay
s 
 
IV
:2
 
9 
co
ng
en
ita
l 
no
rm
al
 
48
 
23
 
no
 
no
 
- 
3 
22
 
10
0 
no
 
63
13
6e
 
I:2
 
85
 
ch
ild
ho
od
 
N
T 
80
 
83
 
- 
- 
- 
0 
82
 
90
 
no
 
 
II:
2 
54
 
26
 
no
rm
al
 
58
 
28
 
ye
s 
ye
s 
1.
0 
28
 
28
 
10
0 
ve
rt
ig
o 
ep
is
od
es
 
w
ith
 
tin
ni
tu
s 
du
rin
g 
pu
be
rt
y 
an
d 
at
 a
ge
 o
f 4
0 
ye
ar
s 
la
st
in
g 
fo
r d
ay
s 
 
II:
3 
52
 
co
ng
en
ita
l 
no
rm
al
 
11
2 
11
3 
ye
s 
ye
s 
1.
1 
37
 
N
D
 
10
 
ve
rt
ig
o 
ep
is
od
es
 w
ith
 ti
nn
itu
s 
in
 
th
e 
pa
st
 la
st
in
g 
fo
r h
ou
rs
 
 
II:
4 
40
 
35
 
no
rm
al
 
45
 
57
 
ye
s 
ye
s 
1.
6 
10
 
36
 
92
 
ve
rt
ig
o 
ep
is
od
es
 
w
ith
 
tin
ni
tu
s 
ar
ou
nd
 
th
e 
ag
e 
of
 
40
 
ye
ar
s 
la
st
in
g 
m
in
ut
es
 t
o 
ho
ur
s,
 a
nd
 
BP
PV
 
yr
s,
 y
ea
rs
; P
TA
, p
ur
e 
to
ne
 a
ve
ra
ge
, m
ea
n 
of
 0
.5
, 1
 a
nd
 2
 k
H
z 
ai
r c
on
du
ct
io
n 
th
re
sh
ol
ds
; R
, r
ig
ht
; L
, l
ef
t; 
H
I, 
he
ar
in
g 
im
pa
irm
en
t; 
YO
F,
 y
ea
rs
 o
f f
ol
lo
w
-u
p;
 S
RT
, s
pe
ec
h 
re
ce
pt
io
n 
th
re
sh
ol
d;
 M
ax
, m
ax
im
um
; S
RS
, s
pe
ec
h 
re
co
gn
iti
on
 s
co
re
; N
T,
 n
ot
 te
st
ed
. a
In
di
vi
du
al
 p
ro
gr
es
si
on
 o
f H
I w
as
 c
al
cu
la
te
d 
w
ith
 lo
ng
itu
di
na
l l
in
ea
r r
eg
re
ss
io
n 
an
al
ys
es
, u
si
ng
 a
ll 
av
ai
la
bl
e 
au
di
og
ra
m
s 
fo
r t
he
 b
et
te
r h
ea
rin
g 
ea
r. 
A
ud
io
gr
am
s 
w
er
e 
us
ed
 o
nl
y 
if 
th
ey
 w
er
e 
ob
ta
in
ed
 a
ft
er
 th
e 
ag
e 
of
 5
 y
ea
rs
. T
he
 o
ns
et
 le
ve
l o
f H
I 
(t
hr
es
ho
ld
 in
te
rc
ep
t, 
in
 d
B 
H
L 
at
 a
ge
 0
 y
ea
rs
) a
nd
 p
ro
gr
es
si
on
 o
f H
I (
sl
op
e 
in
 d
B/
ye
ar
), 
w
er
e 
de
te
rm
in
ed
 fo
r e
ac
h 
fr
eq
ue
nc
y 
(0
.2
5,
 0
.5
, 1
, 2
, 4
 a
nd
 8
 k
H
z)
. P
ro
gr
es
si
on
 
of
 H
I w
as
 c
on
si
de
re
d 
to
 b
e 
si
gn
ifi
ca
nt
, i
f t
he
 re
gr
es
si
on
 c
oe
ﬃ
ci
en
t d
iﬀ
er
ed
 s
ig
ni
fic
an
tly
 (p
 ≤
 0
.0
5)
 fr
om
 0
 fo
r a
t l
ea
st
 tw
o 
of
 th
e 
si
x 
ev
al
ua
te
d 
fr
eq
ue
nc
ie
s,
 a
nd
 if
 th
e 
sl
op
es
 w
er
e 
po
si
tiv
e.
 P
ro
gr
es
si
on
 o
f H
I c
ou
ld
 n
ot
 b
e 
ca
lc
ul
at
ed
 in
 s
ub
je
ct
 I:
2 
of
 fa
m
ily
 6
31
36
, b
ec
au
se
 o
nl
y 
on
e 
au
di
og
ra
m
 w
as
 a
va
ila
bl
e.
 b
Pr
og
re
ss
io
n 
ra
te
 is
 th
e 
m
ea
n 
(P
TA
0,
5-
4 
kH
z) 
in
cr
ea
se
 in
 d
B 
pe
r 
ye
ar
 f
or
 t
he
 b
et
te
r 
he
ar
in
g 
ea
r. 
c R
es
ul
ts
 o
f 
sp
ee
ch
 d
is
cr
im
in
at
io
n 
fo
r 
th
e 
be
tt
er
 h
ea
rin
g 
ea
r 
ar
e 
pr
es
en
te
d.
 d
PT
A
 o
f 
bo
ne
 
co
nd
uc
tio
n 
th
re
sh
ol
ds
 is
 d
is
pl
ay
ed
, b
ec
au
se
 o
f m
ix
ed
 H
I d
ue
 to
 fe
ne
st
ra
l o
to
sc
le
ro
si
s 
co
nd
uc
tiv
e 
H
I) 
an
d 
th
e 
LM
X1
A
 v
ar
ia
nt
 (s
en
so
rin
eu
ra
l H
I).
 e F
am
ily
 6
31
36
 d
id
 
no
t p
ar
tic
ip
at
e 
in
 o
ur
 c
lin
ic
al
 e
va
lu
at
io
n;
 o
nl
y 
re
tr
os
pe
ct
iv
e 
da
ta
 w
er
e 
an
al
yz
ed
.  
Heterozygous variants of LMX1A lead to HI and vestibular dysfunction |
189
4.2
References
1. Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: 
development of a new clinical scale. Neurology. Jun 13 2006;66(11):1717-1720.
2. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief 
screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. Apr 
2005;53(4):695-699.
3. Schmand B, Lindeboom J, van Harskamp F. Nederlandse leestest voor volwassenen. . Lisse: Swets 
en Zeitlinger; 1992.
4. Schmidt M. Rey auditory verbal learning test: A handbook. Los Angeles, CA: Western Psychological 
Services; 1996.
5. Wechsler D. The Wechsler intelligence scale for children. San Antonio: TX: The Psychological 
Corporation; 1991.
6. Beery KE, Buktenica NA, N.A. B. The Beery-Buktenica developmental test of visual-motor 
integration: Administration, scoring, and teaching manual Minneapolis: MN: NSC Pearson; 2010.
7. Wallis Y, Payne S, McAnulty C, et al. Practice Guidelines for the Evaluation of Pathogenicity and the 
Reporting of Sequence Variants in Clinical Molecular Genetics. ACGS /VGKL. 2013.

5
General discussion

General discussion |
193
5
This thesis had the aim to contribute to optimal diagnostics and counseling for patients 
with hereditary HI in the Netherlands and beyond, by identification of novel deafness 
genes and (further) characterization of correlations between types of HI and underlying 
genetic causes. Chapter 2 evaluated the yield and outcomes of the most commonly used 
diagnostic test for hereditary HI in the Netherlands: whole exome sequencing (WES) with 
targeted analysis of a deafness gene panel. Here, the (dis)advantages and ethical issues of 
this technique are discussed, as well as developments in molecular diagnostics. In chapter 
3, we have described phenotype characterizations and genotype-phenotype correlations 
of two recessive types of HI. The importance of these types of studies will be commented, 
and we shall discuss phenotype characteristics that should be described when publishing 
a (novel) genotype-phenotype correlation. Chapter 4 described two novel deafness genes 
and the associated phenotype. Here, we will discuss strategies for identification of novel 
deafness genes.
Diagnostic yield, (dis)advantages, and ethical issues of WES with targeted 
analysis of a deafness gene panel
Retrospective research into test outcomes of 200 Dutch patients with HI, described in 
chapter 2 of this thesis, revealed that in only 33.5% of cases a genetic diagnosis could 
be established. This diagnostic yield is comparable to other studies1-7, which means 
that worldwide in circa 65% of HI patients no genetic diagnosis can be provided. There 
are several reasons why the diagnostic yield for hereditary HI is low. First of all, at least 
tens of deafness genes are to be identified, illustrated by the number of deafness loci 
for which the causative gene is currently unknown (Hereditary Hearing Loss Homepage, 
http://hereditaryhearingloss.org/). The number of monogenic forms of nonsyndromic HI 
(NSHI) that await identification is probably even higher, as there are many genes known 
to be expressed in the cochlea or involved in hearing in animals, that are possibly also 
involved in HI in human. An example of this LMX1A. This gene was found to be associated 
with dominant NSHI in humans (described in chapter 4.2), but was already associated with 
deafness in mice since 1999.8 Each unidentified gene is most likely involved in less than 1% 
of the cases, or even in only one or a few families with NSHI, as most frequently involved 
genes are already known. This is illustrated by recently identified deafness genes, such as 
KITLG9 and CLIC510, that have so far been associated with HI in three families and one family, 
respectively. The prevalence of the identified founder variant in MPZL2 (c.72del, chapter 
4.1) in the Dutch population is 0.33%, based on population-frequency data of the Radboud 
university medical center in-house exome database. This reveals that the prevalence of 
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homozygotes is 1 in 100.000 individuals, demonstrating that mutations in MPZL2 are rare, 
but occur in a significant number of Dutch HI patients.
 The second reason for the low diagnostic yield might be the suboptimal technological 
WES conditions. Part of causal variants in known deafness genes probably remained 
unidentified due to insuﬃcient enrichment or coverage. In our study, two enrichment 
kits (Agilent version 50 Mb and version 4) were used, both not targeting 121 of the 2347 
exons of the analyzed deafness genes, of which 51 exons (50 Mb kit) and 56 exons (version 
4 kit) were coding. We have not investigated whether poor enrichment has a significant 
impact on the diagnostic yield. We expect that the number of causative variants might 
slightly increase with improved enrichment, as more than half of coding exons was not 
targeted for a few genes (PTPRQ in the 50 Mb kit, and OTOA and STRC in the version 4 kit). 
However, poor enrichment of OTOA and STRC does not aﬀect the identification of large 
copy number variations (CNVs) in these genes, although small CNVs can be missed. Indeed, 
large deletions could be identified in the investigated cohort despite bad enrichment. In 
addition, the coverage was suboptimal, as the median coverage of at least 20x was reached 
for 72.0% to 97.8% of the targeted genes. Coverage, however, seemed not to be the major 
cause of the high percentage of unidentified variants, as the identification rate of causative 
variants remained stable with improvement of coverage over time. Diagnostic yield was 
not influenced by improvement of sequence quality and read length by using a better 
sequencing system (switch from the 5500xl SOLiD system to the Illumina HiSeq2000TM 
machine). 
 Third, in 5% of cases, variants of uncertain significance were identified. Further 
research into these variants and subsequent classification as pathogenic or (likely) 
benign will probably increase the diagnostic yield. Functional validation is the gold 
standard to prove pathogenicity of a variant, but this is usually not feasible in diagnostic 
settings. Although population based frequency data, such as the Exome Aggregation 
Consortium browser11, and computational tools for variant prioritization, such as CADD12, 
are increasingly available, interpretation of variants is still a challenge. This is especially 
true for interpretation of missense and splice site variants. In addition, these tools have 
important drawbacks, as variant frequency data are often not population-specific, and 
pathogenic founder variants can be misinterpreted because of high prevalence. Validation 
of computational tools has shown that the predictive value is limited, as variants that are 
predicted to be pathogenic are often benign and vice versa.13 Scores for intolerance to 
genetic variation are not applicable for HI, as many deafness genes have a high tolerance 
to variation, because HI does not (significantly) reduce fitness. This is illustrated by the 
relatively high residual variation intolerance score of USH2A (4.2, overall range -8.3 to 29.8), 
as calculated by Petrovski et al. (2013).14 In our study, variants of uncertain significance were 
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mainly reported in patients for whom no DNA of family members was available, which 
hampered segregation analysis. This highlights the importance of taking an accurate 
family history and collecting clinical data and DNA samples of as many as possible family 
members.
 Fourth, deep intronic variants aﬀecting splicing, complex chromosomal 
rearrangements, and variants in non-coding exons, repeat regions and regulatory regions 
are missed in WES, which probably explains the largest part of unidentified variants. Several 
pathogenic intronic variants in frequently involved HI genes have been described, for 
example in MYO615, SLC26A416, and USH2A17,18. These variants can only be found using other 
techniques, such as whole genome sequencing (WGS) or targeted genome sequencing. 
 Finally, involvement of non-genetic causes or a combination of (multiple) genetic and 
non-genetic factors cannot be excluded for cases in which no causative variants could be 
identified. We expect that the number of patients with non-genetic and multifactorial HI is 
significant. This is strengthened by the fact that the diagnostic yield declined significantly 
with increased age of HI onset. Whereas the percentage of identified causal variants was 
37-49% in individuals with congenital or 1st decade HI onset, this declined radically to 
8-18% in individuals with 2nd to 4th decade HI onset. No causal variants were identified in 
the subjects with an age of HI onset in the fifth or sixth decade. 
Besides WES, targeted next-generation sequencing (NGS) of a deafness gene panel 
is commonly used as a diagnostic test for HI (e.g. OtoSCOPE19). The advantage of WES 
targeting a gene panel compared to targeted NGS, is that the gene panel can be constantly 
updated according to newest insights on genes involved in HI, and reanalysis of previously 
tested cases on novel deafness genes is possible. Besides, if gene panel analysis is negative, 
analysis of all WES data (open exome analysis) can be performed.20 Since WGS can identify 
variants in non-coding regions, it could be questioned whether this has a better diagnostic 
applicability and yield for HI, compared to WES. WGS has the mentioned advantages of 
WES and outperforms WES regarding coverage and sequencing biases (e.g. problems with 
mapping, strand coverage, or allele distribution)21, partly because the enrichment step 
is entirely omitted in WGS. In addition, complex rearrangements, such as inversions and 
translocations, can be identified in WGS.22 Despite the superiority of WGS, only one case of 
diagnostic use of WGS for syndromic HI has been described.23 This is due to the high costs 
of WGS, making WES currently more cost-eﬀective.20 But in the nearby future, lower costs 
of WGS will enable the application of WGS as a diagnostic test, and will eventually replace 
WES. There are, however, also other hurdles to take, such as storage of the enormous 
amount of data that is generated by WGS, and strategies for analysis and interpretation of 
the large number of sequencing variants.
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The rapid progress in unraveling exomes, and soon genomes, obliges us to be guided 
by ethical principles. As described in chapter 2 of this thesis, we identified variants of 
uncertain significance in USH2A, which is associated with Usher syndrome type 2, in 
children without symptoms of retinitis pigmentosa. This is diﬃcult for genetic counseling, 
as parents have to be informed about the possible development of Usher syndrome later 
in life. Therefore, development of better computational tools for prediction of variant 
pathogenicity and/or novel techniques for cost-eﬀective functional validation is urgent. 
Although presymptomatic testing enables eﬀective management and rehabilitation, 
parents should be counseled on the risk of diagnosing a syndrome, to make an informed 
decision on whether or not to perform genetic testing.24 A presymptomatic diagnosis can 
have a huge psychosocial impact, although this has not been studied for HI. Therefore, if 
presymptomatic diagnostics is applied, one should be able to provide aftercare for patients 
and their relatives if needed.  
 Another ethical issue is the risk of incidental findings, which only occurs when 
performing open exome (or genome) sequencing. Whereas some argue that incidental 
findings should be reported and actively searched for, others are of the opinion that 
they should be avoided if possible.25 In the Radboud university medical center, the risk of 
incidental findings with WES is 0.7% (unpublished data). If an incidental finding occurs, the 
results are discussed in a panel of independent experts who decide whether the incidental 
finding is important for the patient to know, in accordance with the recommendations 
of the European Society of Human Genetics26, and the guidelines for diagnostic NGS, as 
published by Eurogentest (http://www.eurogentest.org/). In the scientific research team 
of the Radboud university medical expertise center Hearing & Genes, 59 genes associated 
with severe disease are excluded from analysis, to exclude incidental findings. For this 
purpose, the list of genes compiled and updated by the American College of Medical 
Genetics and Genomics, for reporting of secondary findings in clinical exome and genome 
sequencing, is used.27 Since the diagnostic yield of open exome analysis for HI is extremely 
low, even lower than the chance of incidental findings, it could be questioned whether 
open exome analysis should be performed in a diagnostic setting. When a de novo 
approach is applied, i.e. analyzing exome or genome sequencing data in parent-child trios, 
the probability of an incidental finding is low (no numbers available). The risk of incidental 
findings can also be lowered by analysis of shared exomic or genomic variants of several 
aﬀected family members, although the risk will remain significantly higher compared to a 
de novo approach. 
 Finally, we demonstrated in chapter 2 that we could not find any pathogenic variants 
in patients with an HI onset in the 5th or 6th decade. These results demonstrate that – at 
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least in the Dutch population – WES should probably not be performed in patients with an 
age of onset after the 4th decade of life, as the costs of the test do certainly not outweigh 
the chance of finding the genetic defect. In these individuals, COCH (DFNA9) should be 
tested when clinically suspected, and special attention should be paid to non-genetic 
causes. Probably, combinations of multiple genetic factors are involved, as in age-related 
multifactorial HI.28
The importance of thorough characterization of the phenotype and 
establishment of genotype-phenotype correlations
The reported phenotype of several cases described in chapter 2, was diﬀerent from the 
type of HI known to be associated with mutations in the gene. An example of this is the 
identification of pathogenic variants in TRIOBP, a gene known for severe to profound HI, in 
two patients with mild and moderate HI (further described in chapter 3.1). This illustrates 
that novel genotype-phenotype correlations can be identified by targeted analysis of a 
deafness gene panel, provided that one does not discard these variants because the 
phenotype does not match with the reported type of HI. In addition, it underlines the 
enormous phenotypic heterogeneity that can result from pathogenic variants in an HI-
related gene. Many deafness genes are associated with a highly variable phenotype, such 
as TRIOBP (chapter 3.1 of this thesis), LOXHD1 (chapter 3.2), LMX1A (chapter 4.2), CDH2329,30, 
TECTA31,32, and DFNA933,34.
 Establishment of well characterized phenotypes and genotype-phenotype 
correlations is essential for adequate counseling, to prevent further diagnostic testing, and 
to identify possible medical comorbidities.35,36 In addition, knowledge on the phenotype 
and genotype-phenotype correlations can help to understand the function of the gene in 
humans. Patients with HI pursue a genetic diagnosis to obtain information on treatment 
options, prognosis and risk of inheritance.37 However, phenotype information is scarce for 
many types of HI, due to the limited number of patients diagnosed with a specific type of HI 
and due to insuﬃcient description of the phenotype. Evaluation of a phenotype of a small 
kindred is considered less reliable and precise than characterization of a large number of 
patients with a genetic defect in the same gene, preferably from several families and origin. 
Examples of insuﬃcient phenotype descriptions are described in chapter 3, as a number of 
publications on DFNB28 (chapter 3.1) and DFNB77 (chapter 3.2) do not provide a phenotype 
description at all. We endorse the recommendations of the GENDEAF study group for 
description of the HI phenotype, who propose that all published HI phenotypes at least 
describe type and severity of HI, audiometric configuration, (a)symmetry of HI, estimated 
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age of onset, HI progression, tinnitus, vestibular symptoms and function, and intrafamilial/ 
interfamilial variability.38 It is obvious that the description of sequence variants should be 
in accordance with the HGVS recommendations39, and that classification of the identified 
DNA variant should meet the globally accepted recommendations of the American College 
of Medical Genetics and Genomics.40 The ClinGen Hearing Loss Working Group is currently 
working on a variant assessment framework for HI-related genes, which will describe, 
amongst others, a cut-oﬀ point of the minor allele frequency for specific genes.
Strategies for identification of novel genes for nonsyndromic deafness 
As described at the start of this chapter, it is very likely that HI in part of genetically 
undiagnosed patients is caused by pathogenic variant(s) in yet undiscovered deafness 
genes. Identification of these genes increases the eﬃcacy of genetic testing and enables 
adequate genetic counseling on prognosis, recurrence risk, rehabilitation options and, if 
applicable, diagnosing of additional symptoms. In addition, identification of underlying 
genetic defects opens the doors for development of genetic therapies for HI. Unraveling the 
pathophysiological mechanisms that result from a specific genetic defect, or identification 
of specific types of causative variants, enable future development of targeted therapy. 
There are a number of strategies that can be used for therapy, depending on the type 
of causal variant and the eﬀect of the genetic defect on protein function. For example, 
dominant-negative eﬀects can be addressed with an allele silencing approach41, whereas 
compounds that enhance read-through can abolish eﬀects of a nonsense mutation42. Mis-
splicing of pseudo-exons that are inserted due to intronic variants can be prevented using 
antisense oligonucleotide-mediated exon skipping43.
 Before the introduction of NGS, identification of NSHI-related genes relied on 
Sanger sequencing of candidate deafness genes and/or positional cloning, usually after 
identification of a shared genotype region by homozygosity mapping or linkage analysis. 
Since 2010, targeted NGS and WES have enabled the rapid and more cost-eﬃcient 
identification of genes involved in NSHI (Figure 1).44 Up to now, genes involved in NSHI 
have not been identified with WGS, although recently three syndromic HI-related genes 
have been discovered by WGS.45-47 The identification rate of deafness genes has not 
increased as fast as expected, as can be seen in Figure 1, mainly due to diﬃculties in variant 
interpretation. 
 DNA variant interpretation is all about reducing the number of sequence variants, 
typically tens of thousands when using WES, to a manageable number of candidate 
variants, which are to be further investigated. This eventually leads to identification of 
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one or two (likely) causative variants.48 The first step in reducing the number of candidate 
variants is based on variant quality, population frequency of the variant, the type of variant, 
and the predicted eﬀect of the variant on protein level using computational tools. The 
remaining candidate variants are further analyzed using (homology) protein modeling, 
segregation analysis, available information on function and expression of the candidate 
gene, interactions of the candidate gene/protein with genes/proteins involved in hearing, 
and existing phenotype data of animal models. If indicated, functional or animal studies 
can be performed to prove the deleterious eﬀect of the variant(s) and the function of the 
gene in hearing.
Figure 1 Identification of NSHI-related genes and method of discovery, from 1995 to 2016. The figure was 
adapted from Vona et al. (2015).44 CGH, comparative genomic hybridization.
 
 Elucidating pathogenic variant(s) by analyzing WES or WGS data of one aﬀected 
individual is often not successful, because too many candidate variants remain. If the (likely) 
causative variant can be identified, we need to beware of seemingly causative variants 
that segregate by chance, especially in dominant NSHI. This is illustrated by the recent 
disqualification of MYO1A as a deafness gene.49,50 Both the remaining of too many variants 
and the risk of classifying a benign variant as causative, are reasons to combine WES or WGS 
with other molecular techniques, or to perform WES or WGS in several patients from one or 
WES only
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a number of families. These strategies have been described by Gilissen et al. (2012), and are 
depicted in Figure 2.48 The linkage based (Figure 2a) and homozygosity based (Figure 2b) 
strategies are often used for identification of novel deafness genes, as can be seen in Figure 
1, and we have applied them for discovery of several deafness genes (e.g. MPZL2, described 
in chapter 4.1). These strategies have the advantage of statistical support for the variant’s 
causality.51 However, for linkage analysis and homozygosity mapping a significant number 
of (aﬀected) family members is needed, whereas in many cases there is no family history 
of HI, the number of aﬀected family members is small, or DNA and clinical information of 
family members is not available. In addition, these strategies always lead to identification 
of only one novel deafness gene at a time. 
Figure 2 Strategies for identification of disease-causing variant(s) using WES or WGS. The figure was obtained 
from Gilissen et al. (2012)48, with approval from the Nature Publishing Group. Dashed rectangles indicate 
subjects in which WES is performed. Circles below the pedigrees represent WES variants of the diﬀerent 
subjects and grey dots (a en f) and grey filled spaces (b-e) symbolize candidate variants that remain after 
application of the strategy. Details on the strategies are described in the main text.
e
Overlap based
strategy
 De novo based
strategy
Linkage based
strategy
Homozygosity based
strategy
Double-hit based
strategy
Candidate based
strategy
a b c
d f
 
 If only WES or WGS data is available, one of the alternative strategies for identification 
of causative variant(s) can be used. Whichever of these strategies is used, one should search 
for a number of families segregating unique pathogenic variant(s) in the same gene, and 
prove that these variants do not occur in a significant number of normal hearing controls. 
Although rareness of the involvement of a deafness gene can impede the identification 
of additional families, (inter)national collaborations and databases may oﬀer a solution 
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(e.g. the online database GeneMatcher).52 In chapter 2, we demonstrate that 2% of the 
investigated cases harbors a de novo variant, which shows that a de novo based strategy 
(Figure 2e) can be eﬀective. However, the relative number of causative de novo variants 
in HI is expected to be low, as HI does not (significantly) reduce fitness and consequently 
most variants are inherited. In chapter 4.2, we describe the discovery of LMX1A as a novel 
deafness gene, identified by a candidate based strategy (Figure 2f ). This strategy, and 
the double-hit based strategy (Figure 2c) are only successful if a clear candidate variant 
is present based on current (biological) knowledge, for example because defects in a 
candidate gene are associated with HI in mice.48 The a priori chance of identifying disease-
causing variant(s) using the candidate based or double-hit based strategy is low.
 The overlap based strategy (Figure 2d) has, as far as we know, never been used 
extensively for NSHI. This strategy requires accurate and systematic phenotyping and 
genotyping, and can only be applied if the disease is a monogenic disorder.48 Although di-, 
oligo-, or polygenic inherited forms of HI probably exist53,54, we assume that the majority of 
early-onset NSHI causes is monogenic. The genetic and phenotypic heterogeneity of NSHI 
complicates the use of the overlap based strategy. Genetic heterogeneity and rareness of 
involvement of a specific disease-causing gene can be circumvented by analyzing a large 
cohort of NSHI patients in a meta-analysis. This strategy has been used for other disorders, 
and could eﬀectively identify a number of disease-related genes at once.55,56 One could 
analyze WES data of uncategorized patients, or a subset with a specific mode of inheritance 
or a distinct phenotype. However, it could be questioned whether the phenotype of the 
latter subset can be characterized well enough for proper categorization, as we lack tools for 
deep phenotyping of HI. Although audiometric and vestibular examination give objective 
phenotype information, there are no tests available that can determine which part of the 
inner ear is aﬀected (e.g. outer or inner hair cells, tectorial membrane, stria vascularis, or 
the cochlear nerve). Additional techniques, such as determination of the auditory profile 
through psychophysical measurements57, sophisticated imaging techniques, or even the 
use of organoids58,59, could enable deep phenotyping. As described in the first paragraph of 
this chapter, environmental factors can often not be excluded, especially in cases without a 
family history of HI and in patients with late-onset HI, in particular patients with an age of 
onset after the 4th decade of life. These cases could be excluded from analysis.
 A preliminary meta-analysis of 117 exomes revealed that the number of candidate 
variants that remain after a first selection – based on variant quality, population frequency, 
type of variant, and predicted pathogenicity based on computational tools – is excessive 
(M. Wesdorp and S. Lelieveld, Radboud university medical center, unpublished data). To 
reduce this number, only families could be included of which exomic or genomic data 
of at least two aﬀected or aﬀected and unaﬀected family members is available, and only 
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shared variants could be used for analysis. Statistical calculations on genetic variation rates 
in functional domains could be used to significantly reduce the number of variants and to 
unveil novel candidate deafness genes. 
Conclusions and implications of this thesis 
In conclusion, the studies described in this thesis contribute to identification of all genes 
involved in hearing and their associated phenotype. Enhanced knowledge on genes and 
proteins essential for hearing in humans enables further elucidation of the physiology of 
hearing and provides clues for genetic therapies. We should seek for sophisticated ways to 
unveil the disease-causing variants in yet undiagnosed patients, such as a meta-analysis of 
WES or WGS data. In addition, we should thoroughly characterize the associated phenotypes, 
ideally using strategies for deep phenotyping, such as psychophysical measurements. 
Rarity of specific genetic types of HI and diﬃculties encountered during sequence analysis 
could be tackled if we collaborate (inter)nationally with bio-informaticians, biologists, 
physicians, and molecular geneticists. Finally, we should not only focus on coding variants 
and monogenic causes, as has been done in the last decades. We now have the tools to 
address intronic splice variants, regulatory variants, and multifactorial causes, which might 
well explain a significant part of HI cases.
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English summary
Hearing impairment (HI) is the most common sensorineural disorder, and can have a 
significant impact on life. To cope with HI, it is essential that patients and their relatives 
are well informed about their diagnosis. In case of presumed hereditary HI, it starts with 
establishing a (genetic) diagnosis, after which counseling on prognosis, recurrence 
risk, rehabilitation options, and, if applicable, additional symptoms can take place. This 
thesis has the aim to contribute to optimal diagnostics and counseling for patients with 
hereditary HI in the Netherlands and beyond, by identification of novel deafness genes 
and (further) characterization of phenotypes and correlations between types of HI and 
underlying genetic causes. 
Chapter 1 provides a general introduction on hearing and hereditary hearing impairment, 
and describes the scope of this thesis.
Chapter 2 serves as the starting point of this thesis. We evaluated the yield and outcomes of 
the most commonly used diagnostic test for hereditary HI in the Netherlands: whole exome 
sequencing (WES) with targeted analysis of a deafness gene panel. Retrospective analysis 
of test outcomes of 200 Dutch patients with presumed hereditary, mainly nonsyndromic, 
HI revealed that in 33.5% of cases a genetic diagnosis could be established, which is 
comparable to other studies. Variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were 
the leading causes for autosomal recessive and dominant HI, respectively. Evaluation of the 
utility of prescreening single genes prior to gene panel analysis led to the conclusion that 
prescreening should be reduced to a minimum. Our recommendations, which particularly 
apply for the Dutch population, are to prescreen GJB2 in case of congenital or 1st decade 
onset nonsyndromic HI, and specific genes associated with recognizable phenotypes 
such as DFNA9, DFNB4/Pendred syndrome and Usher syndrome. In all other cases, we 
recommend to perform WES targeting a panel of deafness genes as a first diagnostic test. 
In chapter 3, the phenotypes of two recessive types of HI are further characterized and 
genotype-phenotype correlations are extended, which enables better counseling. 
Chapter 3.1 describes the identification of pathogenic variants of TRIOBP in two isolated 
cases of Dutch origin. Disease-causing variants in TRIOBP have previously been associated 
with prelingual, severe to profound HI, known as DFNB28. Audiovestibular characterization 
of the two individuals in this study, however, displayed moderate HI, demonstrating that 
DFNB28 can be milder than reported so far. Vestibular function was normal. The relatively 
mild phenotype cannot be explained by predicted eﬀects of the causative variants on 
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protein function. In the second presented subject, location of one of the underlying variants 
might well contribute to the milder HI, as it only aﬀects isoform class TRIOBP-5, whereas 
all previously reported variants aﬀect both TRIOBP-4 and TRIOBP-5. The identification of a 
pathogenic variant that only aﬀects TRIOBP-5, suggests that a single TRIOBP copy encoding 
wild-type TRIOBP-4 is insuﬃcient for normal hearing, and that at least one TRIOBP copy 
encoding TRIOBP-5 is indispensable for normal inner ear function. 
In chapter 3.2, we report on nine families with DFNB77, caused by deleterious variants 
of LOXHD1. Twelve of fifteen identified variants were novel. There was high inter- and 
intrafamilial variation of the audiovestibular phenotype with regard to both severity and 
progression of HI. This is in line with previous studies. The phenotypic diﬀerences could not 
be related to type or location of the variants. Since objective evaluation of the vestibular 
function has not been reported before for DFNB77, we extensively assessed the vestibular 
system, which revealed normal function. Rare heterozygous missense variants of LOXHD1 
have been associated with Fuchs corneal dystrophy (FCD), a dominantly inherited disorder 
of the corneal endothelium. To assess whether family members who carry a heterozygous 
pathogenic LOXHD1 variant are at risk for FCD, we screened them for corneal abnormalities. 
None of the carriers showed (preclinical) symptoms of FCD. We argue that rare LOXHD1 
alleles are a risk factor for FCD, rather than a monogenic cause. In addition, there are 
indications for LOXHD1 variants associated with HI to induce a loss-of-function eﬀect and 
for gain-of function variants to be related to FCD. 
Chapter 4 describes the identification of two novel deafness genes, the associated 
phenotypes. In addition, we investigated and/or discussed the function of these genes 
in the inner ear. In chapter 4.1, we describe the discovery of MPZL2 as a novel gene for 
recessive deafness. Phenotype characterization of three families with truncating variants 
of MPZL2 showed early-onset, moderate, slowly progressive HI, without vestibular 
involvement or syndromic features. One of the identified variants is a founder mutation, 
which occurs homozygously in 0.001% of the Dutch population. We demonstrate that 
MPZL2 is relatively highly expressed in the human fetal cochlea. Audiometric evaluation of 
mutant mice confirmed that MPZL2 is essential for normal hearing, as these mice displayed 
progressive moderate to severe HI, similar to the human phenotype. Histological studies in 
three-month-old Mpzl2 mouse mutants revealed loss of cochlear hair cells and supporting 
cells, which was most severe in the basal cochlear turn, corresponding to the downsloping 
audiogram configuration in the investigated individuals. We hypothesize that MPZL2 
mediates epithelial adhesions in the inner ear and that defects of MPZL2 therefore lead to 
loss of structural integrity of the organ of Corti and progressive degeneration of hair cells 
and supporting cells.
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Chapter 4.2 describes the identification of mono-allelic variants in LMX1A as a cause of 
HI and vestibular dysfunction in two families of Dutch origin. There was large phenotypic 
variability in the age of onset (congenital to 35 years), (a)symmetry, severity (mild to 
profound) and progression rate of HI. About half of the aﬀected individuals displayed 
vestibular dysfunction and experienced symptoms thereof. Bi-allelic variants of Lmx1a 
have previously been associated with a complex phenotype in mice, including deafness 
and vestibular defects, caused by early-stage arrest of inner ear development. In humans, 
however, LMX1A seems to be (also) involved in maintenance of the inner ear, as most 
investigated subjects displayed a late-onset progressive phenotype, and absence of 
cochleovestibular malformations on computed tomography scans. Although Lmx1a 
mouse mutants demonstrate neurological, skeletal, pigmentation and reproductive 
system abnormalities, no syndromic features were seen in the participating subjects of 
either family. LMX1A has previously been suggested to be a candidate gene for intellectual 
disability, but our data do not support this, as aﬀected subjects displayed normal cognition. 
We argue that haploinsuﬃciency is probably the main pathogenic mechanism of HI and 
vestibular dysfunction caused by mono-allelic LMX1A variants.
Lastly, chapter 5 provides an overview of our main findings and implications of our 
results. In addition, we discuss strategies for future research into hereditary HI. The studies 
described in this thesis contribute to optimal diagnostics and counseling for patients with 
hereditary HI in the Netherlands and beyond. They expand knowledge on the epidemiology 
of hereditary HI in the Netherlands, (dis)advantages of our currently used diagnostic test, 
characteristics of phenotypes and genotype-phenotype correlations, and genes involved 
in hearing. 
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Nederlandse samenvatting
Slechthorendheid is de meest voorkomende zintuigstoornis en kan een aanzienlijke impact 
hebben op de kwaliteit van leven. Het is essentieel dat patiënten en hun familieleden goed 
worden geïnformeerd over hun aandoening, omdat dit hen kan helpen bij het omgaan 
met hun slechthorendheid. Bij verdenking op erfelijke slechthorendheid wordt geprobeerd 
eerst een (genetische) diagnose gesteld, waarna counseling plaatsvindt ten aanzien 
van prognose, herhalingsrisico, mogelijke revalidatie-opties en, indien van toepassing, 
bijkomende symptomen. Dit proefschrift heeft als doel om bij te dragen aan optimale 
diagnostiek en counseling van patiënten met erfelijke slechthorendheid in Nederland en 
ook daarbuiten, door nieuwe genen voor erfelijke slechthorendheid te ontdekken, en door 
fenotypen en correlaties tussen type slechthorendheid en genetische oorzaak (verder) in 
kaart te brengen.
Hoofstuk 1 geeft een algemene introductie over het gehoor en erfelijke slechthorendheid, 
en beschrijft de kaders van dit proefschrift.
Hoofdstuk 2 dient als het startpunt van dit proefschrift. Hierin hebben we de opbrengst 
en resultaten geëvalueerd van de meest gebruikte diagnostische test voor erfelijke 
slechthorendheid in Nederland: whole exome sequencing (WES) met gerichte analyse van 
een panel van doofheidsgenen. Uit een retrospectieve analyse van de testuitslagen van 
200 Nederlandse patiënten met, voornamelijk niet-syndromale, erfelijke slechthorendheid 
bleek dat in 33.5% van de gevallen een genetische diagnose kon worden vastgesteld. Dit is 
vergelijkbaar met andere studies. Varianten in GJB2, USH2A, MYO15A en STRC, en in MYO6, 
waren de belangrijkste oorzaken van respectievelijk autosomaal recessieve en dominante 
slechthorendheid. Onderzoek naar het nut van het testen van een specifiek gen voorafgaand 
aan genpanel analyse leidde tot de conclusie dat deze testen tot een minimum moeten 
worden beperkt. Onze aanbevelingen, die specifiek gelden voor de Nederlandse populatie, 
luiden dat een GJB2 voortest dient te worden gedaan in het geval van niet-syndromale 
slechthorendheid die congenitaal of in het eerste levensjaar is ontstaan. Daarnaast dienen 
voortesten te worden gedaan voor specifieke genen die geassocieerd zijn met herkenbare 
fenotypen zoals DFNA9, DFNB4/Pendred syndroom of Usher syndroom. In alle andere 
gevallen adviseren we om WES gericht op het doofheidspanel als eerste diagnostische test 
uit te voeren. 
In hoofdstuk 3 worden de fenotypen van twee recessieve vormen van slechthorendheid 
verder gekarakteriseerd en worden genotype-fenotype correlaties beschreven. Deze 
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studies hebben als doel om meer kennis te vergaren ten behoeve van verbeterde 
counseling. Hoofdstuk 3.1 beschrijft de identificatie van pathogene varianten in TRIOBP 
in twee patiënten van Nederlandse afkomst. Mutaties in TRIOBP zijn in eerdere studies 
geassocieerd met prelinguale, ernstige tot zeer ernstige slechthorendheid, bekend als 
DFNB28. Echter, audiovestibulair onderzoek bij de twee aangedane personen in deze 
studie liet zien dat er sprake is van matige slechthorendheid. Dit toont aan dat DFNB28 kan 
leiden tot een milder gehoorverlies dan tot nu toe gerapporteerd. De evenwichtsfunctie 
was normaal. Het relatief milde fenotype kan niet worden verklaard door het voorspelde 
eﬀect van de varianten op de functie van het eiwit. De locatie van één van de gevonden 
varianten draagt bij één van de patiënten mogelijk wel bij aan het milde gehoorverlies. 
Deze variant heeft namelijk alleen invloed op isovormklasse TRIOBP-5, terwijl alle eerder 
gerapporteerde varianten invloed hebben op zowel TRIOBP-4 als TRIOBP-5. De identificatie 
van deze variant suggereert dat één enkele kopie van TRIOBP coderend voor wildtype 
TRIOBP-4 onvoldoende is voor normaal gehoor, en dat tenminste één TRIOBP kopie 
coderend voor TRIOBP-5 nodig is voor een normale functie van het binnenoor.
In hoofstuk 3.2 rapporteren we over negen families met DFNB77, veroorzaakt door 
pathogene varianten in LOXHD1. Twaalf van de vijftien geïdentificeerde varianten waren 
nog niet eerder beschreven. Het audiovestibulaire fenotype laat een hoge inter- en 
intrafamiliaire variatie zien ten aanzien van ernst en progressie van de slechthorendheid. 
Dit komt overeen met resultaten van eerdere studies. De verschillen in fenotype kunnen 
niet worden toegeschreven aan het type of de locatie van de variant. Aangezien objectieve 
evaluatie van de vestibulaire functie tot op heden niet was beschreven, werden uitgebreide 
vestibulaire metingen uitgevoerd, welke een normale vestibulaire functie lieten zien. 
Heterozygote pathogene missense varianten in LOXHD1 zijn in een eerdere studie 
geassocieerd met Fuchse corneale dystrofie (FCD), een dominant overervend ziektebeeld 
van het endotheel van de cornea. Om te beoordelen of familielieden met een heterozygote 
LOXHD1 variant een verhoogd risico hebben op FCD, werden zij gescreend op corneale 
afwijkingen. Bij geen van hen werden (pre)klinische symptomen van FCD gevonden. We 
beargumenteren dat pathogene varianten in LOXHD1 een risicofactor zijn voor FCD in 
plaats van een monogene oorzaak. Daarnaast zijn er aanwijzingen dat LOXHD1-varianten 
geassocieerd met slechthorendheid leiden tot een loss-of-function eﬀect, terwijl varianten 
met een gain-of-function eﬀect gerelateerd zijn aan FCD.
Hoofdstuk 4 beschrijft de identificatie van twee nieuwe doofheidsgenen en de 
bijbehorende fenotypen. Daarnaast onderzoeken en/of bediscussiëren we de functie 
van deze genen in het binnenoor. In hoofdstuk 4.1 beschrijven we de identificatie van 
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MPZL2, een nieuw doofheidsgen voor recessieve slechthorendheid. Onderzoek naar het 
fenotype in drie families met defecten in MPZL2 laat zien dat er sprake is van een matige, 
langzaam progressieve slechthorendheid, die ontstaat in de eerste levensdecade. Er was 
geen sprake van vestibulaire of syndromale afwijkingen. Eén van de geïdentificeerde 
varianten is zeer waarschijnlijk afkomstig van een gemeenschappelijk voorouder van de 
patiënten en komt in 0.001% van de Nederlandse bevolking homozygoot voorkomt. We 
laten zien dat MPZL2 relatief hoog tot expressie komt in de humane foetale cochlea. Dat 
MPZL2 een rol speelt bij het gehoor werd bevestigd middels audiometrie bij mutante 
muizen. Hierbij werd een progressieve milde tot ernstige slechthorendheid vastgesteld, 
vergelijkbaar met het humane fenotype. Histologische studies bij 3 maanden oude Mpzl2 
mutante muizen toonde een verlies van cochleaire haarcellen en ondersteunende cellen. 
Dit verlies was het meest ernstig in de basale winding van de cochlea, wat overeenkomt 
met de aflopende audiogramconfiguratie bij de onderzochte individuen. We suggereren 
dat MPZL2 bijdraagt aan celadhesie in het binnenoor en dat MPZL2-defecten leiden tot 
verlies van structurele integriteit van het orgaan van Corti, en een progressief verlies van 
haarcellen en ondersteunende cellen.
Hoofdstuk 4.2 beschrijft de identificatie van mono-allelische varianten in LMX1A als 
oorzaak van slechthorendheid en vestibulaire dysfunctie in twee families van Nederlandse 
afkomst. Er is sprake van een zeer variabel fenotype ten aanzien van ontstaansleeftijd 
(congenitaal tot 35 jaar), (a)symmetrie, ernst (mild tot zeer ernstig) en snelheid van 
progressie van de slechthorendheid. Bij ongeveer de helft van de aangedane personen 
was er sprake van vestibulaire dysfunctie, waar zij ook klachten van ondervinden. Bi-
allelische Lmx1a varianten zijn in eerdere studies geassocieerd met een complex fenotype 
in de muis, waaronder doofheid en vestibulaire defecten. Dit wordt veroorzaakt door 
vroegtijdige beëindiging van de ontwikkeling van het binnenoor. Aangezien de meesten 
van de onderzochte patiënten pas op latere leeftijd een progressief fenotype ontwikkelden 
en de CT-scans geen cochleovestibulaire malformaties lieten zien, lijkt LMX1A in de mens 
(ook) betrokken te zijn bij het behouden van de binnenoorfunctie. Hoewel muizen met 
een defect in het Lmx1a-gen afwijkingen hebben van het centrale zenuwstelsel, het skelet, 
huidpigmentatie en het voortplantingssysteem, werden er geen syndromale afwijkingen 
waargenomen bij de patiënten van beide families. In de literatuur is gesuggereerd dat 
LMX1A een kandidaatgen is voor mentale retardatie. De resultaten van onze studie 
ondersteunen dit niet, aangezien de aangedane personen een normale cognitie 
hadden. We beargumenteren dat de geïdentificeerde mono-allelische LMX1A-defecten 
slechthorendheid en vestibulaire dysfunctie veroorzaken, doordat één kopie van het gen 
onvoldoende is voor het behoud van volledige cochleovestibulaire functie. 
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Tot slot geeft hoofdstuk 5 een overzicht van de belangrijkste bevindingen en de 
implicaties van onze resultaten. Daarnaast bediscussiëren we strategieën voor verder 
onderzoek naar erfelijke slechthorendheid. De studies beschreven in dit proefschrift 
zijn een stap in de richting van optimale diagnostiek en counseling van patiënten met 
erfelijke slechthorendheid in Nederland en daarbuiten. Ze dragen bij aan kennis over 
de epidemiologie van slechthorendheid in Nederland, voor- en nadelen van de huidige 
diagnostiek, fenotypen en genotype-fenotype correlaties, en genen betrokken bij het 
gehoor.
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List of abbreviations
ABR  auditory brainstem response
adHI  autosomal dominant hearing impairment
adNSHI  autosomal dominant nonsyndromic hearing impairment
AJ  adherens junction
arHI  autosomal recessive hearing impairment
arNSHI  autosomal recessive nonsyndromic hearing impairment
ART  acoustic reflex threshold
ARTA  age-related typical audiogram
BERA  brainstem evoked response audiometry
bp  base pair
cDNA  complementary deoxyribonucleic acid
cM  centiMorgan
CMV  cytomegalovirus
CNV  copy number variation
CT  computed tomography
cVEMP  cervical vestibular evoked myogenic potentials
dB   decibel
dBnHL  decibel normal hearing level
dbSNP  database of single nucleotide polymorphism 
DNA  deoxyribonucleic acid
DFN  deafness
DFNA  autosomal dominantly inherited hearing impairment
DFNB  autosomal recessively inherited hearing impairment
DFNX  X-linked inherited hearing impairment
DFNY  Y-linked inherited hearing impairment
DFNM  modifier of hereditary hearing impairment
ENG  electronystagmography
ENT  ear-nose-throat
ExAC  exome aggregation consortium database
FCD  fuchs corneal dystrophy
HI  hearing impairment
HI  hearing level
Hz  hertz
IHC  inner hair cell
ISO  international organization for standardisation
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ISO  isolated
Kb  kilobase
kHz  kilo hertz
LOVD  leiden open variation database
MAF  minor allele frequency
Mb  megabase
MIPS  molecular inversion probes
MLPA  multiplex ligation-dependent probe amplification
MRI  magnetic resonance imaging
mRNA  messenger ribonucleic acid
NGS  next generation sequencing
NSHI  nonsyndromic hearing impairment
nt  nucleotide
OAE  otoacoustic emission
OHC  outer hair cell
OMIM  Online Mendelian Inheritance in Man
PCR  polymerase chain reaction
PTA  pure tone acerage
qPCR  quantative polymerase chain reaction
RNA  ribonucleic acid
SNP  single-nucleotide polymorphism
SPL  sound pressure level
SRS  speech recognition score
SRT  speech reception threshold
TJ  tight junction
vHIT  video head impulse test
VNTR  variable number tandem repeat
VRA  visual reinforcement audiometry
VOR  vestibulo-ocular reflex
WES  whole exome sequencing
WGS  whole genome sequencing
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Dankwoord
Niet voor niets is het dankwoord het meest gelezen deel van een proefschrift, en wel 
om drie redenen. Dit is het enige hoofdstuk dat makkelijk te lezen en te begrijpen is, wat 
ervoor zorgt dat de lezer niet na drie zinnen de weg kwijt is. Ten tweede is dit hoofdstuk 
in beperkte oplage verkrijgbaar, want je kunt ‘m niet vinden op pubmed − dat maakt een 
mens nieuwsgierig. Maar de belangrijkste reden is dat de mensen die op deze pagina’s 
worden genoemd een (groot) aandeel hebben gehad aan dit proefschrift, of mij na aan 
het hart liggen. 
In de allereerste plaats wil ik alle patiënten die hebben deelgenomen aan het onderzoek 
bedanken voor hun inzet, tijd, geduld en doorzettingsvermogen. De onderzoeksdagen 
waren soms lang en vermoeiend, maar jullie enthousiasme en bereidwilligheid leken 
oneindig. Bij velen ben ik thuis langs geweest, bedankt voor de gastvrijheid!
Beste Hannie, je hebt je rol als promotor met verve vervuld. Dankzij jou is elk woord in dit 
proefschrift en elke assay of hypothese goed doordacht. Waar ik in het begin vaak moest 
slikken als ik een manuscript rood van de revisies van je terug kreeg, zijn we in de loop der 
jaren steeds dichter naar elkaar toe gegroeid. Vooral in het laatste jaar hebben we veel 
leuke en leerzame discussies gehad over de inhoud, maar ook over allerlei dingen die ons 
bezig houden in het leven. Ik waardeer je enorm om je kennis, eerlijkheid en oprechte 
interesse. Je hebt me oneindig veel geleerd!
Beste Ronald, ik had me geen betere copromotor kunnen wensen. Vanaf dag één heb je 
me bij de hand genomen en wegwijs gemaakt in de (politieke) wereld van de wetenschap. 
Maar je had vooral ook oog voor mijn persoonlijke ontwikkeling en ambities, en dat is 
absoluut jouw kracht. Het is jammer dat ik je teleur heb moeten stellen, omdat ik geen 
KNO-arts wil worden, maar zoals je weet heeft jouw enthousiasme voor het vak en de 
fantastische sfeer op de afdeling me erg doen twijfelen. Ik heb ontzettend genoten van de 
promovendi-etentjes bij jou thuis. Bedankt voor de fantastische tijd!
Dit proefschrift is mede tot stand gekomen in samenwerking met onze nationale 
werkgroep DOOFNL (Diagnostiek & Onderzoek Oto-genotype-Fenotype Nederland), 
waarbij het ErasmusMC, LUMC, MUMC+ en UMCG betrokken zijn. Hierbij wil ik Jet de Gier, 
Lies Hoefsloot, Marc van der Schroeﬀ, Marieke van Dooren, Liselotte Rotteveel, Pia de 
Konings Gans, Sarina Kant, Els Vanhoutte, Janny Hof, Robert Stokroos, Suzanne Frints, Jolien 
Klein Wassink, Rolien Free en Ton van Essen bedanken voor de goede samenwerking en het 
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warme onthaal tijdens mijn bezoekjes aan jullie afdelingen. Ik hoop dat dit proefschrift het 
begin zal zijn van een vruchtbare samenwerking!
Leden van de otogenetica werkgroep, de leerzame woensdagmiddagen hebben mij niet 
alleen meer inzicht gegeven in de otogenetica, maar ook in het beleid en management van 
ziekenhuisdiagnostiek en poliklinische zorg. Fijn dat jullie me deze kans hebben geboden. 
Helger, we hebben vaak samengewerkt, vooral aan hoofdstuk 2: de opbrengst van het 
WES genpanel. Ik heb veel van je geleerd, met name door de tijd die je hebt genomen 
om samen de revisies te schrijven. Bedankt! Ronald Admiraal, jouw kennis over erfelijke 
slechthorendheid is van onschatbare waarde. Dat, in combinatie met je onuitputtelijke 
enthousiasme voor je vak, maakten dat ik graag bij je langskwam om te discussiëren over 
patiënten en de klinische implicaties van ons onderzoek. Ilse, je hebt me op een hele leuke 
en persoonlijke manier wegwijs gemaakt in de klinische genetica en het counselen van 
patiënten. Dank daarvoor!
Margit, jouw kennis en ervaring op het gebied van de otogenetica waren voor mij 
onmisbaar. Fijn dat we zoveel uur samen hebben kunnen werken! Jaap, jouw engelengeduld 
gecombineerd met goede humor zorgde ervoor dat ik uit keek naar de dagen op het 
lab. Erwin, ik bewonder je enthousiasme en liefde voor je vak, het werkt aanstekelijk! 
Alle mensen uit de ‘Usher-groep’: het was fantastisch om jullie te kennen. Ik heb goede 
herinneringen aan de etentjes en vooral de escape room!
Stefan, ondanks mijn eindeloze vraag om bio-informatische analyses was je altijd 
bereid om ze uit te voeren. Ik ben je daar heel erg dankbaar voor. Het heeft je, naast co-
auteurschappen, in ieder geval een chocoladetaart opgeleverd!
Andy, bedankt voor alle leerzame momenten waarin je me telkens geduldig hebt 
uitgelegd hoe ons ingewikkelde evenwichtssysteem in elkaar zit. Je bent een fantastische 
leermeester! 
Lieve Loes, ik bewonder je nuchtere, maar ó zo betrokken houding. Het was heerlijk om met 
je te praten over werk en privé, en om samen voorbereidingen te treﬀen voor symposia en 
vergaderingen. Dank voor alle gezelligheid en administratieve ondersteuning!
Beste medewerkers en staf van de afdeling KNO, de fantastische sfeer en de leuke 
samenwerkingen hebben ervoor gezorgd dat ik elke dag met veel plezier naar mijn werk 
ging. Dank voor alle mogelijkheden die jullie mij hebben geboden.
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Lieve (oud)-assistenten, het was heerlijk om deel uit te maken van jullie gezellige, uitbundige 
groep! Ik ben blij dat jullie mij als vreemde-huisarts-in-de-bijt hebben opgenomen in de 
groep. Ik heb genoten van elk moment! Ik verlaat jullie met pijn in mijn hart, maar met 
fantastische herinneringen aan de assistentenweekenden, skivakanties, véle borrels, 
research-uitjes en KNO-dagen.
Lieve Ivo, wat heb jij een heerlijke kritische blik op de wetenschap en alles wat los en vast 
zit. Ik bewonder je nuchterheid en tegelijkertijd betrokkenheid in je werk en daarbuiten. 
We hebben aardig wat gezellige feestjes en borrels gehad; sorry voor de vechtpartijtjes, je 
bent een goede tegenpartij. Maar er zal toch altijd één ding op mijn netvlies blijven staan: 
assistentenweekend, een Duits accent en een megafoon. Je bent echt te gek!
Lieve Bas, tweeënhalf jaar lang hebben wij bijna elke dag onze onderzoekskamer gedeeld, 
dat is zeker 4000 uur! We hebben lief en leed gedeeld: van een artikel dat binnen 5 minuten 
na submissie werd afgewezen, tot eindeloze discussies over ons onderzoek en het leven, 
vele biertjes in Anneke, logeerpartijtjes van jou en Eva bij ons thuis, en niet te vergeten: 
onze trip naar Hinxton! Ik mis je gezelligheid, je goede smaak voor muziek, eten en wijn, 
maar vooral je goede smaak voor het leven. Mochten we elkaar ooit uit het oog verliezen 
(ik ga er alles aan doen om dat te voorkomen), weet dan dat je nooit uit mijn hart bent. 
Lieve Anne-Marie, jouw nuchtere kijk op ons beroep en onze gezamenlijke interesse in de 
niet-klinische geneeskunde maken dat ik het heerlijk vind om met je te sparren over het 
dokter-zijn. Maar los van dat, ben je vooral een hele leuke, vrolijke en attente vriendin!
Lieve Marjolein en Frank, vanwege mijn promotieonderzoek zijn we tijdelijk verhuisd naar 
Nijmegen en woonden jullie ineens heel dicht bij ons. Het was fantastisch om elkaar zo vaak 
te kunnen zien! Onze tijd in Nijmegen is mede dankzij jullie een prachtige tijd geweest. Ik 
hoop dat onze vriendschap altijd zo mag blijven. Marjolein, onze hechte band kan na al die 
jaren niet meer stuk, ik vind je geweldig!
Lieve Leontien, je bent er altijd voor me, je begrijpt me en voelt me feilloos aan. Ik ben zo 
blij dat ik je ken! Hoewel het jou verschrikkelijk lijkt om te promoveren wilde je toch altijd 
weten waar ik mee bezig was en kreeg ik telkens weer lofbetuigingen van je. Ik waardeer 
je enorm om wie je bent. Je bent me ontzettend dierbaar! Pat, fijn dat jij, inmiddels als man 
van, achter Leontien staat, met je nuchtere en vrolijke kijk op het leven.
Marlies en Emmy, wat ben ik blij dat ik zulke lieve, attente, zorgzame zussen heb! Ondanks 
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dat we allemaal ambitieus zijn en drukke agenda’s hebben is er gelukkig altijd tijd om even 
bij te kletsen en te horen hoe het met de ander gaat. Fijn dat we nu weer dichter bij elkaar 
wonen en zo vaker bij elkaar kunnen binnenlopen.
Lieve mam, bij jou ligt de oorsprong van het doorzetten en dicht bij jezelf blijven. Dank 
voor je nuchtere opvoeding en je onvoorwaardelijke, liefdevolle steun. Het maakt niet 
uit of je dichtbij of ver weg woont, want onze band overstijgt tijd en afstand. Waar je me 
vroeger hielp om mijn eerste kleine stapjes te zetten, helpen we elkaar nu om grote, nieuwe 
stappen te zetten. Op naar de toekomst!
Lieve, lieve Steev, onze liefde en geluk kan ik niet in woorden uitdrukken. Je bent er altijd 
voor me met je eindeloze optimisme en (dezelfde) grapjes, je geloof en vertrouwen in mij, 
en je geduld en luisterend oor als ik weer eens ongeduldig ben. Je bent een levensgenieter, 
en als ik het nodig heb herinner je me er aan dat genieten van het leven altijd boven werk 
gaat. Je hebt me geholpen en gesteund om keuzes te maken voor een toekomst die bij mij 
en bij ons past. Ik ben verschrikkelijk gek op je en gelukkig met je, en ik wil niks liever dan 
een leven samen met jou!
Mieke
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naar Nijmegen verhuisde. Tevens heeft zij bijgedragen aan de oprichting van werkgroep 
DOOFNL, een landelijke samenwerking van vijf academische centra gericht op diagnostiek 
en onderzoek naar erfelijke slechthorendheid. De liefde voor de stad Utrecht deed haar 
terug verhuizen naar het midden van het land. In augustus 2017 startte zij als ANIOS 
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Hearing impairment is the most common sensorineural disorder, and can 
have a signiﬁ cant impact on life. To cope with HI, it is essential that patients and 
their relatives are well informed about their diagnosis. In case of hereditary 
hearing impairment, it starts with establishing a (genetic) diagnosis, after 
which counseling on prognosis, recurrence risk, rehabilitation options, and, if 
applicable, additional symptoms can take place. 
This thesis aims to contribute to optimal diagnostics and counseling for 
patients with hereditary hearing impairment in the Netherlands and beyond, 
by identiﬁ cation of novel deafness genes and (further) characterization of 
correlations between types of hearing impairment and underlying genetic 
causes.
